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I. List of Abbreviations 
3α/βAdiol  3α/β-Androstanediol (5α-Androstane-3α/β,17β-diol) 
3α/βHSD  3α/β-hydroxysteroid dehydrogenase 
17β-HSD  17β-Hydroxysteroid Dehydrogenase  
17αOHProg  17α-Hydroxyprogesterone 
20α/βOHProg  20α/β-Hydroxyprogesterone 
17α,20α/βdiOHProg 20α/βdihydroxyprogesterone 
ADT   Androgen deprivation therapy 
ANOVA   Analysis of variance 
AR    Androgen Receptor  
AKR    Aldo-Keto Reductase  
ATCC   American Type Culture Collection 
CAM   Cell Adhesion Molecule 
CYP    Cytochrome P450  
CBR1   Carbonyl reductase 1 
CRPC   Castration resistant prostate cancer 
Ct-value  Cycle threshold-value 
DHRS7 (B/C)  Dehydrogenase/Reductase Short Chain Dehydrogenase Family Member 7 (B/C) 
DHEA   Dehydroepiandrosterone 
DHP   Dehydroprogesterone 
DHT   5α-Dihydrotestosterone 
DMEM    Dulbecco's Modified Eagle's Medium  
DMSO    Dimethyl Sulfoxide  
DTT   Dithiothreitol 
E1   Estrone 
E2   Estradiol 
ECM   Extracellular Membrane 
EDTA   Ethylenediaminetetraacetic acid 
EMT   Epithelial-mesenchymal transition 
ER   Endoplasmic Reticulum 
ERα/β   Estrogen Receptor α/β  
FBS    Fetal Bovine Serum  
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FDR   False discovery rate 
FGF   Fibroblast growth factor 
HEPES    4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid  
HMDB   Human Metabolome Database 
HPLC   High Performance Liquid Chromatography 
HSD    Hydroxysteroid Dehydrogenase  
IC50    Half-Maximal Inhibitory Concentration  
LNCaP   Lymph node carcinoma of the prostate 
mRNA    Messenger Ribonucleic Acid  
n.d.    Not Detected  
NADPH   Nicotinamide Adenine Dinucleotide Phosphate 6  
NR    Nuclear Receptor  
MAPK   Mitogen-activated protein kinase 
MEM    Minimum Essential Medium  
MW   Molecular Weight 
PCa   Prostate cancer 
PCR    Polymerase Chain Reaction  
PPAR    Peroxisome Proliferator-Activated Receptor  
PVDF   Polyvinylidene fluoride 
RIPA   Radioimmunoprecipitation assay 
RT    Room Temperature  
SD    Standard Deviation  
SDS   Sodium dodecyl sulfate 
SDR    Short-Chain Dehydrogenase/Reductase  
T   Testosterone 
TBS-T   Tris-buffered saline with 0.1% (v/v) Tween 20 
TEMED   Tetramethylethylenediamine   
TLC    Thin-Layer Chromatography  
Tris   Tris(hydroxymethyl)aminomethane 
(UHP)LC-MS/MS (Ultra High Performance) Liquid Chromatography/tandem Mass Spectrometry  
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1 Summary 
The short chain dehydrogenase DHRS7 has been previously described as a possible tumor suppressor, 
regulated during prostate cancer progression, with the potential of being a marker of prostate cancer. 
However, the function of DHRS7 and substrates with good affinity to be of potential physiological meaning 
remains unknown leaving it still classified as an “orphan” enzyme. These observations furthered the need 
to identify physiologically relevant substrates and understand the mechanisms affected by DHRS7 in 
endogenously expressing cell lines. In this thesis, in vitro assays were performed to help to characterize 
the activity of DHRS7. They showed DHRS7 has 3α and 20β reductase activities on the carbonyl of steroidal 
substrates, and interestingly revealed conversion of the main ligand of the androgen receptor 
dihydrotestosterone (DHT) toward the inactive 5α-androstane3α,17β-diol (3α-Adiol). This activity was 
further characterized through androgen receptor (AR) transactivation activity in an overexpressing system 
and biochemically through kinetic enzyme turnover assays. Moreover, this activity allowed to develop a 
novel screening lysate assay for substrates and inhibitors identification. However, no other promising 
physiologically relevant substrates were revealed. 
In the second part, the phenotypic changes upon DHRS7 silencing were investigated in endogenous cell 
models by functional cancer assays, mass spectrometry and untargeted proteomics supported by cell 
cycle analysis, immunofluorescence, real time qPCR and western blot. These results disproved the 
modulation of the endogenous AR in the prostate cancer cell line LNCaP under DHRS7 depletion but 
supported the hypothesis of DHRS7 having a tumor suppressor role with protein changes observed for 
cell cycle, adhesion and migration relevant to the phenotype. Interestingly, protein changes involved in 
mechanisms relevant for tumor biogenesis were observed. 
In conclusion, the results presented in this thesis extend the knowledge about DHRS7 in vitro activity, 
provide the characterization of an in vitro tool to test hypothesized substrates and inhibitors and suggest 
further investigation toward androgen receptor independent mechanisms. 
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2 Introduction 
2.1 Prostate Cancer 
Prostate cancer is the second most common cancer in men and is the leading cause of cancer related 
death among men globally (1.1 million cases, 307’000 deaths per year) [1]. Even though the prognosis is 
improving (the 5 years survival rate in Europe is currently about 93%) [2], some patients develop an 
aggressive form of the disease, despite primary treatment, leading to disease progression and death. The 
etiology of prostate cancer is complex but known to be associated with the non-modifiable risk factors 
age, ethnicity, and a family history of the disease [3, 4], and with environmental risk factors such as insulin-
like growth factor-I (IGF-I) [5]. Inherent to this complexity seems to be the diversity of involved genetic 
and environmental factors. 
The prostate is an exocrine gland in the male reproductive system located underneath the urinary bladder, 
in front of the rectum, and that surrounds the urethra. Usually, the cellular origin of prostate cancer is 
attributed to the epithelial cells of the peripheral zone (PZ) [6] (Figure 1A). The prostate zones consist of 
the prostatic epithelial acini, which are glandular structures arranged in a fibromuscular stromal network 
composed of columnar luminal and basal layer cells (Figure 1B). The basal layer is populated by stem cells, 
transit amplifying cells and committed basal cells. The prostatic epithelial acini are responsible for 
prostate secretions that drain into the urethra together with the spermatozoa and secretions from the 
seminal vesicles [7]. Prostatic acini, which progress into cancerous acini, are identified by specific micro 
environmental and molecular changes and with luminal hyperproliferation. The luminal epithelial cells, 
which in the healthy acini represent up to 60% of the total epithelial cell population increases to >99% in 
the cancerous acini, which coincides with the loss of the basal layer, disruption of the basement 
membrane, as well as immune infiltration and stroma reactivity [8]. 
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Figure 1: Adapted from [8]: Human prostate anatomy (A) and prostatic acinus architecture in health and cancer (B). CZ = central 
zone, TZ = transition zone, PZ = peripheral zone, TA = transit amplifying, CB = committed basal. 
Luminal epithelial cells of the prostate are differentiated cells that synthesize and secrete the products of 
the seminal plasma, including prostatic-specific antigen (PSA, also called KLK3), prostate-specific acid 
phosphatase (PAP), polyamines and prostaglandins [7]. Luminal epithelial cells express the androgen 
receptor (AR) [9, 10], and they survive only in the presence of androgens [11]. Therefore, androgens, play 
a crucial role in the regulation of normal prostate physiology, but importantly, the dysregulation of 
androgen levels can aid cancer development and progression. In fact, in a healthy prostate and in 
androgen-dependent tumors, castration induces endothelial cell apoptosis, vascular regression and 
decreased blood flow [12, 13]. The production and secretion of androgens is regulated by the 
hypothalamus and the pituitary gland, as shown in Figure 2A. 
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Figure 2: Regulation and production of androgens in the prostate and their use in the healthy prostate and in prostate cancer. A. 
Schematic representation of androgen production and secretion in the human body; B. Conversion of DHT into either healthy or 
cancerous acini (prostatic acini adapted from [8]); C. Schematic representation of the mechanisms of androgen dependent and 
independent prostate cancer adapted from [14]. GnRH = gonadotropin releasing hormone; T = testosterone, DHT = 
dihydrotestosterone, AD = androstenedione, CRH = corticotropin releasing hormone; LH = luteinizing hormone; ACTH = 
adrenocorticotropic hormone, DHEA = dehydroepiandrosterone, DHEAS = dehydroepiandrosterone sulfate, AR=androgen 
receptor, ARE = androgen response element. 
The hypothalamus releases gonadotropin releasing hormone (GnRH) and corticotropin releasing hormone 
(CRH), stimulating the secretion of luteinizing hormone (LH) and adrenocorticotropic hormone (ACTH) 
from the pituitary. Circulating LH then stimulates the Leydig cells of the testes to produce and secrete 
testosterone (T) (ca. 95% of the total production) [15]. ACTH instead induces the adrenal production of 
weak androgens such as androstenedione (AD), dehydroepiandrosterone sulfate (DHEAS) and 
dehydroepiandrosterone (DHEA) that are subsequently converted to testosterone in peripheral tissues. 
The majority of circulating T is bound to plasma proteins (sex hormone binding globulin) and only a small 
portion remains free. As depicted in Figure 2B, it is commonly accepted that in a healthy prostatic acinus, 
free T diffuses into the stromal cells where it is converted into its active form DHT by the enzyme 
5α-reductase [16]. DHT may signal within the stromal cell or participate in paracrine signaling with 
neighboring luminal cells that lack the internal machinery to produce its own DHT. Once in the cell, DHT 
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can exert its function by binding to the cytoplasmic AR with a dissociation constant of Kd = 10 pM [17], 
accounting as the most potent physiologically active androgen in humans [18]. The DHT/AR interaction 
results in a conformational change of the AR, leading to the dissociation of accessory proteins [19] and 
enabling its translocation into the nucleus, binding to androgen response elements (ARE) in the promoter 
region and initiating target gene transcription [20]. 
The molecular mechanisms initiating and driving prostate cancer are not fully understood, however, its 
development is a multistep process and androgen dependency initially plays a major role, which is 
reflected in the clinics since treatment options include androgen deprivation therapy (ADT). However, in 
some cases, patients can progress to develop androgen independent prostate cancer (or castration 
resistant prostate cancer); a clinical definition generally accepted for ADT refractory prostate cancer 
patients. Some of the currently hypothesized molecular mechanisms promoting prostate cancer are 
shown in Figure 2C [14].  
In the setting of androgen dependent prostate cancer, the transformation into an aggressive phenotype 
is associated with a shift from paracrine towards an autocrine androgen stimulation [21], resulting in the 
activation of the AR in spite of low serum concentrations of testosterone [9, 10, 22, 23] (see Figure 2B). 
However, there are also AR independent mechanisms that drive prostate cancer [24], including increased 
protein expression levels or increased stability of the AR which condition the cancer cell to be 
hypersensitive to lower concentrations of ligands [25], as well as mutations within the ligand binding site 
of the AR that makes it responsive to non-natural AR ligands such as corticosteroids or antiandrogens such 
as flutamide [26-28]. A good example is the well-studied mutation T877A, also present in the prostate 
cancer cell line LNCaP [27]. The AR can also be activated by ligand independent processes such as growth 
factor pathways [29] (referred in this case as “outlaw” receptor [30]). Importantly, a common feature of 
the examples given above is that androgen dependent and independent mechanisms result in the 
dysregulated activation of the AR. 
Alternatively, prostate cancer can be driven by truly AR-independent mechanisms [31], often present in 
AR negative tumors [32]. Specific proteins or pathways such as the anti-apoptotic B-cell CLL/lymphoma 2 
(BCL2) [33], Wnt/β-catenin signaling [34], dysregulated or mutated oncogenes and tumor suppressor 
genes as ERG [35], RB1 and TP53 [36], phosphatase and tensin homolog (PTEN) and NKX3.1 [37], and many 
others have been suggested to play a role in prostate cancer development and progression [38]. 
Prostate cancer is asymptomatic; however, some men may suffer from urinary problems that persist over 
a long period of time [39]. In the clinic, prostate cancer is indicated by high serum PSA levels, a digital 
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rectal exam, and diagnosis is then confirmed with a transrectal biopsy [40]. The clinical stage is then 
assessed microscopically by Gleason score based on pathological scores ranging from 1 to 10. Lower 
scores represent tissue biopsies with small and more differentiated acinar glands, and higher scores 
represent tissue biopsies that are poorly differentiated with irregular and occasional gland formation [41]. 
The prostate cancer treatments used nowadays are mainly radiation therapy, chemotherapy, prostate 
surgery often by radical prostatectomy, but as gold standard ADT is used. ADT includes orchiectomy (the 
removal of the testis), administration of antiandrogens (e.g. flutamide, nilutamide, bicalutamide, 
enzalutamide, cyproterone acetate), androgen synthesis inhibitors (e.g. the CYP17A1 inhibitor 
abiraterone), and antigonadotropins [42]. Nevertheless, for metastatic castration-resistant prostate 
cancer, the effectiveness of current therapies is palliative, with an improvement in overall survival of 2-5 
months compared to placebo [43, 44]. 
As prostate cancer lethality is still very high and clinical biomarkers such as PSA are limited by a lack of 
specificity [45], the molecular mechanisms leading to the formation and progression toward an aggressive 
prostate cancer phenotype as well as the identification of new informative biomarkers urgently need to 
be discovered. 
2.2 Associations of Short Chain Dehydrogenases (SDRs) and Aldo Keto Reductases (AKRs) 
with Cancer  
Several carbonyl reductase enzymes of the Short Chain Dehydrogenase (SDR) and the Aldo Keto 
Reductase (AKR) superfamilies have been shown to be associated with a number of different cancers, 
often hormone-related [46-48]. These enzymes may represent potential prognostic biomarkers or drug 
targets or anti-targets. However, for most of the enzymes identified, a direct mechanistic link with the 
cancer related endpoints highlighted in the studies remains to be elucidated. Table 1 summarizes main 
observations collected regarding the associations of AKRs and SDRs with human cancer in patients. 
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Table 1: Examples of SDR enzymes known to be associated with human cancer, their observed substrates, and intracellular 
localization. References are described throughout the text and complemented by [49]. ER=endoplasmic reticulum. 
Enzyme Type of human cancer Known substrates Intracellular 
localization 
CBR1 lung, breast, intestine, colon, 
uterine endometrial 
xenobiotics, prostaglandin F2α cytoplasm 
3βHSD1 breast, prostate pregnenolone, 
17α-hydroxypregnenolone, DHEA 
ER, mitochondria 
17βHSD1 breast, prostate E1, DHT - 
17βHSD2 breast, prostate E2, T, androstenediol ER 
17βHSD4 breast, prostate DHT, fatty acids peroxisome 
17βHSD12 ovarian, breast E2, very long fatty acids ER 
RDH10 non-small-cell lung cancer, glioma all-trans retinol ER, mitochondria, 
lipid droplets 
RDH11 non-small-cell lung cancer all-trans-retinal, 9-cis, all-trans-
retinol 
ER 
DHRS9 colorectal retinoic acid, progesterone, 
allopregnanolone, 3αAdiol 
peroxisome 
AKR1C1 breast, prostate DHT, progesterone, 
5α-androstanedione 
cytoplasm 
AKR1C2 breast, prostate DHT, progesterone, 
dihydroprogesterone, 
5α-androstanedione 
cytoplasm 
AKR1C3 breast, prostate, adenocarcinoma 
and squamous cell carcinoma in 
the lung, skin squamous cell 
carcinoma, gastrointestinal 
tumors 
DHT, 5α-androstanedione, 
androsterone, prostaglandin E2 
cytoplasm 
17βHSD6 prostate retinoic acid, DHT ER 
 
For example, carbonyl reductase 1 (CBR1) has been found to play a role in tumor metastasis and growth 
[50], possibly by inducing epithelial to mesenchymal transition [51]. This enzyme was decreased with 
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progressive uterine endometrial cancer development [51]. Moreover, decreased expression of CBR1 
promoted ovarian cancer cell proliferation and invasion, and its overexpression decreased cell 
proliferation [52]. Among different metabolites, CBR1 can convert the prostaglandin E2 (PGE2) to 
prostaglandin F2α (PGF2α) [53-55]. PGE2, in the setting of endometrial cancer has been shown to increase 
proliferation through activation of the PGE2 receptor subtype 4 (EP4) [56]. However, CBR1 can convert 
many xenobiotics with higher affinity, and therefore its endogenous role in prostaglandin metabolism is 
questionable [57, 58]. To add to the complexity of the associations between CBR1 and different cancer 
types, CBR1 was shown to be elevated in cancer tissues of lung, breast, intestine, and colon [59]. Clearly 
further research needs to be conducted to understand the link between the expression of CBR1 in 
different cancer types and identify the physiological substrate(s) responsible for the association with 
cancer.  
Another SDR, 3βHSD1, was shown to be a prognostic factor in hormone-dependent estrogen receptor 
(ER) positive breast cancer, indicating a decreased risk of recurrence [60]. Additionally, it has been 
recently shown to be a prognostic biomarker in advanced prostate cancer [61]. Interestingly, a gain of 
function single nucleotide polymorphism (SNP) (1245C; N367T, population frequency 22%) has been 
associated with hereditary and sporadic prostate cancer susceptibility and castration-resistant recurrence 
[62-64]. 3βHSD1 seems to be important in the pathophysiology of steroid hormone-related disease 
because of its crucial role in the synthesis of steroids. In fact, 3βHSD1 has been characterized for the 
following reactions: the oxidation and isomerization of progesterone from pregnenolone, 17OHProg from 
17α-hydroxypregnenolone, and androstenedione from DHEA [65, 66]. The products of these reactions 
may enhance cancer cell proliferation, in particular progesterone by activating the progesterone receptor. 
Other SDRs implicated in hormone-related cancers belong to the 17β-hydroxysteroid dehydrogenase 
(17βHSD) family, which includes enzymes that catalyze the oxidation or reduction of sex steroids on their 
17β-hydroxy or -keto groups. For example, the expression of 17βHSD1 has been positively associated with 
breast cancer. In fact, 17βHSD1 was reported in up to 60% of breast cancer cases [67, 68] and it associates 
with adverse clinical outcome for the patients [67]. In vitro, its expression positively correlates with the 
increased proliferation of breast cancer cell line T47D, estradiol (E2) to estrone (E1) activation, and 
concomitant DHT inactivation [69]. Furthermore, stable overexpression of 17βHSD1 in the breast cancer 
cell line MCF-7 increased migration and altered estrogen receptor α (ERα), ERβ and AR pathways [70]. 
SiRNA 17βHSD1 mediated knock-down in MCF-7 cells further impeded S phase entry from G0-G1, 
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suggesting cell cycle arrest [71]. This body of work offers a convincing mechanism to bridge the association 
observed between 17βHSD1 and breast cancer development. 
Another important 17βHSD, 17βHSD2, has been oppositely shown to be involved in the inactivation of 
estrogens and androgens (catalyzing the conversion of E1 to E2, testosterone to androstenedione, and 
androstenediol to DHEA) [72, 73], The immunoreactive detection of 17βHSD2 is lost in the vast majority 
of breast cancer patients [67], and has polymorphisms associated with breast and prostate cancer 
progression (rs1364287, rs2955162, rs1119933, rs9934209) [74]. However, the 17βHSD2 knock-out 
mouse model suggests a phenotype that was not due to a reduced estrogen or androgen action, but 
instead to an impairment of retinoic acid signaling [75, 76]. To address 17βHSD2’s specific role in different 
types of hormone dependent and independent cancers, molecular mechanisms needs to be further 
investigated. 
17βHSD4, also known as peroxisomal multifunctional enzyme type 2 (MFP-2) because of its peroxisomal 
localization [77, 78], is important in the context of prostate cancer. Specifically, 17βHSD4 mRNA and 
protein overexpression have been associated with prostate cancer mortality [79], and positively correlates 
with the Gleason grading system [80]. Additionally, the presence of a single SNP in 17βHSD4 has been 
associated with the efficacy of androgen-deprivation therapy [63]. Moreover, a recent publication shows 
that 17βHSD4 isoform 2 is the unique isoform able to inactivate testosterone and DHT to AD and 5α-
Androstanedione, respectively, and has been shown to be lost in castration-resistant prostate cancer [81]. 
This enzyme is also known to inactivate estrogens and plays an important in the bile acid metabolism, and 
peroxisomal β-oxidation [78]. However, the expression of 17βHSD4 tissue specific isoforms and its 
peroxisomal localization adds to the complexity of its different physiological role in different organs. For 
example, supporting 17βHSD4’s ability to take on multiple roles in different tissues, in the liver of 17βHSD4 
knock-out mice show a phenotype characterized by the accumulation of very long chain fatty acids and 
branched fatty acids, as well as altered bile acid metabolism [82, 83]. The testis of the same animal showed 
an accumulation of very long chain fatty acids and branched fatty acids which was accompanied by fertility 
problems which may be due to altered androgen metabolism [83].  
17βHSD7 has not been shown to correlate to cancer severity in clinical samples; however, inhibition of 
17βHSD7 using specific small molecules, resulted in the significant shrinking of breast cancer tumors in 
xenograft models [84]. Interestingly, in in vitro models 17βHSD7 seems to activate E1 and inactivate DHT 
into the weak estrogen 5α-Androstane-3β,17β-diol (3β-Adiol) [85]. Inhibition of 17βHSD7 in the ER 
positive breast cancer cell lines MCF-7 and T47D resulted in reduced levels of E2, higher levels of DHT and 
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decreased proliferation accompanied by G0/G1 cell cycle arrest [71, 84]. This body of work offers a 
convincing mechanism to bridge the association observed between 17βHSD7 and breast cancer 
development in xenograft models. 
17βHSD12 overexpression has been associated with poor survival in patients with ovarian cancer [86, 87], 
however its role in breast cancer is contradictory [88, 89]. Silencing 17βHSD12 in ovarian tumor cells 
resulted in growth inhibition and increased apoptosis [86, 87], however its enzymatic activity, converting 
E1 to E2 [90], was not altered in T47D breast cancer cells with 17β-HSD12 knock-down [91]. Supporting 
other substrates to be explanatory for the role of 17β-HSD12 in this breast cancer cell line, it has been 
shown that 17β-HSD12 performs reactions resulting in the elongation of very long chain fatty acids [90, 
92]. Its role in long chain fatty acid metabolism in the setting of breast cancer is further supported by the 
observation that in clinical samples the presence of 17β-HSD12 correlates with COX2 expression as 
opposed to ER expression [87]. 
Another SDR, 17βHSD6, has a misleading nomenclature, since it shows the ability to catalyze oxidation 
reactions at the 3-hydroxy position and not on the 17β-hydroxy group. It has been found to be decreased 
in human prostate cancer biopsies of greater severity according to the Gleason grade [93], and to be 
upregulated in patients undergoing androgen deprivation therapy [94]. This enzyme has been shown to 
activate 3α-Androstanediol (3α-Adiol) in DHT [94], providing a possible mechanism by which it is linked to 
prostate cancer. 
Recently, also the SDRs retinol dehydrogenases RDH10 and RDH11 have been associated with cancer. 
RDH10, an enzyme localized in endoplasmic reticulum, mitochondria and lipid droplets [95], has been 
linked to glioma progression and non-small cell lung cancer [96, 97]. In the glioma cell lines U87 and U251, 
upregulation of RDH10 is associated with a more aggressive phenotype and silencing using specific siRNA 
reduced the survival, proliferation and invasiveness as well as tumor growth in nude mice through the 
regulation of the TWEAK-NF-κB axis [96]. RDH10 has been shown to oxidize all-trans retinol to all-trans 
retinal in overexpressing cells [98], but this observation has not been linked to its role in glioma. In fact, 
the retinoic acid all-trans retinal is a precursor of all-trans retinoic acid that functions as a ligand towards 
the nuclear receptors RARs, RXRs, or PPARβ/-δ. Binding of all-trans retinoic acid to these receptors results 
in the inhibition of cell-cycle progression in a variety of human cancer cells though direct or indirect 
modulation of cyclins, CDKs, and cell-cycle inhibitors [99]. Further, RDH11 was significantly decreased in 
non-small-cell lung cancer [100], and similar to RDH10, it has been reported to metabolize retinoic acids 
[101], but this reaction has not been linked to its role in cancer. Low protein expression of another SDR, 
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DHRS9, correlates with colorectal cancer progression and poor survival, suggesting it also as potential 
prognostic biomarker [102]. Like RDH10 and RDH11, DHRS9 has a role in retinoid metabolism by 
conversion of all-trans retinal to retinoic acid, however with low activity. DHRS9 can also metabolize the 
conversion of allopregnanolone to dihydroprogesterone (DHP) and 3α-Adiol to DHT [103, 104], but it is 
not clear if its ability to metabolize these substrates explains DHRS9’s associations to colorectal cancer. 
AKRs have also been associated with the pathogenesis and progression of several types of cancer. 
Overexpression of AKR1C1 and AKR1C2 have been observed in invasive bladder cancer [105, 106], breast 
cancer [107], and prostate cancer [108, 109]. AKR1C1 and AKR1C2 appear to have a major role in androgen 
metabolism, where they function as 3α-hydroxysteroid dehydrogenases inactivating the AR ligand DHT. 
in prostate cancer cells. If these mechanisms would be physiologically relevant in these prostate cancer 
samples because of their overexpression, you would expect these enzymes to act as tumor suppressors 
but in respect this association these mechanisms do not correlate [110]. However, in breast cancer cell 
lines AKR1C1 and AKR1C2 mainly affect progesterone signaling by deactivating progesterone, as 
suggested by overexpression and siRNA mediated silencing studies in T47D and MCF-7 cells [107].  
On the other side, AKR1C3 overexpression has been associated with many cancer types: prostate cancer 
[17, 47, 111], breast cancer [17], adenocarcinoma and squamous cell carcinoma in the lung [112], skin 
squamous cell carcinoma [113], cervical cancer [114], and gastrointestinal tumors [115]. Specifically, 
AKR1C3 overexpression seems to be a promising biomarker for prostate cancer progression [116, 117]. 
Stable expression of AKR1C3 in the androgen-independent prostate cancer cell line, DU145, increased its 
proliferation [118]. Alternatively, siRNA depletion of AKR1C3 decreased DHT-dependent MCF-7 breast 
cancer cell growth [119]. These results do not clearly define whether AKR1C3 exerts its cancer promoting 
effects by hormone dependent or independent mechanisms and this could be partly explained by its 
ability to react with multiple substrates in different tissues. For example, AKR1C3 catalyzes the conversion 
of prostaglandins H2 and D2 into PGF2α and 9α,11β-PGF2α, respectively [120], however, can also 
metabolize the androgens testosterone to Δ4-androstene-3,17-dione [121] and deactivates DHT, and as 
well estrogen and progesterone [48]. Positive promoter regulation of the oncogene lipocalin 2 following 
AKR1C3 downregulation, decreased migration and invasiveness and changed cytoskeleton dynamics in 
cervical cancer cells SiHa and 293T, but this has not been linked with the enzymatic activity of AKR1C3 
[114]. Many potent and selective inhibitors of AKR1C3 have been developed and described; most still 
require preclinical optimization [122], but one is currently prepared in phase I [personal communication]. 
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Taken together, the mechanisms underpinning the numerous SDR and AKR associations with cancers are 
complex and further research is required to enable to understand the usefulness of these enzymes as 
potential novel clinical targets, anti-targets, or biomarkers. The reasons why a number of the enzymes 
belonging to the two super-families, SDR and AKR, are so selective for specific substrates and yet others 
can be rather promiscuous, can partially be explained by their biochemical characteristics, which will be 
discussed in detail in the following subchapter.  
2.3 Carbonyl Reductases of the SDR and AKR Families 
The short-chain dehydrogenase reductase (SDR) superfamily [Figure 3] is one the largest protein classes 
of oligomeric oxidoreductases. There are currently a total of 163,120 identified members as in Uniprot, 
and they are present in all forms of life [123]. They are subdivided in the following subfamilies; the classical 
SDR folds, subdivided into three clusters C1 (yellow), C2 (green) and C3 (blue), the extended SDR fold 
(violet), and the atypical members (dark pink). 
 
Figure 3: Adapted from [124]: SDR superfamily divided in “classical folds” clustered in C1, C2 and C3, “extended fold”, and “atypical 
members”. Short branch lengths represent proteins that are phylogenetically close, while longer branch lengths indicate broader 
evolutionary relationship. 
SDRs can be cytosolic, microsomal or mitochondrial, and show catalytic activities toward a wide range of 
substrates (e.g. retinoids, steroids, polyols, fatty acids derivatives, prostaglandins, and xenobiotics), with 
enzymes showing also multifunctionality [123, 125]. More than 70 SDR members have been identified in 
the human genome [46, 126]. They are implicated in a wide range of physiological functions, with several 
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exerting an essential role in the synthesis and inactivation of steroid hormones. The active steroids in their 
target tissues can activate their respective nuclear receptors leading to target gene expression [127]. 
Additionally, SDRs have an important toxicological role in phase I or functionalization metabolism, by 
inactivating potentially toxic xenobiotics or by activating relatively harmless xenobiotics into reactive 
metabolites that may be conjugated and excreted from the body [128]. Moreover, an increasing number 
of single-nucleotide poly-morphisms have been identified in SDR genes, and a variety of inherited 
metabolic diseases are linked to genetic defects in SDR genes [129]. However, currently the physiological 
roles of most of the SDRs are unknown or inadequately characterized with structural information available 
for only approximately 20 members [127]. This knowledge gap has driven the search to uncover their 
physiological substrates and characterize their molecular mechanisms. The SDRs currently characterized 
target a broad substrate spectrum, which can be explained by the relatively low sequence identity 
between different SDR enzymes (15–30%). SDRs only inherit a few conserved sequence regions (e.g. 
glycine-rich motif (TGxxxGxG amino acid sequence) or a catalytic triade/tetrade that form the active site 
(S-Y-K/N-S-Y-K amino acid sequence)) [123, 124, 130]. In contrast, the tertiary structure is similar [131], 
with the highly conserved Rossman-fold responsible for the NAD(P)(H) cofactor binding site that 
participates in the catalysis in the ligand binding region.  
Besides the SDRs, the AKR superfamily contains many carbonyl reductases. The AKRs share a common 
catalytic reaction mechanism and consist of approximately 40 multi-functional enzymes [132]. Similar to 
the SDRs, several AKRs are known to play a role in steroid metabolism but they have a broad range of 
substrates. The human members of the AKR1C subfamily comprise four monomeric cytosolic 
NADP(H)-dependent enzymes: AKR1C1, AKR1C2, AKR1C3 and AKR1C4 [48, 133]. In contrast to the SDRs, 
they share an increased sequence identity of ca. 86% and consist of a basic structure containing α-helices 
and β-strands repeated 8 times to form a barrel like tertiary structure [134]. Interestingly, AKR1C4 is 
liver-specific, AKR1C3 is mostly prominent in the prostate and mammary glands, and AKR1C1 and AKR1C2 
are the major isoforms in the testis, brain, and are also highly expressed in the lung and liver [48]. 
Members of the SDR and AKR superfamilies often exert their action toward a specific ketone or aldehyde 
moiety of a carbon of the common basic sterane structure of the steroids (Figure 4, carbon positions 
numbered). In some cases, the enzymes name refers to the reaction toward a moiety on a specific carbon 
position (e.g. 11βHSDs act on carbon 11 leading toward a hydroxyl substituent on a beta plane of the 
steroid). However, names can be misleading as there may be activity toward multiple carbon positions to 
which the name does not reflect the preferred reaction.  
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Figure 4: Common steroid structure with numbered carbons and ring letters used for nomenclature and three rotational plans x, 
y, z of the steroid molecule. 
The steroidal core structure consists of three cyclohexane rings (A,B,C) and one cyclopentane ring 
(D) fused together [135]. Because of the molecular symmetry of this structure, SDR and AKR enzymes 
often show ligand promiscuity by binding carbonyl or hydroxyl groups on carbons opposite on specific 
symmetry plans (x, y or z) of the structure [136]. Usually, AKRs work at the 3-, 17-, and 20-ketosteroid 
positions [137], instead SDRs work either similarly on the same positions, or on the 11- or 7- positions. A 
good example is 11βHSDs that acts preferentially toward the carbon in 11-position, but also toward 7-
position for 7-ketocholesterol and 7-ketolitocholic acid [138]. The similar catalytic mechanism for both 
SDRs and AKRs is a bi-bi kinetic in which the cofactor binds first and leaves last in two sequential 
isomerization steps [110], as depicted in Figure 5.  
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Figure 5: The reaction mechanism catalyzed by carbonyl reduction by SDR and AKR enzymes. A. Under reduction, the cofactor 
NAD(P)H binds and donates a proton to the carbonyl residue of the substrate, that binds to the tyrosine (Tyr) of the active site of 
the enzyme AKR or SDR accepting another proton. B. Under oxidation, the cofactor NAD(P)+ accepts a proton from the hydroxy 
group of the substrate, and tyrosine (Tyr) of the active site of the enzyme donates electrons to create a carbonyl group. 
It is generally believed that the enzymatic preference toward dehydrogenation or reduction in vivo is 
determined by the cellular localization, pH conditions (reduction is more likely to happen in acidic 
conditions, instead oxidation is more likely to happen in alkaline conditions), cellular compartment 
concentration ratio of cofactor NA(P)D+/NAD(P)H [139], as well as substrate and product availability. 
Usually, because of the prevalence of oxidised NAD(H), NAD(H)-dependent enzymes with cytosolic 
localization will likely oxidize their substrates; on the other side and due to abundance NADPH in the 
cytosol, NADP(H)-dependent enzymes localized to cytoplasm will likely act as reductases [49]. 
A schematic overview of the synthesis and inactivation of steroid hormones with the key reactions 
performed by HSDs (in orange) and AKRs (in green) is depicted in Figure 6. These enzymes work 
concomitantly with cytochrome P450 (CYP) and 5α reductases (SDR5) enzymes [140]. 
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Figure 6: Schematic overview of steroidogenesis and androgen synthesis according to [17, 137, 140, 141].  
2.4 The “Orphan” Enzyme DHRS7 
The SDR family member 7 (DHRS7), also named retSDR4, and according to the systematic nomenclature 
SDR34C1, is a poorly characterized microsomal enzyme, which is a member of the cluster C3 (Figure 3). 
The DHRS7 gene is located on human chromosome 14q23.1 and encodes two isoforms produced by 
alternative splicing: the isoform 1 consists of 339-amino acid enzyme (ca. 38 kDa) and the isoform 2 
consists of 289-amino acids and misses the amino acids 1-50 of isoform 1 at the N-term (ca. 32 kDa). 
Isoform 1 with its sequence, predicted Rossman fold, active site, and intermembrane domain regions is 
shown in Figure 7.  
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Figure 7: Predicted 2D structure of DHRS7. Amino acid sequence of DHRS7 from N- to C- term (A), with predicted intermembrane 
domain (Rossman Fold (RF) in green and active site (AS) in yellow adapted from [125], and intermembrane domain in violet based 
on TMHMM prediction [142], and relative 2D structure (the positively charged amino acids close the membrane spanning domain 
are labelled in red, the negative amino acids are labelled in blue) (C). 
DHRS7 was first cloned from the retina [143], and its mRNA is present in various tissues including the 
retina, liver, kidney, adrenal gland, digestive tract, thyroid, being particularly high in prostate and salivary 
gland [144]. At the protein level, DHRS7 is particularly high in thyroid, liver, intestine, adrenal gland and 
prostate (but not measured in the salivary gland) [145]. Interestingly, DHRS7 is localized to the membrane 
of the endoplasmic reticulum, as shown in endoplasmic reticulum preparation [146], in human prostate 
cell lines [147], as well as in heart muscle and the spleen of the rat [148, 149]. However, nuclear rim 
staining in rat liver has also been observed [148, 149]. 
Reduced expression of DHRS7 was observed in the epithelial cells of prostate cancer [150], and later 
confirmed in biopsies of greater severity as measured by Gleason score [147]. SiRNA depletion of DHRS7 
resulted in enhanced proliferation, migration and decreased adherence in a prostate cancer cell line [147]. 
Moreover, an upregulation in DHRS7 protein was shown in prostate cancer LNCaP cells treated with miR-
663, which induced proliferation with an increased number of cells in S-phase cell cycle [151]. They 
investigated DHRS7 as it was suggested to have a sequence that would be mutually complementary to 
miR-663, a potential player in the transition to a castration resistant prostate cancer phenotype. 
Additionally, an abstract indicated that the androgen receptor positive breast cancer cell line MCF-7 [152] 
transfected with DHRS7 was shown to have an increased number of cells in the S-phase and DHRS7 
depletion using shRNA transfected into the MCF-7 cell line increased the number of cells in the G2/M 
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phase of the cell cycle [153], suggesting cell cycle arrest and cell cycle downregulation, respectively. They 
also observed downregulation of DHRS7 in breast infiltrating carcinoma compared to breast cancer in situ. 
However, detailed information reporting these results are not accessible. 
Taken together, the role of DHRS7 in cancer through androgen receptor dependent or independent 
mechanisms is still unclear. Based on the mechanisms of metabolism of other SDRs and the proliferation 
effects observed upon its silencing, DHRS7 may play a role in androgen receptor dependent prostate 
cancer by decreasing the levels of active androgens, eventually leading to diminished nuclear 
translocation and activation of the androgen receptor (AR); on the other hand, it might contribute to the 
metabolism in castration resistant prostate cancer (CRPC), promoting cancer progression, even in the 
absence of testicular or adrenal androgens. This could happen through the production of a ligand that 
would inhibit prostate cancer progression. Its role as possible tumor suppressor needs to be further 
elucidated. 
In addition to prostate cancer, altered expression of DHRS7 has been observed in other human diseases, 
animal and cellular models. However, the following observations were not the primary focus of the 
publications. An increase in DHRS7 mRNA was observed in the muscle of patients with diabetes mellitus 
type 2 [154]. Additionally, DHRS7 was upregulated following fatty acid treatments in MIN6 insulinoma 
cells [155]. Moreover, altered expression of DHRS7 has been observed in the liver of rat and mouse models 
of the following conditions/diseases: DHRS7 mRNA was upregulated during liver regeneration following 
hepatectomy [156], and DHRS7 mRNA was downregulated in streptozotocin induced diabetic rats 
following resveratrol treatment [157]. Furthermore, DHRS7 protein expression was increased in the liver 
of protein kinase C (PKC) knock-out mice when fed with high-fat diet [158]. Instead, DHRS7 mRNA 
upregulation was observed also under free fatty acids treatment in goose hepatocytes in vitro [159].These 
observations could be due to a cellular adaptation in response to altered fatty acid metabolism or 
inflammation changes. 
Interestingly, DHRS7 mRNA was determined to be ca. 180 times higher in male compared with female 
obese ZSF1 rats (a model of type 2 diabetes) [160], suggesting sex related effects. As well, DHRS7 mRNA 
increased ca. 30 fold and 20 fold in mouse liver treated with the murine constitutive androstane receptor 
(CAR) agonist TCPOBOP (1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene, 3,3ʹ,5,5ʹ-Tetrachloro-1,4-
bis(pyridyloxy)) and the pregnane X receptor (PXR) ligand PCN (pregnane-16α-carbonitrile), respectively 
[161]. CAR and PXR are nuclear receptor which play an important role for the elimination of cholesterol 
and xenobiotic metabolism [162]. 
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As shown in Figure 3, the phylogenetically closest SDR genes to DHRS7 are the poorly characterized 
DHRS7b (SDR32C1) and DHRS7c (SDR32C2), the well characterized 11β-HSD1 (SDR26C1), the sparsely 
characterized 17β-HSD12 (SDR12C1) and well characterized 17β-HSD3 (SDR12C2) [163]. DHRS7B loss of 
function studies in mice showed this protein to be important for adipogenesis and consequent PPARγ 
activation [164], whereas DHRS7C, whose expression is enriched in adipose tissue and muscles, seems to 
have a role in maintaining intracellular Ca2+ homeostasis, its overexpression in muscle activates mTORC2 
enhancing glucose metabolism and muscle performance, and works as an all-trans-retinol dehydrogenase 
[165-167]. Further, 11β-HSD1 is well known to metabolize the inactive cortisone to the active steroid 
cortisol and to have a role in the regulation of local tissue glucocorticoid concentrations [168-172]. 
17β-HSD12 seems to be important for the fatty acid elongation cycle by regulating arachidonic acid 
synthesis by the reduction of 3-ketoacyl-CoAs [173, 174]. Finally, 17β-HSD3 metabolizes androstenedione 
into the active androgen testosterone [175, 176]. 
In vitro assays reported that DHRS7 metabolizes endogenous substrates bearing a carbonyl group; on a 
steroid structure (estrone, cortisone, Δ 4-androstene-3,17-dione), toward the retinoid all-trans-retinal, 
and on exogenous substances (1,2-naphtoquinone, 9,10-phenantrenequinone, benzoquinone, nicotine-
derived nitrosamine ketone (NKK), isatin, nitrosamine 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone), 
3,4-hexanedione, and diphynylethandione), with preference toward the cofactor NADP(H) [145, 146]. 
However, these activities were shown with supraphysiologic concentrations of candidate substrates 
toward the purified DHRS7, and they were calculated mainly with indirect cofactor measurements 
methods. Michaelis–Menten kinetic parameters were calculated only for all-trans-retinal leading to low 
affinity (Km = 24.3 mM, Vmax = 270.3 nmol/ (min x mg)) [145]. However, DHRS7 is still considered an 
“orphan" enzyme, i.e., an enzyme whose endogenous substrates are not known, as these in vitro 
observations do not provide as yet convincing evidence for a physiological function of the enzyme. 
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2.5 Deorphanization 
To “deorphanize” proteins is a crucial step to understand their physiological roles in health and disease 
and to evaluate and understand adverse and/or beneficial unintentional “off-target” drug effects. 
Unfortunately, the exciting opportunity to characterize the function of these “orphan” proteins remains 
a major challenge, and especially for membrane proteins, such as many of the SDRs, which are embedded 
in the organelle bilayers or the cell surface [177].  
Approaches to deorphanize SDRs vary from targeted methods such as sequence comparison, structural 
insight with the help of crystallization and in silico modelling, as well as assays were by targeted substrates 
are used. On the other hand, with the absence of a priori knowledge of substrates, untargeted high 
throughput biology methods (DNA and RNA microarrays, proteomics, lipidomics and metabolomics) are 
often chosen [177-179]. A summary of the current techniques is depicted in Table 2.   
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Table 2: Adapted from [179]: Strategies for identification of new enzyme functions and metabolic pathways of orphan enzymes. 
Techniques 
available 
Enzyme/ 
genetic 
requirements 
Purposes Advantages Inconveniences Key technologies 
In vitro activity-
based profiling 
Purified, 
homogeneous 
enzyme 
Track enzyme-
induced changes in a 
complex metabolite 
extract 
High throughput. No a priori knowledge of 
substrates and products, and type of 
chemistry catalyzed.  
Purification of enzyme to homogeneity. Culture 
of host species. Recombinant expression might 
lead to loss of native partner or post-translational 
modifications required for activity. Substrates 
might not be present at quantifiable levels in 
molecular extract. 
Protein 
purification, 
LC/GC/CE-MS, 
NMR, libraries of 
spectral data 
Ex vivo 
metabolomics 
profiling – 
genetically 
modified/chemicall
y treated organism 
None or verified 
genetic knock-
out/over-
expression 
strain of 
organism of 
interest 
Identify one 
enzymatic reaction or 
pathway that is 
disturbed upon 
deletion/alteration of 
levels of a particular 
enzyme 
High throughput. No a priori knowledge of 
substrates and products, and type of 
chemistry catalyzed. No enzyme 
purification required. Preservation of 
native enzyme partners and post-
translational modifications. 
Culture of host species. Candidate substrates and 
products might constitute secondary effect 
changes. Levels of substrates/products might be 
tightly controlled and not change. Chemical with 
a clear phenotype must be available. 
Genetic 
manipulation 
LC/GC/CE-MS, 
NMR, libraries of 
spectral data 
Activity-based 
protein profiling 
None Track of a specific 
class of enzymes 
towards a probe 
High throughput. Identify active enzymes. 
Highly specific for chemistry and enzyme 
class. No enzyme purification required. 
Preservation of native enzyme partners 
and post-translational modifications. 
Culture of host species. Highly selective and 
specific probe need. Subsequent identification of 
physiological substrates. 
Chemical probe, 
gel 
electrophoresis, 
imaging, protein 
identification 
Computational 
enzymology 
High-resolution 
structure 
Identification of 
putative substrates, 
products and 
intermediates based 
on structural 
determinants. 
High throughput in silico approach. No a 
priori knowledge of substrates, and type 
of chemistry catalyzed. 
Relies on strength of ligand docking software and 
accuracy of crystal structure. Identified 
compounds might not exist in the host organism. 
Docking virtual 
libraries, 
computation 
X-ray 
crystallography 
Purified, 
homogenous 
enzyme 
High resolution 
structure 
Identity trough co-
purified small 
molecules 
Tightly bound ligands can directly lead to 
the identity of 
substrates/products/intermediates 
Co-purification with tightly bound metabolite. 
Enzymes must be crystallized, and structure 
solved at high resolution. 
Protein 
purification, 
crystallization, 
structure, 
determination 
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3 Aims of the Thesis 
Mechanisms leading to prostate cancer development and progression are heterogeneous and not clearly 
understood; therefore, it remains a major challenge to fill the knowledge gaps to help improve the therapy 
of patients. Reduced expression of DHRS7, a member of the SDR family, is associated with prostate cancer 
progression and severity. Loss of DHRS7 through siRNA depletion caused prostate cancer cell lines to 
exhibit a more aggressive phenotype. However, as with many other SDRs associated with cancer, the 
specific mechanisms underlying the observational phenotype have not been characterized. Particularly, it 
remains unclear if DHRS7 plays a role through androgen -dependent or -independent mechanisms. 
Experiments conducted using purified DHRS7 identified several potential low affinity endogenous and 
exogenous substrates. However, the candidate substrates were not tested in biological systems, the 
activity assays were mainly performed using supraphysiological concentrations, and they were measured 
via indirect cofactor consumption measurements. Additionally, the known endogenous physiological 
actions of these candidates provide no explanation for the functional effects observed in the prostate 
cancer cell lines. 
The work undertaken in this thesis was designed to provide further insights into the function of DHRS7. In 
a first part, data will be presented showing the in vitro activity of the “orphan” enzyme DHRS7 toward 
selected substrates. In addition, further characterization of the observed association between the 
expression of DHRS7 and cancer progression will be explored using molecular and cell biology techniques 
in cancer cell lines endogenously expressing DHRS7. The following experimental aims have been 
addressed: 
(1) To identify potential DHRS7 substrates. Recombinant and stable human DHRS7 expression in 
intact HEK-293 cells was used to test DHRS7 activity towards selected substrates. Candidate 
substrates were chosen based on literature search, phylogenetic similarity of DHRS7 to other SDR 
enzymes, and the potential of the candidates to stimulate cellular proliferation. Analytical 
methods used to identify and quantify the analytes comprised mass spectrometry and 
radioactivity assays. Functional relevance of promising relevant activity for proliferative effect in 
prostate cancer was further explored with androgen receptor transactivation assays in 
overexpressing cells. Furthermore, an activity assay using cell lysates and microsomal endoplasmic 
reticulum preparation of stably transfected DHRS7 cells was used to validate previous results and 
screen for new potential substrates and inhibitors. 
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(2) To understand potential physiological roles of DHRS7. Human cell lines endogenously expressing 
DHRS7 derived from breast and prostate cancers were used to characterize functional and 
phenotypic effects of DHRS7 following siRNA depletion. Techniques used range from cancer cell 
phenotypic assays, disruption of adrenal steroidogenesis assay, and an improved time-dependent 
untargeted proteomics method based on LC-MS/MS analysis. Some of the altered proteins 
detected through proteomics analysis were validated by cell cycle analysis, as well as western blot 
and immunofluorescence analyses. Some of these altered proteins following siRNA mediated 
DHRS7 knock-down raised new hypotheses on phenotypical changes denoting increased cancer 
aggressivity.  
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4 Chapter 1: Toward the Identification of Substrates of DHRS7 
As it is the case for other SDRs and AKRs enzymes, a clear explanation for the mechanism of action that 
underpins the association of DHRS7 with cancer remains to be uncovered. DHRS7 is an “orphan” enzyme 
and may exert metabolic activity toward substrates present in the tissue of interest, which may, in part, 
be responsible for the observed aggressive cancer phenotype. The manipulation of DHRS7 may contribute 
to clinical adverse health effects, since DHRS7 showed the potential to be a tumor suppressor gene in 
prostate cancer. Therefore, it is important to identify and characterize the substrates and potential non-
selective inhibitors of DHRS7. In this first chapter, the aim was to characterize the in vitro activity of 
potential physiologically relevant substrates of DHRS7. 
As highlighted in chapter 2.5 of the introduction, “deorphanization” remains a major challenge and the 
strategy selected to undertake this difficult task must be planned carefully according to the knowledge 
available on the enzyme of interest. Regarding DHRS7, the following strategies were taken into 
consideration and led to the selection of a targeted “deorphanization” method: 
- DHRS7 is an endoplasmic reticulum membrane bound enzyme. This makes a x-ray crystallization 
approach with further structural studies very difficult as with other membrane bound proteins [177]. 
However, with this approach, an important challenge with respect to the protein is to obtain high 
quantity and purity following overexpression and isolation from the endoplasmic reticulum, as well 
as solubilization and reconstitution of the protein while preserving the macromolecular organization 
[180]. The latter aspect is specifically tedious regarding membrane proteins as it must be performed 
in a physiological buffer and this leads to complications in the x-ray analysis. Because of these 
complexities a crystallization approach was not considered in the present project.  
 
- DHRS7 is a member of the SDRs superfamily. SDRs enzymes have a broad substrate spectrum, share 
low sequence similarity, and are in most cases also able to convert multiple substrates [129]. Thus, 
phylogenetically related and well characterized members, such as 11βHSD1 (sequence identity (38%) 
and similarity of alignment (57%)), may not necessarily be structurally similar enough to set up a in 
silico tool for DHRS7 substrate prediction and substrate docking studies. Moreover, substrate 
docking based on publicly available databases, such as the human metabolome database (HMDB, 
www.hmdb.ca), is only successful if the predictable active site shows clear spatial hints for the 
docking of substances. This approach was previously used by our group but showed to be too 
speculative to generate valuable hypotheses for selection of substrates to screen [unpublished data]. 
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Nevertheless, functional redundancy regarding 3D structure could translate in activity towards 
similar substrates between 11bHSD1 and DHRS7 and represents a valuable point of departure for 
selecting compounds to test. Consequently, the known substrate of the well-characterized and 
phylogenetically related 11βHSD1 and 17βHSD3, the glucocorticoid cortisone and the androgen 
androstenedione, respectively, represent interesting candidates to test.  
 
- DHRS7 shows reductive activity towards carbonyl compounds in the presence of a cofactor and 
behaves as tumor suppressor in prostate cancer cell lines. Specifically, a recent study based purely 
on activity assays with purified DHRS7 to test potential substrates revealed that DHRS7 catalyzed 
the reduction of cortisone to cortisol, androstenedione to testosterone, and all-trans-retinal to all-
trans-retinol [145, 146]. However, the affinities calculated in these studies were at 
supraphysiological concentrations. Nevertheless, it is important to note that measurements of 
activities of purified membrane enzymes such as DHRS7 have their disadvantages; one being the 
potential for inaccurate folding during expression and purification steps, which may result in 
potential loss of activity (according to [145, 146] DHRS7 was purified from microsomes of DHRS7 
overexpressed Sf9 insect cells), another disadvantage being suboptimal conditions of the activity 
measurements. Taking these limitations into account, studies carried out in the DHRS7 
endogenously expressing prostate cancer LNCaP cell line do not support or do not clearly 
demonstrate activity towards the previously mentioned reductive reactions. In fact, DHRS7 has been 
shown to be a potential tumor suppressor in prostate cancer by increasing proliferation and 
migration and decreasing adhesion in LNCaP under siRNA mediated downregulation [147]. Current 
evidence does not indicate the potential for one of the afore mentioned substrates to be linked with 
DHRS7 in LNCaP, since: 
o cortisone and cortisol addition showed no proliferation effects in LNCaP [181]; 
o testosterone, the potential product of the reaction by reduction to androstenedione, 
causes an increase rather than a decrease in the proliferation of LNCaP cells [182]; 
o all-trans retinal and the reductive product all-trans retinol are not known for their 
proliferation effects in LNCaP. However, all-trans retinoic acid (a product of all-trans 
retinal) and its analogues, showed divergent proliferation effects in LNCaP [182, 183] with 
a biphasic profile [182] that seems to be dependent on the passage of the cells [184]. 
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For these reasons, and in addition to the glucocorticoid cortisone and the androgen 
androstenedione, the retinoid all-trans retinal was also validated in activity assay with DHRS7 in 
low concentrations ranges. 
- DHRS7 is expressed in many organs of the human body with increased protein expression in tissues 
involved in exocrine and/or endocrine metabolism. The protein expression patterns of DHRS7 
suggest that potential substrates may be hormones, chemicals involved in or a part of exocrine 
secretion, or chemicals important for epithelial phenotype and/or differentiation. Thus, as for other 
SDRs, glucocorticoids, steroidal hormones, prostaglandins, and retinoic acids could all represent 
potential candidates to investigate. Regarding these classes of substrates, in addition to cortisone, 
androstenedione, and all-trans retinal, the androgen DHT and progesterone – both important 
metabolites in the context of prostate cancer, will be tested. Interestingly, both DHT and 
progesterone have been shown to increase proliferation in LNCaP cells by activation of their 
respective nuclear receptors [185-190]. Additionally, other substrates which share steroidal 
biochemistry symmetry will be further explored (see Figure 4 of the introduction). 
 
- Immortalized human cell lines are biological models expressing functional transport systems and 
they are metabolically active. Human cell models allow us to study the metabolism of substrates in 
the presence of cofactor at physiological concentrations in a cellular environment. However, it is 
important to understand their limitations with respect to the substrates tested. For example, for an 
activity assay to work the substrate must be transported across the plasma membrane and be able 
to directly access the intracellular compartment in which the tested enzyme resides by avoiding 
binding to intracellular proteins (e.g. DHRS7 is expressed at the endoplasmic reticulum membrane). 
Metabolites unable to pass through cell membranes must be tested using protein preparations. 
Moreover, the candidate substrates should not be metabolized by other enzymes in the chosen cell 
model. For these reasons, different biological systems are used and validated to study enzyme 
activity. 
 
These aspects set the basis for the following planned strategy summarized as a workflow in Figure 8. 
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Figure 8: Workflow of strategy attempted to characterize in vitro DHRS7 activity. 
The first section of this chapter presents a published article showing activity assays in intact HEK 293 cells 
ectopically expressing human DHRS7 (validated in the result section 4.2.2.1) for the candidate substrates 
cortisone, androstenedione and the main AR ligand DHT. All experiments where performed at a 
physiological concentration and LC-MS/MS and radioactivity following TLC separation (further referred 
only as radioactivity) methods were used to analyze the activity of DHRS7. DHT showed the most promising 
potential to be a relevant substrate and was investigated further using an AR transactivation reporter 
assay. Results suggest that DHRS7 may potentially play a protective role by reducing the AR activity in the 
presence of DHT. Moreover, the orientation of microsomal DHRS7 was tested and confirmed that the 
active site faces the cytoplasm and not the lumen of the endoplasmic reticulum. 
With the previous publication, in vitro overexpression assays showed that DHRS7 possess characteristics 
of a 3α/20β reductase toward steroidal structures showing similarity to AKR1C enzymes, especially 
AKR1C2, and that DHRS7 metabolized the active androgen dihydrotestosterone (DHT) to the inactive 
3αAdiol. In the second section of this chapter, to further characterize DHRS7’s metabolism toward steroids 
in the 3α/20β positions, the DHRS7 HEK 293 cell line was used for in vitro screenings. Results are presented 
for four compounds with the potential for metabolism in the 3α/20β positions using intact cells and LC-
MS/MS analysis. 
Next, the model compound DHT was used to develop an optimized DHRS7 lysate activity assay to validate 
previous observations and to be used as a screening tool for the discovery of new substrates and inhibitors 
of DHRS7. The lysate activity assay avoids a priori development of an analytical LC-MS/MS method for 
quantification of the each of the studied metabolites, which is low throughput, time consuming, and 
expensive. Using the screening tool, results are presented from 24 candidate substrates selected based on 
 33 
 
the publication and results presented in this chapter, the compounds potential biochemistry activity 
according to literature, and xenobiotics having a possible role in cancer. 
Finally, data will be presented showing our attempts to calculate an apparent Km for DHT using lysate and 
microsomes isolated from the DHRS7 HEK 293 cells and analyzed by radioactivity.  
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4.1 Published article: DHRS7 (SDR34C1) - a New Player in the Regulation of Androgen 
Receptor Function by Inactivation of 5α-Dihydrotestosterone? 
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A B S T R A C T
DHRS7 (SDR34C1) has been associated with potential tumor suppressor effects in prostate cancer; however, its
function remains largely unknown. Recent experiments using purified recombinant human DHRS7 suggested
several potential substrates, including the steroids cortisone and Δ4-androstene-3,17-dione (androstenedione).
However, the substrate and cofactor concentrations used in these experiments were very high and the
physiological relevance of these observations needed to be further investigated. In the present study,
recombinant human DHRS7 was expressed in intact HEK-293 cells in order to investigate whether glucocorti-
coids and androgens serve as substrates at sub-micromolar concentrations and at physiological cofactor
concentrations. Furthermore, the membrane topology of DHRS7 was revisited using redox-sensitive green-
fluorescent protein fusions in living cells. The results revealed that (1) cortisone is a substrate of DHRS7;
however, it is not reduced to cortisol but to 20β-dihydrocortisone, (2) androstenedione is not a relevant substrate
of DHRS7, (3) DHRS7 catalyzes the oxoreduction of 5α-dihydrotestosterone (5αDHT) to 3α-androstanediol
(3αAdiol), with a suppressive effect on androgen receptor (AR) transcriptional activity, and (4) DHRS7 is
anchored in the endoplasmic reticulum membrane with a cytoplasmic orientation. Together, the results show
that DHRS7 is a cytoplasmic oriented enzyme exhibiting 3α/20β-hydroxysteroid dehydrogenase activity, with a
possible role in the modulation of AR function. Further research needs to address the physiological relevance of
DHRS7 in the inactivation of 5αDHT and AR regulation.
1. Introduction
DHRS7 belongs to the large family of short-chain dehydrogenase/
reductase (SDR) enzymes, with at least 75 members in the human
genome that are involved in various essential physiological functions
[1,2]. SDRs share a conserved NAD(P)(H) cofactor binding region, the
so-called Rossmann-fold, a catalytic tetrad Asn-Ser-Tyr-Lys motif in the
majority of the members, and a dimerization region [3]. They are
involved in the metabolism of a wide array of substrates including
steroids, bile acids, oxysterols, fatty acids, retinoids, carbohydrates and
xenobiotics, and they typically share low sequence identity between 20
and 30%. To date, the functions of about half of all SDR enzymes is still
unknown and uncovering their functions remains a challenge.
The physiological function of DHRS7 still remains to be elucidated.
Nevertheless, reduced DHRS7 expression has been found in prostate
cancer [4,5], and knock-down of DHRS7 in human LNCaP prostate
cancer cells enhanced cell proliferation and migration but reduced cell
adhesion [5], suggesting a role as tumor suppressor. DHRS7 was shown
to be an endoplasmic reticulum (ER) membrane protein, and its
catalytic moiety proposed to face the ER-luminal compartment [6].
Previous studies reported the expression in Sf9 cells and purification of
recombinant human DHRS7 [7] and proposed several endogenous
(cortisone, estrone, Δ4-androstene-3,17-dione (androstenedione), all-
trans-retinal) and exogenous substrates (diphenylethanedione, 3,4-
hexanedione, metyrapone, isatin, the tobacco constituent NNK, oxcar-
bazepine, 1,2-naphthoquinone) [6,8]. However, so far, the relevance of
DHRS7 in the metabolism of these substrates was not further studied.
The present work aimed to further characterize possible physiolo-
gically relevant steroidal substrates of DHRS7 that might play a role in
the observed inhibitory effects on prostate cancer cell proliferation and
tumor aggressiveness. A possible role of DHRS7 in the interconversion
of cortisone/cortisol was studied due to the anti-proliferative, pro-
apoptotic effects of cortisol, whereas a possible role in the interconver-
sion of androstenedione/testosterone and 5α-dihydrotestosterone
(5αDHT)/3α-androstanediol (3αAdiol) was assessed due to the mod-
ulation of androgen receptor (AR) activity and prostate cancer cell
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proliferation/aggressiveness. As the reaction direction of SDR enzymes
depends on the intracellular cofactor availability, an intact cell system
was used for the activity experiments. Finally, regarding its potential
AR modulatory function, the membrane topology of DHRS7 was
revisited.
2. Experimental procedures
2.1. Molecular cloning and expression constructs
The full-length untagged (DHRS7), C-terminally (DHRS7-FLAG) and
N-terminally (FLAG-DHRS7) FLAG-tagged DHRS7 constructs were
produced by PCR amplification of the coding sequence from a donor
vector and subcloned into pcDNA3 vector (Life Technologies, Zug,
Switzerland). PCR amplified untagged (AKR1C2) and C-terminally
FLAG-tagged AKR1C2 (AKR1C2-FLAG) were also cloned into pcDNA3
vector. All constructs were verified by sequencing. Untagged hexose-6-
phopshate dehydrogenase (H6PDH) and C-terminally Myc-tagged
H6PDH (H6PDH-Myc), untagged and C-terminally FLAG-tagged 11β-
HSD1, 11β-HSD2 and 17β-HSD3 expression plasmids were described
earlier [9–12]. The N-terminally FLAG-tagged AR (FLAG-AR) construct
was kindly provided by Dr. J. J. Palvimo (Institute of Biomedicine,
Helsinki, Finland) [13].
The plasmids for the expression of roGFP2 fusion proteins with full-
length DHRS7 (DHRS7-roGFP2) or with the N-terminal DHRS7 mem-
brane anchor region (aa 1–56) (DHRS7(1–56)-roGFP2) were generated
using a pcDNA3 plasmid containing the roGFP2 nucleotide sequence
between the endonuclease restriction sites EcoRV and XbaI. A linker
sequence (TCAGGAGGA) was added upstream of the roGFP2 sequence.
The sequences corresponding to nucleotides 1–168 of DHRS7 or full-
length DHRS7 were PCR amplified from a donor vector and subcloned
upstream of roGFP2 between the restriction sites HindIII/EcoRV. The
resulting DHRS7 proteins contain at the C-terminus a three amino acid
linker (Ser-Gly-Gly) followed by roGFP2.
2.2. Cell culture
Human Embryonic Kidney-293 cells (HEK-293, ATCC, Manassas,
VA, USA) were cultured at 37 °C and 5% CO2 in Dulbecco’s Modified
Eagle Medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA) supple-
mented with 10% fetal bovine serum (FBS, Connectorate, Dietikon,
Switzerland), 100 U/mL penicillin, 100 μg/mL streptomycin, 10 mM
HEPES buffer, pH 7.4, and 1% MEM non-essential amino acid solution.
2.3. Western blot
HEK-293 and LNCaP cells in 6-wells plates were lyzed using 100 μL
RIPA buffer (Sigma-Aldrich) and centrifuged at 14,000× g for 10 min
at 4 °C. Supernatants were collected and protein concentrations quan-
tified using the Pierce bicinchoninic acid protein assay kit (Thermo
Scientific, Rockford, IL, USA). Samples were prepared in Laemmli
solubilization buffer containing 5% β-mercaptoethanol and incubated
at 95 °C for 5 min. Total protein (20 or 30 μg) was separated by SDS-
PAGE on a 12% acrylamide gel and transferred to Immun-Blot poly-
vinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories,
Hercules, CA, USA). For detection of the FLAG epitope, the membrane
was blocked using 10% defatted milk in 20 mM Tris buffer, pH 7.4,
containing 140 mM NaCl and 0.1% Tween-20 (TBS-T) for 1 h and
incubated with the mouse monoclonal FLAG M2 antibody (Sigma-
Aldrich) at a dilution of 1:2000 in 5% defatted milk in TBS-T overnight
at 4 °C. After washing with TBS-T, the membrane was incubated with
horseradish peroxidase (HRP)-conjugated goat anti-mouse secondary
antibody (Sigma-Aldrich) for 1 h at room temperature. The protein
bands were visualized using a Fujifilm ImageQuant™ LAS-4000 (GE
Healthcare, Glattbrugg, Switzerland) using the Immobilon Western
Chemiluminescent HRP substrate kit (Merck, Kenilworth, NJ, USA).
Thereafter, membranes were stripped for 10 min at room temperature
in 200 mM glycine, pH 2.2, containing 1% Tween-20 and 0.1% SDS,
washed twice with PBS and twice with TBS-T, followed by reincubation
using rabbit anti-Myc polyclonal antibody (ab9106, Abcam, Camdridge,
UK) at a dilution 1:2000 in 5% defatted milk in TBS-T for 1 h, followed
by visualization of H6PDH-Myc using a HRP-conjugated goat anti-
rabbit secondary antibody (1:2000) in 5% defatted milk in TBS-T.
Endogenous DHRS7 was detected as described earlier [5]. The house-
keeping control cyclophilin A (PPIA) was detected using a rabbit anti-
human PPIA polyclonal antibody (1:2000) (Abcam, Camdridge, UK) in
blocking solution for 1 h, followed by incubation with HRP-conjugated
goat anti-rabbit secondary antibody (1:2000) in 5% defatted milk in
TBS-T.
2.4. Enzyme activity measurements
HEK-293 cells (1.5× 106) seeded into 10 cm dishes were transi-
ently transfected by the calcium phosphate precipitation method with
8 μg of either construct DHRS7-FLAG, 11β-HSD1-FLAG or 17β-HSD3-
FLAG and 8 μg of pcDNA3 vector without insert. For cotransfection
with H6PDH-Myc, cells were transfected with 8 μg of the corresponding
SDR plasmid and 8 μg of H6PDH-Myc. Cells transfected with 16 μg of
pcDNA3 served as negative control. Transfected cells (30,000) were
seeded in 100 μL medium in 96-well plates pre-coated with poly-lysine
(Sigma-Aldrich), followed by incubation for 24 h at 37 °C. The medium
was replaced by 50 μL charcoal-treated DMEM (2 g charcoal/500 mL
medium, stirring for 1 h at room temperature, followed by centrifuga-
tion at 3200× g for 10 min and sterile filtration using 0.2 μm
nitrocellulose membranes) supplemented with 100 U/mL penicillin,
100 μg/mL streptomycin, 10 mM HEPES buffer, pH 7.4, with or without
the 11β-HSD1 inhibitor BNW16 [14], and enzyme activity measure-
ments were performed by adding cortisone or androstenedione (Sigma-
Aldrich) at a final concentration of 200 nM, containing 50 nCi 3H-
cortisone or 50 nCi 3H-androstenedione (American Radiolabeled Che-
micals, St. Louis, MO, USA). At different time points reactions were
stopped by adding 20 μL of methanol containing 2 mM unlabeled
cortisone and cortisol (Sigma-Aldrich) or androstenedione and testos-
terone (Steraloids, Newport, RI, USA). An amount of 20 μL of super-
natant was loaded onto TLC plates (Macherey-Nagel, Oensingen,
Switzerland). Steroids were separated using chloroform/methanol at a
9:1 ratio for cortisone/cortisol, and chloroform/ethyl acetate at a 4:1
ratio for androstenedione/testosterone. Corresponding substrate and
product amounts were determined by scintillation counting.
To determine possible formation of cortisol from cortisone by
DHRS7 expressing HEK-293 cells, samples were separated by TLC as
described above. Cortisol and 20β-dihydrocortisone (20βDHE) mi-
grated with comparable Rf values. Spots were excised, followed by
steroid extraction from the silica matrix and LC–MS/MS analysis of the
extracts.
To measure the oxoreduction of 5αDHT to 3αAdiol, 100,000 cells
transfected with 0.5 μg of either plasmid for DHRS7-FLAG or AKR1C2-
FLAG or with pcDNA3 vector without insert (negative control) in 24-
well plates were incubated in 500 μL charcoal-treated DMEM supple-
mented with 100 U/mL penicillin, 100 μg/mL streptomycin, 10 mM
HEPES buffer, pH 7.4, and 5αDHT as indicated. After incubation at
37 °C, supernatants were collected and stored at −20 °C prior to
quantification of steroids by LC/MS.
2.5. Quantification of steroids by LC/MS/MS
Steroid concentrations were determined as described in the
Supplementary information. Briefly, to each sample (400 μL) internal
standard (cortisol-D4, 100 μL, 125 nM) was added and proteins were
precipitated with ice cold acetonitrile (1 mL). Samples were incubated
for 20 min at 4 °C by thoroughly shaking and centrifuged (10 min,
16,000× g, 4 °C). Supernatants were evaporated to dryness and
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reconstituted in 50 μL methanol. Steroids were separated and quanti-
fied by ultra-pressure LC–MS/MS (UPLC–MS/MS) using an Agilent
1290 UPLC coupled to a 6490 triple quadrupole mass spectrometer
equipped with a jet-stream electrospray ionization interface (Agilent
Technologies, Santa Clara, CA, USA). Analytes were separated using a
reverse-phase column (1.7 μm, 2.1× 150 mm; Acquity UPLC BEH C18;
Waters). Masshunter software (Agilent Technologies) was used for data
acquisition and analysis.
2.6. Androgen receptor transactivation assay
AR transactivation was assessed as described previously [15], with
minor modifications. Briefly, HEK-293 cells (100,000 cell/well) were
transiently transfected with Fugene HD (Promega, Fitchburg, WI, USA)
at a reagent to DNA ratio of 3 to 1 with plasmids for FLAG-AR
(0.135 μg/well), and either DHRS7-FLAG, AKR1C2-FLAG or pcDNA3
without insert (0.225 μg/well), pCMV-lacZ β-galactosidase control
(0.012 μg/well) and TAT3-TATA luciferase reporter (0.133 μg/well).
After 24 h cells were transferred to charcoal-treated DMEM and
cultivated for 1 h at 37 °C. The medium was replaced with fresh
Fig. 1. Oxoreduction of cortisone by 11β-HSD1 and DHRS7. (A) The absence of endogenous expression of DHRS7 in HEK-293 cells was verified by western blotting (20 μg total protein),
with PPIA serving as loading control. (B) The expression of DHRS7-FLAG and 11β-HSD1-FLAG, and H6PDH-Myc with PPIA serving as loading control were detected by western blotting
(30 μg total protein). The time-dependent oxoreduction of (C) cortisone to cortisol, and (D) cortisone to 20β-DHE was determined in HEK-293 cells transiently expressing either 11β-
HSD1-FLAG or DHRS7-FLAG (mean ± S.D. from three independent experiments performed in triplicates). The effects of 11β-HSD1 inhibitor and coexpression with H6PDH were
analyzed on the oxoreduction of cortisone to (E) cortisol or (F) 20β-DHE. Steroids were separated by TLC and quantitated following scintillation counting (C,E) or analyzed by LC–MS/MS
(D,F). ns (not significant); ****p < 0.0001.
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charcoal-treated DMEM containing various concentrations of 5αDHT
(diluted from stock solutions in DMSO, final concentration of 0.1%
DMSO) or vehicle control (0.1% DMSO), followed by incubation for
24 h. Cells were lyzed in 60 μL of Tropix lysis solution (Applied
Biosystems, Foster City, CA) supplemented with 0.5 mM dithiothreitol
(DTT) and frozen at−80 °C prior to determination of luciferase and β-
galactosidase activities on a SpectraMax-L luminometer (Molecular
Devices, Devon, UK) as described earlier [15].
2.7. Immunofluorescence and imaging analysis
HEK-293 cells seeded on glass coverslips were transiently trans-
fected with either construct 11β-HSD1-FLAG, 11β-HSD2-FLAG, DHRS7-
FLAG or FLAG-DHRS7, and washed twice 48 h later with PBS, fixed
with 4% formaldehyde for 12 min and washed three times with PBS.
For permeabilization of all cellular membranes cells were treated with
0.3% Triton X-100 for 5 min while for selective permeabilization of the
plasma membrane the cells were incubated with 14 μΜ digitonin for
3 min at room temperature. Cells were washed twice with PBS and
incubated for 30 min with blocking solution containing 2% defatted
milk. Cells were then incubated for 1 h at room temperature with
mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich), and
washed four times with PBS, followed by incubation for 40 min with
Alexa Fluor 488 goat anti-mouse IgG and Hoechst-33342 nucleic acid
stain (Molecular Probes, Eugene, OR). After four washes with PBS, cells
were mounted in Mowiol 4–88. The samples were analyzed using an
Olympus Fluoview 1000 laser scanning confocal microscope (Olympus,
Center Valley, PA). To determine the number of cells staining positive
in the presence of Triton X-100 or digitonin, approximately 1000 cells
were counted per sample in three independent experiments.
The live cell microscopy experiments to determine the oxidation
status of the roGFP2-fusion proteins were performed essentially as
described earlier [9]. Briefly, following 48 h of expression of the
roGFP2-fusions in HEK-293 cells, fluorescence emission intensities were
measured after excitation at 405 nm and 488 nm at steady state, after
complete oxidation of roGFP2 with 5 mM diamide, and after complete
reduction with 20 mM DTT. The degree of oxidation (OxD) of roGFP2
was calculated, based on the following equation:
O xD R R
R R R R
roGFP2 = −
( − ) + ( − )
red
I
I ox red
min
max
where R, Rred and Rox are the 405/488 nm emission ratios at steady
state, after complete reduction and oxidation, respectively, and Imin and
Imax the fluorescence intensities of fully oxidized and reduced roGFP2
after excitation at 488 nm.
2.8. Statistical analysis
Activity assay data were analyzed using two-way ANOVA with
Bonferroni post-test for multiple comparisons with GraphPad Prism 5
software. Values represent mean ± S.D.
3. Results
3.1. DHRS7 shows low activity in converting cortisone to 20β-DHE
Based on recent reports on the ability of DHRS7 to convert cortisone
to cortisol [6,8], the present study aimed to assess the relevance of
DHRS7 in the oxoreduction of cortisone by comparing its activity with
that of 11β-HSD1, the well-known SDR responsible for this reaction
[16]. Since the function of DHRS7 remains largely unknown and the
membrane-bound enzyme might lose its activity upon removal from the
ER, an intact cell system, HEK-293, was chosen to investigate potential
substrates of DHRS7. Using an antibody that yields a strong signal for
DHRS7 in LNCaP prostate cancer cells (Fig. 1A) and in the human
prostate, as reported earlier [5], no signal could be detected in HEK-293
cells, thus indicating the absence of endogenous DHRS7 expression in
this cell line. HEK-293 cells also do not express endogenous 11β-HSD1
[11]. For facilitated detection, C-terminally FLAG-tagged DHRS7
(DHRS7-FLAG) and 11β-HSD1 (11β-HSD1-FLAG) were expressed in
HEK-293 cells in the presence or absence of H6PDH-Myc (Fig. 1B),
yielding bands in western blots at the expected sizes. Cells were
subsequently incubated with 200 nM cortisone, followed by the deter-
mination of cortisol formation. Time-dependent cortisol formation was
observed for 11β-HSD1 (Fig. 1C). A 6–8 times lower activity for the
formation of a product migrating on TLC with a Rf comparable to that
of cortisol was observed for DHRS7 (Fig. 1D); however, LC–MS/MS
analysis revealed that this product corresponds to 20β-DHE. Interest-
ingly, while coexpression with H6PDH significantly increased 11β-
HSD1 activity as reported earlier [12] (Fig. 1E), it had no or even a
slight inhibitory effect on the DHRS7-mediated 20-oxoreduction activ-
ity (Fig. 1F), indicating that DHRS7 functions independently of ER-
luminal H6PDH-generated NADPH. Furthermore, the selective 11β-
HSD1 inhibitor BNW16 [14] abolished 11β-HSD1 activity (Fig. 1E) but
did not affect DHRS7-mediated 20-oxoreduction of cortisone (Fig. 1F).
3.2. DHRS7 does not play a relevant role in the conversion of
androstenedione to testosterone
Since androstenedione was recently proposed as a substrate of
DHRS7 [6,8], its metabolism was analysed in intact HEK-293 cells
expressing either 17β-HSD3-FLAG or DHRS7-FLAG. 17β-HSD3 time-
dependently converted the supplied 200 nM androstenedione to testos-
terone (Fig. 2A). In contrast, no activity could be detected for DHRS7,
even after prolonged incubation time (Fig. 2B). Knock-down of DHRS7
was earlier found to enhance prostate cancer cell proliferation and
aggressiveness [5]. Thus, a role for DHRS7 in androgen inactivation
rather than activation would be in line with these earlier observations.
Therefore, the reverse reaction was also tested but no activity could be
detected upon incubation of DHRS7 expressing HEK-293 cells for 4 h
with 200 nM testosterone (not shown).
3.3. DHRS7 catalyzes the inactivation of the AR ligand 5αDHT to 3αAdiol
Next, a possible role of DHRS7 in the inactivation of 5αDHT was
investigated. The metabolism of 5αDHT to 3αAdiol was analyzed by
LC–MS/MS in culture supernatants of intact HEK-293 cells expressing
either human DHRS7-FLAG or AKR1C2-FLAG as positive control, or in
supernatants of cells transfected with pcDNA3 as negative control. A
time-dependent (Fig. 3A) and concentration-dependent (Fig. 3B) for-
mation of 3αAdiol was detected for both DHRS7 and the positive
Fig. 2. Lack of substantial oxoreduction of androstenedione to testosterone by DHRS7.
HEK-293 cells transiently expressing 17β-HSD3-FLAG or DHRS7-FLAG were incubated
with 200 nM radiolabeled androstenedione for 15 to 120 min, followed by determination
of testosterone formation. Data represent mean ± S.D. from three independent experi-
ments.
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control AKR1C2, whereby approximately two times higher activity was
observed for the latter. The reaction of DHRS7 was stereo-specific and
no 3βAdiol was formed. The oxidation of 3αAdiol to 5αDHT was also
not catalyzed in intact HEK-293 cells expressing DHRS7 (not shown).
3.4. DHRS7 suppresses the 5αDHT-mediated AR transactivation
A concentration-dependent increase of 5αDHT-driven AR transacti-
vation was observed in the absence of androgen metabolizing enzymes,
reaching a plateau at a concentration of 1 nM (Fig. 3C). Upon
coexpression with DHRS7 or the positive control AKR1C2 a similar
concentration-dependent stimulation of AR activity was observed at
lower concentrations of up to 0.1 nM 5αDHT; however, at concentra-
tions of 1 nM and higher both DHRS7 and AKR1C2 were able to
suppress AR transactivation.
3.5. The catalytic moiety of the microsomal enzyme DHRS7 is facing the
cytoplasm
The present study showed that DHRS7 activity is not stimulated by
ER-luminal H6PDH-mediated NADPH generation, unlike 11β-HSD1
activity. This suggested either the dependence of DHRS7 on an
alternative ER-luminal source of NADPH or that DHRS7 may not face
the ER-lumen as proposed by a recent report [8]. Therefore, the
membrane topology of DHRS7 was revisited.
First, HEK-293 cells expressing DHRS7-FLAG, 11β-HSD1-FLAG,
11β-HSD2-FLAG or FLAG-DHRS7 were subjected to either selective
permeabilization of plasma membranes using digitonin or complete
permeabilization with Triton X-100. Following immunofluorescence
staining using a primary anti-FLAG antibody and a secondary fluor-
escent anti-mouse antibody, the percentage of cells stained positive
after treatment with digitonin was compared with that of the positive
control Triton X-100 (set as 100%). Fig. 4A shows representative
confocal images and Table 1 summarizes the quantification of three
independent experiments. The percentage of positively stained cells
following treatment with Triton X-100 or digitonin were comparable
for the positive control 11β-HSD2-FLAG and for full-length DHRS7-
FLAG, indicating a cytoplasmic orientation of the catalytic moiety of
these two enzymes. In contrast, the FLAG epitope at the C-terminus of
11β-HSD1 or at the N-terminus of DHRS7 was protected against
antibody staining by the ER membrane in case of selective plasma
membrane permeabilization with digitonin, indicating ER-luminal
orientation of the catalytic moiety of 11β-HSD1 and of the very short
N-terminal part upstream of the membrane-spanning region of DHRS7
(Fig. 4C).
Second, fusion proteins DHRS7-roGFP2 and DHRS7(1–56)-roGFP2
were analyzed by live imaging using laser-scanning confocal micro-
scopy after excitation with 405 nm and 488 nm and calculation of the
percentage of roGFP2 oxidation at steady state (Fig. 4B). Both DHRS7-
roGFP2 constructs showed a relatively low percentage of oxidation at
Fig. 3. Oxoreduction of 5αDHT to 3αAdiol by DHRS7. (A) The time-dependent oxoreduction of 200 nM 5αDHT to 3αAdiol and (B) the concentration-dependent oxoreduction of 5αDHT
upon incubation for 240 min was determined in HEK-293 cells transfected with pcDNA3 vector without insert (negative control), pcDNA3 constructs containing AKR1C2-FLAG (positive
control) or DHRS7-FLAG. Data represent mean ± S.D. from three independent experiments performed in triplicates. (C) Impact of DHRS7 and AKR1C2 on AR transactivation by 5αDHT.
HEK-293 cells were transfected with plasmids for FLAG-AR, and DHRS7-FLAG, AKR1C2-FLAG or empty pcDNA3 vector, the androgen-sensitive TAT3-TATA-luciferase reporter gene and a
galactosidase transfection control. Cells were incubated for 24 h with various concentrations of 5αDHT (DMSO concentration was 0.1% in all samples and 0.1% DMSO served as vehicle
control), followed by determination of luciferase activity normalized to the internal galactosidase control. Data were normalized to vehicle control (0.1% DMSO) and represent
mean ± S.D. from three experiments. ND, not determined.
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steady state (OxD value expressed as a percentage), similar to that of
11β-HSD2-roGFP2, typical for a cytoplasmic orientation of the sensor.
In contrast, 11β-HSD1-roGFP2 showed a high percentage of oxidation,
typical of a ER-luminal orientation of the sensor. The measurements of
oxidation for 11β-HSD1-roGFP2 and 11β-HSD2-roGFP2 have been
performed in previous work [9].
Third, an inspection of the distribution of charged amino acids in
the primary sequence of DHRS7 is in favour of a cytoplasmic orienta-
tion of the catalytic moiety of DHRS7 (Fig. 4C). In fact, the fourth
residue at the N-terminus of the protein is a glutamate, immediately
upstream of the single membrane spanning helix that is followed by an
arginine residue at position 24 and another arginine at position 27.
Positively charged residues at the cytoplasmic and negatively charged
residues at the ER-luminal side are important determinants for the
orientation of a membrane spanning helix and are also present in the
related SDRs 11β-HSD1 and 17β-HSD3 (Fig. 4C) [10,11,17]. The charge
distribution supports a membrane topology of DHRS7 with its N-
terminus in the ER lumen and the main part of the protein with the
cofactor binding site and catalytic center in the cytoplasm.
4. Discussion
The closest relatives of DHRS7 within the SDR family are DHRS7b
Fig. 4. Determination of the membrane topology of DHRS7. (A) Selective permeabilization experiments for determination of the topology of DHRS7. DHRS7-FLAG or FLAG-DHRS7 were
expressed in HEK-293 cells. 11β-HSD1-FLAG and 11β-HSD2-FLAG served as controls for ER-luminal and cytosolic orientation, respectively. Cells were fully permeabilized with Triton X-
100 or plasma membranes were selectively permeabilized with digitonin, followed by incubation with anti-FLAG M2 and Alexa Fluor 488 and Hoechst-33342 (FLAG in green, Hoechst in
magenta). (B) Determination of the percentage of roGFP2 oxidation. DHRS7-roGFP2 or DHRS7(1–56)-roGFP2 fusion proteins were transiently expressed in HEK-293 cells, and 48 h post-
transfection live imaging experiments were performed for determination of the percentage of oxidation of roGFP2 (mean ± S.D. from three independent experiments). The values for
11β-HSD1-roGFP2 and 11β-HSD2-roGFP2 fusions are shown for comparison of a known ER-luminal and cytosolic protein, respectively, and have been calculated from previous
experiments [9]. (C) Topology of DHRS7, 11β-HSD1 and 17β-HSD3 in the ER-membrane with amino acids represented by one letter code notation (positively charged in red, negatively
charged in blue). RF, Rossmann fold; AS, active site.
Table 1
Quantification of selective permeabilization experiments for determination of the
topology of DHRS7. Around 1000 cells were counted per experiment. Data represent
the percentage of Hoechst-33342 positive cells that also showed positive staining with
anti-FLAG antibody. To assess selectively plasma membrane permeablized cells, the
percentage of Triton X-100 positive cells was set as 100% and the relative percentage of
positive cells after digitonin treatment is shown. All values represent mean ± S.D of at
least three independent experiments.
Expressed
protein
Triton X-100 Digitonin Relative rate of digitonin
positive cells [%]
11β-HSD1-FLAG 23.4 ± 1.6 1.3 ± 0.4 5.5 ± 1.5
11β-HSD2-FLAG 26.3 ± 0.8 25.3 ± 0.9 96.2 ± 0.6
DHRS7-FLAG 23.9 ± 1.6 23.0 ± 1.8 96.1 ± 1.6
FLAG-DHRS7 22.9 ± 1.3 1.0 ± 0.4 4.3 ± 2.0
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(SDR32C1), DHRS7c (SDR32C2), 11β-HSD1 (SDR26C1), 17β-HSD12
(SDR12C1) and 17β-HSD3 (SDR12C2) [18]. The evolutionary relation-
ship of these enzymes represents a starting point for a substrate search.
In this respect, Wsol and co-workers proposed for the first time several
potential substrates, including 1,2-naphtoquinone, all-trans-retinal, the
tobacco compound NNK, but also the steroids cortisone and androste-
nedione; some of these substrates are shared with the closely related
enzymes 11β-HSD1 and 17β-HSD3 [6,8,19]. Although DHRS7 can
accept androstenedione as a substrate at very high concentrations
(activity observed at 25 μM or higher) [6,8], the present study showed
that this enzyme is not able to convert androstenedione to testosterone
at a physiologically relevant concentration of 200 nM in intact cells.
Under the same conditions 17β-HSD3 efficiently catalyzed this reaction.
Thus, DHRS7 is unlikely to have a physiological role in generating
testosterone from androstenedione. Such a role would anyhow be
against the evidence that loss of DHRS7 enhances cancer cell prolifera-
tion and aggressiveness [5]. Also, the reverse reaction, which would be
in line with a tumor-suppressive effect of DHRS7, could not be detected.
However, the data of this study suggest a role of DHRS7 in the
inactivation of 5αDHT to 3αAdiol. Compared to the well-described
AKR1C2, the activity of DHRS7 was approximately two times lower.
However, for both DHRS7 and AKR1C2 comparable suppressive effects
on AR transactivation could be observed at 5αDHT concentrations of
1 nM and greater, supporting a role of these enzymes in inactivating
5αDHT. DHRS7 expression has been found in tissues including prostate,
adrenals, thyroid, intestine, kidney and liver [8], where inactivation of
5αDHT is important to control appropriate AR signaling. Although the
present study revealed 5αDHT as a substrate of DHRS7 and suggests a
protective effect towards AR activation, the physiological relevance
remains to be further investigated. The identified oxoreduction of
5αDHT should help optimizing enzyme purification conditions, allow-
ing to determine enrichment factors for specific activity, and measuring
kinetic parameters of DHRS7. Follow-on studies also need to address
the impact of DHRS7 on AR-mediated signaling in cell models expres-
sing endogenous levels of this enzyme. Furthermore, studies using
clinical samples and addressing whether DHRS7 has a role in androgen-
dependent prostate cancer should be performed.
The present study also revealed that DHRS7 can catalyze the 20-
oxoreduction of cortisone, although the observed activity was very low
and its physiological relevance is questionable. Nevertheless, DHRS7
possesses 3α/20β-HSD activity, stimulating further research in this
direction. Steroid molecules can adopt different binding orientations in
metabolizing enzymes, due to their rotational symmetry as illustrated
in Fig. 5 [20], and as shown by structural analyses of the yeast
Streptomyces hydrogenans 3α/20β-HSD [21]. Previous reports, using
HPLC for steroid separation, suggested conversion of cortisone to
cortisol by DHRS7 [6,8]. In the present study, cortisol formation could
not be detected. It needs to be noted that 20β-DHE could not be
separated from cortisol using TLC and a 9:1 methanol:chloroform
solvent, emphasizing that more powerful separation methods and,
ideally, compound fragmentation and mass-spectrometry should be
used. Thus, the use of authentic standards and LC–MS/MS (or GC–MS/
MS) in order to identify substrates and products is advantageous for the
characterization of “orphan” enzymes.
The DHRS7-mediated 20-oxoreduction of cortisone was not stimu-
lated upon coexpression with H6PDH, in line with the cytoplasmic
orientation of the ER membrane-anchored DHRS7 as determined by
using roGFP fusions and selective plasma membrane permeabilization
experiments. These findings are in conflict with an earlier report [6],
who proposed an ER-luminal orientation of DHRS7. These investigators
applied the proteinase K protection assay using microsomes of DHRS7
expressing Sf9 cells. Upon incubation with proteinase K a band for
DHRS7 was still detected, although at a considerably weaker intensity
than that of the positive control. In the presence of Triton X-100 the
band for DHRS7 was no longer detectable and an ER-luminal orienta-
tion was proposed. However, proteinase K is still active in the presence
of detergent; in fact, its activity can be stimulated by detergents because
of an increased accessibility on the protein substrates. Therefore,
suitable positive and negative controls, i.e. similar proteins but with
opposite membrane topology, should ideally be included in proteinase
K protection assays. The roGFP fusions used in the present study offer
the advantage that they provide information on the membrane topology
in living cells. The cytoplasmic orientation of DHRS7 is further
supported by the presence of the negatively charged Glu-4 and the
positively charged residues Arg-24 and Arg-27, flanking the membrane
helix at the ER-luminal and cytoplasmic side, respectively (Fig. 4C).
In conclusion, the present study revealed that the ER-membrane
anchored enzyme DHRS7 is oriented towards the cytoplasm and
Exhibits 3α/20β-HSD activity. The ability of DHRS7 to convert
5αDHT to 3αAdiol suggests a role in the modulation of AR transcrip-
tional activity. Further research is needed to address the potential
tumor suppressor role of DHRS7.
Fig. 5. Rotational symmetry of the two DHRS7 steroid substrates cortisone and 5α-DHT. 3D structures of cortisone (in green) and 5α-DHT (in blue) are shown in the upper panel.
Cortisone rotated 180° (East-West rotation) is shown in the lower panel on the left, and overlay of 5α-DHT and the East-West rotated cortisone, revealing the close proximity of the 3-oxo
group on 5α-DHT and the 20-oxo group on cortisone, is shown on the lower panel on the right. (For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)
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4.2 Further Characterization of DHRS7 Activity 
4.2.1 Methods 
4.2.1.1 Cell Culturing 
The human embryonic kidney cell line HEK 293 (ATCC, Manassas, VA, USA) was cultivated in Dulbecco’s 
modified Eagle’s medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine 
serum (FBS, Connectorate, Dietikon, Switzerland), 100 U/mL penicillin, 100 µg/mL streptomycin (Life 
Technologies, Grand Island, NY, USA), 10 mM 4 (2 hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
buffer at pH 7.4 (Gibco life technologies, Carlsbad, CA, USA), and 1% minimum essential medium (MEM) 
non-essential amino acids solution (Sigma Aldrich, St. Louis, MO, USA). The African green monkey 
Cercopithecus aethiops kidney cell line CV1 cells (ATCC, Manassas, VA, USA) was cultivated in Eagle's 
Minimum Essential Medium with Earleʹs Balanced Salts (Sigma-Aldrich, St. Louis, MO, USA) supplemented 
with 10% fetal bovine serum (FBS, Connectorate, Dietikon, Switzerland), 100 U/mL penicillin, 100 µg/mL 
streptomycin (Life Technologies, Grand Island, NY, USA), 2 mM L-glutamine, 1 mM sodium pyruvate. The 
human prostate cancer cell line LNCaP was purchased from ATCC (LGC Standards GmbH, Wesel, Germany), 
cultivated in RMPI 1649 media (R8758; Sigma) supplemented with 10% fetal bovine serum (FBS) and 
penicillin (100 U/mL) /streptomycin (100 µg/mL).  
4.2.1.2 Transient and Stable Transfection 
For transient transfection, 40’000 CV1 cells/well into 24-well plates were transfected with Fugene© 3 to 
1 plasmid concentration (C-term flagged DHRS7 or empty vector pcDNA3) after 24 h. Instead, for 
production of lysate for western blotting, 1x106 HEK 293 were transfected with the calcium phosphate 
method as described elsewhere [191] with 8 µg of plasmid (C-term FLAG tagged 17βHSD6 [192], or empty 
vector pcDNA3).  
For stable transfection, HEK 293 at a dilution of 200.000 cells/ml were transfected with 8 µg of C-term 
flagged DHRS7 plasmid in a 10 cm3 dish, with the calcium phosphate method as described elsewhere [191]. 
For stable transfection selection, after 24h cells were grown into selection medium for other 24h 
(800 µg/ml G418, (Sigma-Aldrich)), diluted to get single cells in 96well plates, and the following days grown 
into conditioned medium (cell culture media used to cultivate HEK 293 cells). Single colonies of clones 
were passaged until selected based on amount of mRNA and protein of DHRS7 quantified through qPCR 
and western blotting, respectively. Seven clones were selected, based on mRNA amount and clone number 
3 was selected for further experiments based on highest DHRS7 expression per protein amount. 
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4.2.1.3 Determination of RNA Expression 
Cell material was collected, and RNA isolated with the RNeasy Mini Kit and QIAcube (Qiagen, Venlo, 
Netherlands) according to the manufacturer’s instructions. The samples were stored at -80 °C. Quality and 
quantity of RNA was assessed using a NanoDrop ND-1000 (V3.8.1; Witec AG, Lucerne, Switzerland). 
Reverse transcription was performed using the M-MLV Reverse Transcriptase Kit (M368B; Promega, 
Wallisellen, Switzerland) according to the manufacturer’s instructions. Briefly, the tubes were incubated 
at 65 °C for 5 min at low shaking intensity with 500 ng of oligo-dT primers (Ref. AB1247; Thermo Fisher 
Scientific, Waltham, MA, USA) and 2000 ng of total RNA in DNase/RNase free water 
(Bioconcept).Afterwards, to each tube were added 20 U of M-MLV reverse transcriptase (Ref. M368C; 
Promega, Fitchburg, WI, USA), 10 U of RNase inhibitor (Ref. 03 335 402 001; Roche, Basel, Switzerland), 
and 0.5 mM dNTP mix (Ref. U151B; Promega) in a final reaction volume of 20 μL with M-MLT reverse 
transcription buffer (Ref. M531A; Promega) and 10% (v/v) DNase/RNase free water. The tubes were 
incubated in a thermomixer for 1 h at 42 °C at low shaking intensity, chilled on ice, diluted to 5 ng/μL, and 
stored at -20 °C. QPCR was performed with the SYBR Green detection method using the Kapa SYBR FAST 
qPCR Master Mix (Ref. KK4602; Kapa Biosystems, Roche). 10 ng of complementary DNA were mixed with 
SYBR Green Master Mix and 4 pmol of the forward and reverse primer sequences (Microsynth AG, Balgach, 
Switzerland) are shown in the supplementary data). 
qPCR was performed in a Corbett Rotor-Gene 6000 (Qiagen) with an initial hold at 95 °C for 10 min, 
followed by 40 cycles of melting at 95 °C for 10 s, annealing at 60 °C for 15 s, and elongation at 72 °C for 
20 s. Relative quantification of gene expression was done using the 2-ΔΔCt method [193] by normalizing 
genes of interest to cyclophilin A (PPIA). 
4.2.1.4 Western blotting 
60% confluent cells were lysed RIPA buffer and centrifuged at 12,000g for 10 min at 4°C. The supernatant 
was collected and protein concentration quantified using the Bradford method. Samples were heated at 
95°C for 5 min in Laemmli buffer (5 mmol/L Tris HCl, pH 6.8, 10% glycerol [v/v], 0.2% sodium dodecyl 
sulfate [SDS] [w/v], 1% bromophenol blue [w/v]) and stored at −20°C until used. 30 µg of lysates were 
separated by a 12.5% Tris-glycine SDS-polyacrylamide gel and transferred to Immun-Blot® PVDF 
polyvinylidene difluoride membranes (162- 0177; Bio-Rad Laboratories, Hercules, CA) at constant 230 mA 
for 1 h. For detection of DHRS7, the membrane was blocked using 2% milk (v/v) for 1 h at room 
temperature, followed by incubation with the mouse anti-human DHRS7 polyclonal antibody (ab69348; 
Abcam, Cambridge, UK) at a dilution of 1:500 (v/v) in 2% milk (v/v), overnight at 4°C. After washing with 
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Tris- buffered saline (20 mmol/L Tris- base, 140 mmol/L NaCl) containing 0.1% Tween20 (v/v) (TBS- T), the 
membrane was subsequently incubated with horseradish peroxidase-conjugated goat anti-mouse 
secondary antibody (Jackson Immuno Research, Suffolk, UK) for 1 h at room temperature. For PPIA 
detection, the membrane was blocked using 10% milk (v/v) overnight at 4°C, followed by incubation with 
the rabbit anti-human PPIA polyclonal antibody (ab41684; Abcam) at a dilution of 1:2000 (v/v) in 2% milk 
for 1 h at room temperature. After washing with TBS-T, the membrane was subsequently incubated with 
horseradish peroxidase- conjugated goat anti- rabbit secondary antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA) at a dilution of 1:1000 (v/v) in 2% milk (v/v). After washing the membranes in TBS- T, images 
were visualized using the Immobilon Western Chemiluminescent HRP substrate kit (Millipore, 
Schaffhausen, Switzerland), and a FujiFilm ImageQuant™ LAS-4000 detector (GE Healthcare, Glattbrugg, 
Switzerland) using the chemiluminescence detection setting. Membranes were exposed 1 second. For 
microsomes, 6 μg of protein of cytoplasmic fraction were loaded, for the other samples from microsomal 
preparation, 15 μg of protein were used. The antibody for mouse anti-human 17βHSD6 polyclonal 
antibody (ab88892; Abcam, Cambridge, UK) was diluted 1:1000 and for mouse anti-human 
17βHSD10/ERAB monoclonal antibody (ab10260; clone number 5F3, Abcam, Cambridge, UK) was diluted 
1:1000 and 20 µg of lysates were used.  
4.2.1.5 Activity Assay in Intact Cells 
For steroidal background activity measurements with LC/MS, HEK 293 were seeded 120’000 cells/well in 
24-well poly lysine coated wells and activity was performed after 24 h. For CV1, activity performed after 
supplemental 24 h. For the activity, cells were washed with PBS, and incubated at 37°C in charcoal 
treated/serum free medium, containing 200 nM of either progesterone, 17HOProg, cortisol, or DHP 
(Steraloid, Newport, RI, USA). 400 μL of supernatant was collected and stored at -20°C.  
4.2.1.6 Cell Lysates 
Human embryonic kidney cells (HEK 293) stably expressing DHRS7 clone 3 were washed with ice cold 
phosphate-buffered saline and collected in Falcon tubes in 200 µL aliquots. After centrifugation at 1200xg 
for 4 min, supernatant was removed, and the cell pellets were snap frozen and stored at -80°C. Protein 
concentration were determined with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, MA, 
United States). 
4.2.1.7 Microsomes Isolation 
Microsomes preparation was based on [194], with minor modification. Briefly, DHRS7 stably transfected 
HEK 293 10x 10cm dish, washed with PBS, cells were scraped and transferred to falcon tube, washed with 
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ice cold PBS, centrifuged twice at 4°C 4 min 150g. Cell pellet was resuspended in 1.5ml homogenization 
buffer homogenized with a 2 mL glass pestle (15 strokes – 3 min on ice – 15 strokes). The solution was 
centrifuged 4°C 20min at 12’000g. The supernatant was centrifuged at 4°C for 1 h at 106’000g. The 
supernatant was discarded, the pellet was washed once, and further resuspended in 30ul TS2 buffer. 
Samples were snap frozen and stored in -80°C. Protein concentration were determined with Pierce BCA 
Protein Assay Kit. 
4.2.1.8 Radioactivity Assay 
4.2.1.8.1 Intact Cells 
For activity measurements with MS/MS, stable or non-transfected HEK 293 were seeded 120’000 
cells/well poly lysine coated 24-well plates, instead, activity assay in CV1 was performed after 24 h of 
transient transfection into 24-well plates. For the radioactivity assay, HEK 293 non-transfected and DHRS7 
stably transfected cells were seeded (100’000 cells/well) into 96-well plates poly lysine coated, CV1 were 
seeded into (60’000 cells/well) into 96-well plates. After 24 h, cells were washed with PBS, and incubated 
for 0 h - 1 h - 2 h - 4 h - 8 h at 37°C in charcoal treated/serum free medium, containing 200 nM DHT (10 nM 
of radioactive). Reactions were stopped by adding 20 μL of excessive amounts of unlabeled substrate and 
product (1:1, 1 mM in methanol) and 20 μL of mixture was collected and applied to the TLC plate (TLC, 
pre-coated TCL-plates SIL G 25 UV254, Macherey-Nagel, Düren, Germany). Unlabeled steroids were 
purchased from Steraloids (Newport, RI, USA) and radiolabeled steroids from Perkin-Elmer (Boston, MA, 
USA). A 1:4 mixture of ethyl acetate and chloroform was used as solvent to separate steroid using thin-
layer chromatography (TLC, pre-coated TCL-plates SIL G-25 UV254, Macherey-Nagel, Düren, Germany). 
Steroids were separated though a solution of ethyl acetate to chloroform (1:4) and incubated for 1 h. For 
the visualization, the TLC plate was dried for 10 min and sprayed with a 3% v/v sulfuric acid in water, 
incubated 5 min in the oven at 60°C, and 10 min with increasing temperature toward 160°C. Scratch silica 
into vials to be measured for radioactivity and add scintillation cocktail (IRGASAFE Plus, Zinsser Analytic, 
Frankfurt am Main, Germany) was added and liquid scintillation counting (TRI CARB 2100TR, PerkinElmer 
Inc., Wellesley, MA, USA) was performed to quantify the remaining substrate concentration and the 
product formation. 
4.2.1.8.2 Lysate 
To determine enzyme activity, cell pellets of DHRS7 stably transfected in HEK 293 were thawed, diluted to 
2 μg/μL in TS2 buffer (100 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM MgCl2, 250 mM sucrose, 20 mM Tris-
HCl, pH 7.4, with or without 1mM DTT or 250mM glycerol) or MOPS buffer (100mM NaCl, 1mM EGTA, 
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1 mM EDTA, 1 mM MgCl2, 20mM MOPS, with or without 250 mM sucrose), lysed either by freeze-thaw or 
sonicated (0.3 cycles, 20% amplitude, UP50H, Hielscher Ultrasonics, Teltow, DE) and incubated in a 96-well 
polymerase chain reaction (PCR) plate on a thermoshaker (ThermoStat plus, Eppendorf, Hamburg, 
Germany) at 37°C for 1 h with final dilution 1μg/μL. The DHRS7 activity assay was performed in the 
presence of 200 nM DHT, containing 5 nM of [1,2,4,5,6,7-3H(N)]-dihydrotestosterone and either NADPH 
0.5mM or regeneration system (250 μM of the cofactor NADP+, 1 mM glucose-6-phophate, and 1 U of 
glucose 6 phosphate dehydrogenase from baker's yeast S. cerevisiae (all from Sigma-Aldrich, St. Louis, MO, 
USA)). Reactions were stopped by adding 10 μL of excessive amounts of unlabeled substrate and product 
(1:1, 1 mM in methanol) and 10 μL of mixture was collected and applied to the TLC plate. Further steps 
were performed as described previously for intact cells (method section 4.2.1.8.1) 
4.2.1.8.3 Microsomes 
Microsomes of DHRS7 stably transfected in HEK 293 were thawed, diluted to 2 μg/μL in TS2 buffer, and 
incubated in a 96-well polymerase chain reaction (PCR) plate on a thermoshaker (ThermoStat plus, 
Eppendorf, Hamburg, Germany) at 37°C for 1-2-4 h at final dilution 1 μg/μL. Following steps were 
performed as described for lysate. Reactions were stopped by adding 10 μL MeOH of 1 mM DHT and 
3αAdiol and 10 μL of lysate was collected and applied to the TLC plate.  
4.2.1.9 Quantification of Analytes for Activity Assay by LC/MS 
Analysis of analytes from culture supernatants was performed according to [191], with modifications 
depending on the metabolite. Briefly, the activity assay samples and calibrators stored in -20°C were 
thawed and internal standard was added if available (the analytes DHT and 3αAdiol were evaluated based 
on the internal standards DHT-D3, and 3αAdiol-D3, respectively). For 3βAdiol, 5βDHT, and progesterone, 
the amount was estimated based on the calibration curve; and DHP, cortisol, 20β-dihydrocortisol were 
evaluated only qualitatively. Calibration curve was prepared with the analytes to quantify and serial 
dilution of 50% concentration performed in the same matrix used for biological material subjected to 
activity in the cell culture. Protein precipitation was performed by adding 1 mL ice-cold acetonitrile, 
shaking vigorously 30 min at 4°C and 1350 rpm (Thermomixer comfort, Eppendorf), centrifuged at 4°C 10 
min and 16100 rcf, and transferring to fresh tubes. Samples were then evaporated into Genevac with 
settings 35 °C HPLC fraction and reconstituted in 50 µL methanol by shaking vigorously 10 min at 4°C, 
centrifuged (4°C, 10 min; 16100 rcf), and the supernatant transferred in LCMS vial (with inserts V=200 µL). 
Metabolytes were identified and quantified according to standards or calibration curves, performed by Dr. 
Denise Kratschmar. Analytes with S/N≥5 are described as not quantified (NQ), S/N≥3 as not detected (ND). 
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4.2.1.10 Chemicals 
For activity assay analyzed with LC/MS the steroids DHT (CAS Nr. 521-18-6), DHT-D3 (CAS Nr. 79037-34-6), 
3αAdiol (CAS Nr. 1852-53-3), 3αAdiol-D3 (CAS Nr. 7037-33-5), 3βAdiol (CAS Nr. 571-20-0), 5βDHT (CAS Nr. 
571-22-2), DHP (CAS Nr. 566-65-4), cortisol (CAS Nr. 50-23-7), 20β-dihydrocortisol (CAS Nr. 116-58-5), and 
progesterone (CAS Nr. 57-83-0), 20αOHProg (CAS Nr. 145-14-2), 20βOHProg (CAS Nr. 145-15-3), 17OHProg 
(CAS Nr. 68-96-2), 17α,20αdiOHProg (CAS Nr. 652-69-7), and 17α,20β-diOHProg (CAS Nr. 1662-06-2), were 
all purchased from Steraloids (Newport, RI, USA).  
For inhibitors screening, abiraterone acetate (CAS Nr. 154229-18-2), sertaconazole (CAS Nr. 99592-39-9), 
tioconazole (CAS Nr. 65899-73-2), butoconazole (CAS Nr. 64872-76-0), daunorubicin (CAS Nr. 23541-50-
6), all-trans retinal (CAS Nr. 116-31-4), glycyrrhizic acid (CAS Nr. 1405-86-3), 9,10-Phenanthrenequinone 
(CAS Nr. 84-11-7), and 1.2-Naphthoquinone (CAS Nr. 524-42-5) were purchased by Sigma were obtained 
from Sigma–Aldrich (Buchs, CH). As quinones showed low solubility, 9,10-phenanthrenequinone was first 
diluted in a stock solution of 10 mM DMSO, instead 1,2-napthoquinone was diluted in a stock solution of 
1 mM in DMSO. Instead tamoxifen (CAS Nr. 10540-29-1) was obtained by Invivogen (San Diego, CA, USA). 
Drostanolone (CAS Nr. 58-19-5), methasterone (CAS Nr. 3381-88-2), oxandrolone (CAS Nr. 53-39-4), 
oxyndrolone (CAS Nr. 53-39-4), oxystanolon (synthesized by Dr. Daniela Schuster), and mesterolone (CAS 
Nr. 1424-00-6) were obtained from Lipomed (Cambridge, MA, USA). 7,27-dihydroxycholesterol (7oxo, 
27OHC acid) (CAS Nr. 240129-43-5), and 7-keto-25-hydroxycholesterol (7keto-25-OHC) (CAS Nr. 64907-23-
9) were obtained by Avanti Polar Lipids. 5α-dihydro-DOC (CAS Nr. 298-36-2) and cortisone (CAS Nr. 53-06-
5) were diluted in methanol and purchased from Steraloids (Newport, RI, USA), T0504 (Roche, BS, CH). 
Prostaglandin E2 (CAS Nr. 362-24-6) and prostaglandin F2α (CAS Nr. 38562-01-5) were diluted in ethanol 
and purchased from Adipogen (San Diego, CA, USA), and Sigma, respectively. Stock solutions were 
prepared in dimethyl sulfoxide (DMSO) and stored at -20°C. BNW16 was used as a specific 11βHSD1 
inhibitor according to [195]. 
4.2.1.11 Statistics 
Two-way ANOVA with Bonferroni post-test for multiple comparison was used for the activity assay. 
Student t-test was used for comparison of DHT DHRS7 stable lysate activity to assess substrates and 
inhibitors.  
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4.2.2 Results  
4.2.2.1 Selection for Cell Model  
The green monkey CV1 cell line is often used as a model cell line in steroid and oxidoreductase studies 
[134]. In order to confirm if it was possible to study the effects of DHRS7 on DHT metabolism in CV1 cells, 
first, we quantified the endogenous (background) level of DHT conversion. Supernatants from CV1 cells 
transfected with plasmid pcDNA3 or DHRS7 and treated with 100 nM DHT where collected. Supernatant 
spiked with 100 nM DHT that was in quick contact with an empty well (named as “contact well”) was used 
as a control. DHT and 3αAdiol were quantified using ultra-high-pressure LC-MS/MS (Figure 9). 
 
Figure 9: Quantification of DHT (A) and 3αAdiol (B) in supernatant of CV1 transfected with pcDNA3 and DHRS7 compared to 
incubated media after DHT treatment. The experiment was performed in duplicates and expressed as mean ± SD. 
DHT exposed to CV1 cells (Figure 9A) was fully metabolized at both the 4 h and 8 h time points both in the 
pcDNA and DHRS7 transfected cells, indicating strong background conversion. Surprisingly, 3αAdiol (Figure 
9B), the expected product of DHRS7 metabolism, was not detected. This might indicate further metabolism 
of 3αAdiol in CV1 cells. For these reasons, CV1 cells were not selected as model cell line for DHRS7 
metabolism studies. In order to validate the use of HEK 293 cells (shown to have a minimal background 
conversion of DHT [191]), as an alternative to CV1 cells for measuring DHT conversion following DHRS7 
overexpression, the levels of DHT and 3αAdiol were quantified. In addition, the reverse reaction of 3αAdiol 
to DHT was also investigated in this model (Figure 10). 
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Figure 10: Quantification of 3αAdiol (A) and DHT (B) in supernatant of HEK 293 compared to incubated media after 3αAdiol 
treatment, and the absence of 3βAdiol in HEK 293 after 24 h incubation with 200 nM 3αAdiol (C) (in red, compared to 3βAdiol in 
calibrator with concentration of 47.2 nM). The experiment was performed in duplicates and expressed as mean ± SD. 
The oxidative conversion of 3αAdiol to DHT in HEK 293 cells was very weak with only ca. 6 nM of DHT 
detected following 24 h treatment with 200nM 3αAdiol (Figure 10A and B). No 3βAdiol was detected 
(Figure 10C). The oxidation of 3αAdiol to DHT has been reported to be catalyzed by the enzymes 17βHSD6, 
17βHSD10, RDH16, RDH5, and DHRS9 [23, 196-200]. To further support the observation that the HEK 293 
cells lack the sufficient machinery to strongly support the oxidative reaction and would thus be a favorable 
model to study DHRS7 driven DHT reduction metabolism and kinetics in comparison to CV1, the protein 
expression levels of the microsomal 17βHSD6, and the mitochondrial 17βHSD10 protein [201] were 
measured by immunoblotting (Figure 11).  
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Figure 11: Expression of 17bHSD6 and 17bHSD10 in HEK 293. A. Protein expression of 17bHSD6 (30 kDa) in HEK 293. HEK 293 cells 
transfected with C-terminal FLAG tagged 17βHSD6 and the prostate cancer cell line LNCaP were used as positive control according 
to [23]. B. Protein expression of 17bHSD10 (27 kDa) in HEK 293. LNCaP cell lysate was used as positive control according to 
Baumann et al. [198]. 
HEK 293 cells do not express endogenous 17βHSD6 protein (Figure 11A). HEK 293 cells express high 
endogenous 17βHSD10 protein (Figure 11B). The low affinity of 17βHSD10 (ca. 34 µM [202]) to 3αAdiol 
may help explain the observed low 3αAdiol metabolism at the later time points, however the expression 
of other 3α-HSDs should be assessed.  
For the purpose to test the reductive capacity of DHRS7 in HEK cells, a stable HEK 293 cell line expressing 
DHRS7 was established. Seven clones of HEK 293 stably expressing DHRS7 were selected with the G418 
antibiotic and were assessed based on protein expression, compared to non-transfected cells and the 
positive LNCaP cell lysate control (Figure 12). Clone 3 was selected for further experiments according to 
its high DHRS7 expression in the immunoblot (figure 12). 
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Figure 12: Expression of DHRS7 in seven selected DHRS7 HEK 293 stable clones (1,2,3,4,6,8). DHRS7 is highly expressed in all the 
cloned cell lines. Whole LNCaP cell lysates were used as a positive control. 
Clone 3 was selected for further experiments according to its increased DHRS7 expression in the western 
blot (figure 12). 
4.2.2.2 Activity Assay toward Selected Steroids on Position 3! and 20β 
The HEK 293 stably expressing DHRS7 clone 3 cells were incubated with hypothesized potential substrates 
of DHRS7 and compared to the background conversion of non-transfected HEK 293 cells. Based on the 
observations of reductive behavior of DHRS7 toward the carbonyl moiety of cortisone in position 20 
leading to a 20β hydroxy, and DHT in position 3 leading to a 3α hydroxy of the steroidal structure [191], 
and the assumptions made in the introduction of chapter 1 (section 4) , the four candidates’ substrates 
steroids present in Figure 13 were tested. 
 
Figure 13: Tested candidates’ substrates steroids (in light green reaction expected in position 3 leading to a 3α product, light red 
reaction expected in position 20 leading to a 20β product). 
A preliminary qualitative analysis was performed for the analytes DHP (Figure 14A), cortisol (Figure 14B) 
and its expected 20β-reduction product 20β-dihydrocortisol (Figure 14C). 
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Figure 14: Qualitative assessment for activity of DHRS7 in intact cells before and after 24 h incubation with 200nM tested 
substrates DHP (A), cortisol (B) and relative hypothesized product 20b-dihydrocortisol (C). The experiment was performed in 
triplicates and expressed as mean ± SD. *p<0.05. 
The activity assays revealed no qualitative differences between the supernatant of the stable DHRS7 HEK 
293 cells vs. untransfected control cells after 24h DHP incubation (Figure 14A). A small, significant decrease 
was detected for cortisol after incubation for 24 h (Figure 14B) however, the predicted metabolite 
20β-dihydrocortisol was not changed (Figure 14C). These metabolites were not studied further.  
Instead, progesterone was quantified at different incubation times (Figure 15) and the following products 
were also measured: the expected product 20βOHProg, the unexpected reduction product on position 20 
to a 20α carbonyl, 20αOHProg, and finally a potential product 17αOHProg, as highlighted in Figure 6 in the 
introduction. 
 54 
 
 
Figure 15: Quantification of products formation after incubation with progesterone (A) and the hypothesized products 20αOHProg 
(B), 20bOHProg (C), and 17αOHProg (D). The experiment was performed in triplicates and expressed as mean ± SD. 
Quantification by LC-MS/MS revealed no change in the levels of progesterone at any time point in the 
DHRS7 HEK cells, the untransfected HEK 293 control cells, and media control (Figure 15A). 
The expected product 20βOHProg was detected in equal amounts of ca. 10 nM in the DHRS7 HEK cells, the 
untransfected HEK 293 control cells, but was not detected in the media control. (Figure 15B). Instead, a 
minimal time-dependent increase in the levels of 20αOHProg was detected in stably transfected DHRS7 
and untransfected HEK 293 cells (Figure 15C), as well as for 17αOHProg (Figure 15D). The latter metabolite 
was detected at a concentration of ca. 15-35 nM with values close to the limit of detection after 1 h. Taken 
together, no promising differences were observed for the evaluated products from the hypothesized 
substrate progesterone. To support the findings of this experiment, a progesterone receptor 
transactivation experiment was performed by Simon Stücheli, a master student that I supervised. The 
progesterone receptor was activated using 10 nM progesterone in the presence of DHRS7 plasmid 
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transfected into HEK 293 cells as in the published work [191]. No differences in progesterone receptor 
transactivation were observed between DHRS7 and pcDNA3 transfected HEK293 cells (unpublished data). 
To test for DHRS7 activity towards 17OHProg, the potential metabolites 17α,20bdiOHProg and 
17α,20αdiOHProg were quantified. A significant time-dependent increase of 17α,20bdiOHProg and 
17α,20αdiOHProg was observed following incubation of 200 nM of 17OHProg in both DHRS7 HEK 293 and 
untransfected controls (Figure 16A and B). However, comparison of DHRS7 HEK 293 vs untransfected HEK 
controls showed the levels of 17α,20bdiOHProg were higher in the DHRS7 HEK cells, and conversely the 
levels of 17α,20αdiOHProg were lower in DHRS7 HEK cells compared to the untransfected HEK controls. 
This was most pronounced after 4 h were a two-fold difference was observed for both metabolites (Figure 
16A and B). 
 
Figure 16: Quantification of products formation of 17α,20αdiOHProg (A) and 17α,20bdiOHProg (B) after incubation with 200nM 
17αOHProg. The experiment is one representative of two independent experiments and was performed in triplicates and expressed 
as mean ± SD. ns=not significant, *p<0.05, **p<0.001, ****p<0.005. 
4.2.2.3 An in vitro Method to assess Substrates and Inhibitors of DHRS7 
4.2.2.3.1 Visualization and Identification of DHT and 3αAdiol 
A method to evaluate potential competitive substrates and inhibitors of DHRS7 is needed. Based on the 
observed reduction of DHT to 3αAdiol in HEK 293 cells transfected with DHRS7, I used radioactive DHT as 
a model substrate to develop a cell free system to measure conversion using TLC separation and 
scintillation cocktail. 
Before quantifying the levels of radioactive analytes DHT and 3αAdiol, the visualization and identification 
of the two metabolites was established. 10 μL of 1 mM of non-radioactive mixed analytes and pure 
compounds were applied to a TLC plate and separated in a 1:4 mixture of ethyl acetate and chloroform. 
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Following separation, compounds were dried, sprayed with 3% v/v sulfuric acid in water, and heated. The 
visualized analytes on a TLC plate are present in Figure 17, from where the “Rf” was calculated as cm 
analyte front/cm solvent front.  
 
Figure 17: Characteristics of the analytes 3αAdiol and DHT on the TLC plate under UV light after separation. A. Visualization of DHT 
and 3αAdiol. B. Rf values of DHT and 3αAdiol. 
Spraying with 3% v/v sulfuric acid in water allowed to visualize the analytes otherwise not seen under UV 
light (data not shown). The 3αAdiol is visualized as a yellow spot and the DHT as a violet spot (Figure 17A). 
Rf values corresponded to 0.333 for DHT, and 0.166 for 3αAdiol (Figure 17B).  
4.2.2.3.2 Radioactivity Assay in Intact Cells with DHT 
To validate the radioactivity assay, DHRS7 HEK 293 stably expressing cells were seeded in 96 well plates, 
and radioactivity counts of DHT and 3αAdiol were compared to results generated from the mass 
spectrometry method (Figure 18). The radioactivity assay had to be performed in a 96wells for safety and 
costs issues. The LC-MS/MS analysis had to be performed in 24-well plate format to avoid decreased 
sensitivity for the detection of physiological concentrations of the analytes in nM ranges. 
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Figure 18: Comparison of DHT and 3αAdiol analytes in HEK 293 quantified with MS/MS in 24-well plates format (A, B) with 
radioactivity assay in 96-wells format (C, D) after DHT treatment. The experiments were performed in triplicates and expressed as 
mean ± SD. ND=not detected as S/N<3. 
The activity assay performed in intact cells using the 24-well format and analyzed by mass spectrometry 
showed that 3αAdiol formation was increased in a time-dependent manner reaching ca. 30 nM/h 
(Figure 18B), whilst DHT was conversely decreased in a time-dependent manner at ca. 20 nM/h 
(Figure 18B). The formation of 3βAdiol was not detected (supplementary data in section 9.1.1.3), which 
was also observed in transiently transfected HEK 293 cells in the published work [191]. The radioactivity 
assay performed in 96 well plates showed a time-dependent decrease of DHT in DHRS7 HEK 293 cells (ca. 
40% after 1 h, 55% after 2 h, 80% after 4 h, and 95% after 8 h) (Figure 18C) compared to the untransfected 
HEK 293 control cells (ca. 20% after 1 h, 25% after 2 h, 30% after 4 h, and 35% after 8 h). However, the 
3αAdiol radioactive counts in the DHRS7 HEK 293 cells showed similar values after 2 h, 4 h and 8 h, with 
very low background values measured in untransfected HEK 293 control cells (Figure 18D). 
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4.2.2.3.3 Radioactivity Assay in Lysate 
In order to optimize a radioactivity cell lysate assay for further screening of potential substrates or 
inhibitors of DHRS7 according to DHT reduction, the following conditions were compared: cofactor 
supplementation, buffer, lysate solubilization, protein concentration and time dependency from frozen 
pellet. 
First, conversion of DHT to 3αAdiol was measured in 1 µg/µL of untransfected HEK 293 cells or DHRS7 HEK 
293 stable lysates for 1 h in phosphate-free buffers prepared according to manufacturer instructions, 
different to the phosphate buffer previously used [145, 146]. 
The buffers utilized in the following experiments where MOPS pH6.8 or TS2 pH7.4. Both buffers were 
supplemented with either 500 µM NADPH or a regeneration system (described as “RS” in Figure x. Briefly, 
250 μM of the cofactor NADP+, 1 mM glucose-6-phophate, and 0.5 U of glucose 6 phosphate 
dehydrogenase) (Figure 19A). Afterwards, the regeneration system was also modified by the substituting 
NADP+ for NADPH (described in Figure as “NADPH-RS”). TS2 buffer was also supplemented with the 
addition of DTT or glycerol. Finally, the cell lysates were solubilized by sonication or freeze-thawing of the 
frozen cell pellet (see Figure 19B). 
After the reaction with 3% sulfuric acid, the TLC plate appear to display additional unspecific spots when 
tested in the TS2 buffer plus the regeneration system without the lysate incubated for 1 h (Lane 1 in 
Figure 19C), plus lysate incubated for 1 h (Lane 2 in Figure 19B), and plus lysate incubated for 0 h (Lane 3 
in Figure 19C). 
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Figure 19: Radioactivity assay optimization with 1 µg/µL for 2 h. A. Regeneration system versus cofactor NADPH in MOPS pH6.8 or 
TS2 pH7.4 buffers. B. Regeneration system (RS) versus regeneration system with NADPH instead of NADP+ (NADPH-RS), in different 
MOPS pH6.8 and TS2 pH7.4 buffer preparations (Sucr=sucrose, DTT= dithiothreitol, gly=glycerol instead of sucrose), C. Visualization 
of spots under UV light on TLC plate following radioactivity assay in lysate with TS2 pH7.4 buffer, addition of stop mix, separation, 
and reaction with 3% sulfuric acid (1) without lysate incubated for 1 h, (2) with lysate incubated for 1 h, and (3) with lysate 
incubated for 0 h. The experiments were performed in duplicates and expressed as mean ± SD 
The best conversion rates (ca. 25%) were achieved after one hour with the TS2 buffer with a NADPH 
regeneration system under the physiological pH of 7.4 (Figure 19A). These conditions can facilitate the 
oxidation step of NADP+ by the enzyme G6PDH (present in the regeneration system) that facilitates the 
constant NADPH production needed to sustain the reduction of DHT by DHRS7. In fact, with the use of 
NADPH alone without the NADPH regeneration system, the activity assay at pH 6.8 seemed to perform 
better. Importantly, the background DHT activity in the lysate of non-transfected HEK 293 is much lower, 
reflecting what previously observed in intact cells (Figure 18).  
The use of different combinations of MOPS pH6.8 buffer, reducing agent DTT, glycerol instead of sucrose, 
and sonication to solubilize of the lysate, did not increase the conversion rate (Figure 19B). Interestingly, 
the visualization of the selected reaction plus lysate compared to without lysate allowed for the 
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identification of an unspecific band (Figure 19C) that showed no radioactivity counts (data not shown), 
and a black spot that did not migrate, which was identified as sucrose (present only in the sucrose buffer 
conditions previously measured). For this reason, an additional control using no lysate was added to 
ensure the correct spots are scratched from the TCL plate for DHT and 3αAdiol. 
The optimized buffer TS2 pH7.4 was used for evaluating DHRS7 HEK 293 stable lysate for time (Figure 20A 
and B) and lysate protein concentration dependency (Figure 20C and D). The results are shown as for 
Figure 18, with the percentage of DHT (Figure 20A and 20C) and corresponding 3αAdiol counts (Figure 20B 
and 20D) compared to control. 
 
Figure 20: Protein concentration (A, B) and time dependence of DHT (C, D) and 3αAdiol (B) in lysate of HEK 293 stably expressing 
DHRS7. The two experiments were performed in duplicates and expressed as mean ± SD. 
An increasing lysate protein concentration and time dependent DHT metabolism was observed in both 
experiments (Figure 20A-B and Figure 20C-D). However, 3αAdiol counts did not proportionally increase as 
already observed with the intact cells in both cases.  
To understand whether the loss of 3αAdiol counts in the radioactivity assay is due to further metabolism 
in HEK 293 cells in the radioactivity assay, the assay was performed in the presence of CYP7B1 inhibitors, 
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an enzyme hypothesized to metabolize 3αAdiol [203, 204]. However, no changes in DHT and 3αAdiol 
counts were observed (data not shown). For the study of potential novel substrates or inhibitors of DHRS7 
with the potential to inhibit competitively the reduction of DHT, the conditions of 1 h incubation time and 
1 µg/µL of DHRS7 protein lysate concentration for the lysate radioactivity assay was chosen as being in a 
good trade-off between the linear range of DHT consumption (ca. 40±5% decrease) whilst maintaining low 
3αAdiol counts loss. 
4.2.2.3.4 Test of Substrates and Inhibitors with a Lysate Radioactivity Assay 
The screening of possible substrates and inhibitors based on the newly optimized conditions (previous 
subchapter) is shown in Figure 21 and was performed with 24 candidate substrates at a concentration of 
5 μM. Both the substrates and inhibitors were selected for the following reasons: 
- Expected steroidal compounds reacting with DHRS7 based on the results of the intact cells assays: 
17OHProg (Figure 16) and cortisone [191]; 
- The compound all-trans-retinal based on observation by Stambergova et al. [145]; 
- The xenobiotic compounds 9,10-phenanthrenequinone and 1,2-naphtoquinone based on [146, 205]; 
- The AKR1C2 substrate prostaglandin PGE2 with its respective product PGF2α according to Nishizawa 
et al. [206], because of its similar 3αHSD reductive behavior in the literature [191]; 
- Predicted inhibitors and substrates of the related and well characterized enzyme 11βHSD1 through 
an in house in silico model (unpublished data) according to the activity observed for cortisone [191]; 
- Anabolic steroids with a carbonyl in position 3 alpha, hypothesized to produce a 3 alpha reduced 
product; 
- Cancer drugs used in the context of prostate and breast cancer; 
In order to maintain the integrity of the assay, a quality control threshold for the conversion of the model 
substrate DHT was assessed for every individual experiment. Based on the results in Figure 19 the 
conversion threshold of “buffer (- ctrl)” vs. “vehicle 0.5% (+ ctrl)” was set at 23±5%. Experiments failing to 
reach this threshold were repeated.  
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Figure 21: Substrates and inhibitors screening with a concentration of 5 µM through radioactivity assay with 200nM DHT in lysate 
of HEK 293 stably expressing DHRS7: 17αOHProg (A), all-trans-retinal (B), the quinones 1,2-napthoquinone and 9,10-
phenanthrenequinone (C), the prostaglandins PGE2 and PGF2α (D), possible 11βHSD1 substrates and inhibitors (E), the anabolic 
steroids hypothesized to be reduced in position 3alpha (F), and the cancer drugs flutamide, abiraterone, tamoxiphen and 
daunorubicin (G). Lysate with 200 nM DHT, a NADPH regeneration system in buffer TS2 pH 7.4 incubated 1 h with 1 µg/µL of DHRS7 
HEK 293 protein lysate concentration and 0.5% DMSO served as positive control (labelled as “vehicle 0.5% (+ ctrl)”), and buffer 
with 200 nM DHT, a NADPH regeneration system in buffer TS2 pH 7.4 incubated 1 h and 0.5% DMSO served as negative control 
(labelled as “Buffer (- ctrl)”). Data between two until four independent experiments, each performed in duplicates, was normalized 
to 100% vehicle control and expressed as mean ± SD. *p<0.05. 
All but one of the potential inhibitors or substrates screened in the DHRS7 HEK 293 cell lysates assay were 
negative. 9,10-phenanthrenequinone showed a small but significant inhibition of DHT conversion (see 
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Figure 21C). An IC50 value for 9,10-phenanthrenequinone was determined by qualitatively evaluated by LC-
MS/MS after incubation with untransfected HEK and DHRS7 HEK 293 cells for 1 µM. However, the 
preliminary IC50 calculation suggested a super-physiological value of 17.45 ± 1.9 µM (data not shown). 
Additionally, 9,10-phenanthrenequinone was undetectable after 24 h incubation in either the 
untransfected or DHRS7 HEK 293 cells. This may be due to further endogenous metabolism by a yet to be 
identified enzyme present in HEK cells or degradation of the compound (data not shown). Studies for this 
metabolite were not continued. 
4.2.2.4 Approximation of an Apparent Km 
The optimized radioactivity assay showed that the conversion of the substrate DHT to the metabolite 
3αAdiol was significantly enhanced in the DHRS7 HEK 293 stable cells compared untransfected HEK cells. 
However, an important limitation of this experiment was that the total counts disappeared with longer 
incubation times in the radioactivity assay, both in intact cells and lysate protein preparations. Further 
metabolism of 3αAdiol cannot thus be excluded and may affect the kinetics of the DHT reaction. 
Nevertheless, knowing the limitations of the assay, an attempt to calculate an apparent Km in lysate and 
microsomes based on DHT consumption was performed. According to the principles of Michealis-Menten 
kinetic [207], a linear product formation range was chosen. For lysate according to Figure 20, 1 µg/µL 
protein after 1 h was chosen, and an apparent Km value and Vmax were calculated through Bets Fit values 
model and are present in Figure 22A-B. For the microsomal preparations a time-dependent radioactivity 
assay was first performed after control of the preparation with increased DHRS7 concentration per protein 
amount in order to choose the condition for best linear product formation range (see Figure XC-E). Again 
a 1 µg/µL protein after 1 h was chosen. Nevertheless, due to technical limitations using frozen 
preparations of microsomes, resulting in high variability between independent experiments, Km value 
could not be calculated (data not shown). 
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Figure 22: Calculation of apparent Km and Vmax in lysate and microsomes. A-B. Apparent Km in lysate (The experiment was 
performed in three independent experiments, two performed in triplicates, one performed in duplicates), C. Microsomal 
preparation shows increased DHRS7 expression in the microsomes of HEK stably expressing DHRS7. D-E. Time dependent 
radioactivity assay with 200 nM DHT, 1 µg/µL in microsomes. The experiment was performed in duplicates. 
A Vmax of 2.8 ± 0.8 nmol/g/min and a Km of 53.7 ±63.1 nM were shown in whole cell lysates (Figures 22A-
B). To increase the concentration of DHRS7 per total protein compared to whole cell lysate, microsomal 
preparations were used and showed increased DHRS7 amount in the microsomal preparationderived from 
DHRS7 stably expressing HEK 293 cells (Figure 22 C). Microsomal preparations showed a time dependent 
decrease in DHT (Figure 22 D). A concomitant, non-proportional increase in 3αAdiol was observed (figure 
22E). An attempt to calculate a Km in microsomes was also attempted by using the experimental 
conditions; 1 µg/µL protein lysate and 1 h incubation according to the linear activity observed in Figures 
22D-E. However, variability between experiments was consistently observed which prevent the calculation 
of the Km. Because of this technical issue and the high amount of cells needed for the isolation of 
microsomes (1 µg/µL microsomal protein needed for each measurement to be perform in triplicate), this 
experiment was not continued.  
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4.2.3 Discussion 
The investigations presented in this chapter revealed that DHRS7 is oriented towards the cytoplasm of the 
endoplasmic reticulum membrane and shows 3α/20β-HSD reductive activity towards some steroidal 
compounds, similar to AKR1C enzymes, particularly AKR1C2. This reductive activity was observed for the 
20-oxoreduction of cortisone to 20b-dihydrocortisone as well as for the reduction of 17αOHProg to 
17α,20bdiOHProg (low activity of questionable physiological relevance), and for the 3-oxoreduction of 
DHT to 3aAdiol (potential of suppressing AR activity in the presence of DHT), as shown by activity assays 
in DHRS7 overexpressing HEK 293 cells. The information gained with this targeted “deorphanization” 
approach helped to characterize the in vitro activity of DHRS7; however, the physiological relevance of 
these reactions, in particular for the reduction of the potent AR ligand DHT, needs to be further addressed. 
Regarding the activity of DHRS7 towards DHT, Zemanová et al. recently showed DHT to be a substrate by 
use of a combination of in silico structural homology modelling based on the structure of 11bHSD1, 
structure-based docking calculations by screening of an in-house database and a Human Metabolome 
Database publicly available database (HMDB, www.hmdb.ca), as well as experimental evaluations with 
purified DHRS7 where a Km of 48.4 ± 8.2 µM and a Vmax of 34.4 ± 4.2 nmol/mg/min were calculated [208]. 
However, the HPLC technique used was not able to differentiate between the alpha and beta reduced 
forms of the product(s). In the published work presented in this chapter, I addressed this knowledge gap 
by taking advantage of an improved LC-MS/MS method [191]. The Michealis-Menten kinetic values 
obtained are different from those of preliminary observations by Zemanová et al. In fact, the study of the 
reduction of DHT in whole cell lysate radioactivity assays suggests a much lower apparent Km of 
53.7 ± 63.1 nM and a Vmax of 2.8 ± 0.8 nmol/g/min. Zemanová et al. used a phosphate buffer with 
cofactor supplementation using a glucose-6-phosphate dehydrogenase regeneration system for the 
calculation of kinetic values. This buffer/system can interfere with the assay by decreasing the calculated 
affinity values, according to the manufacturer’s instructions and Domagh et al. [209]. Nevertheless, 
observations made in whole cell lysate radioactivity assays should be confirmed using purified DHRS7 
protein and the optimized conditions for the lysate assay (see Figure 19), possibly with a parallel 
measurement using LC-MS/MS, which would need to be improved in order to quantify low nanomolar 
concentrations of DHT and 3aAdiol in a high protein content matrix.  
The investigations described in the result section 4.2.2 on DHRS7 expressing HEK 293 cells revealed that 
only 17αOHProg was reduced on the 20β position, as it was the case for cortisone [191], out of the four 
tested metabolites that were reduced on the 3α and/or 20β position (20β dihydroprogesterone, cortisol, 
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progesterone, and 17αOHProg). Interestingly, both 17αOHProg and cortisone have a hydroxyl moiety in 
position 17 (see chemical structures in Figure 6 of the introduction). This chemical feature could contribute 
to facilitate the reaction. However, this aspect needs to be further addressed. Nevertheless, 17a-OH-
progesterone was not confirmed as a competitive inhibitor of DHT reduction in the lysate radioactivity 
assay (see results section 4.2.2.3.4) and it is highly likely that it has no functional effects in the context of 
prostate cancer. Indeed, Grigoryev et al. [210] observed an increased proliferation of LNCaP prostate 
cancer cells following treatment with 50 nM of 17aOHProg, which corresponds to concentrations about 
10-fold higher than found in the plasma under physiological conditions. Moreover, the reaction of 17a-
OH-progesterone to 17a,20bdiOHProg should be confirmed in transiently DHRS7 overexpressed HEK 293 
cells to exclude adaptive effects encountered following the integration of the transgene in stably 
transfected HEK 293 clones [211], and possibly further explored on a more physiological level by studying 
DHRS7 in endogenously expressing systems. 
The radioactivity assay performed with lysate based on DHT reduction was unable to identify novel 
substrates or confirm all-trans-retinal as substrate by (competitive) inhibition of DHT reduction. Regarding 
this novel screening assay for candidate substrates and inhibitors of DHRS7, a positive inhibitor of DHT 
activity has not been identified yet and future discovery would help to optimize the assay. In this respect, 
4,4-dimethylbenzil and benzyl were predicted as novel exogenous substrates of DHRS7 by docking their 
carbonyl group to the same catalytic amino acid Y203 of the active site of DHRS7 as DHT (see Figure 7 of 
the introduction) allowing the transfer of protons for reduction [208]. Regarding the negative result 
observed for the all-trans-retinal activity, it needs to be considered that this compound is extremely 
sensitive to light, oxidation, air and it is insoluble in water. Therefore, it may be the case that a higher 
degree of enzyme purity with decreased membrane contaminants is required to optimize this specific 
reaction. Similar observations apply for the negative result obtained for prostaglandin E2 (figure 21D). 
However, this potential candidate substrate was confirmed to be a negative substrate with the purified 
DHRS7 preparation, possibly only docking in the active side of DHRS7 observed by fluorescence titration 
of the holoenzyme but not metabolized towards the carbonyl moiety to the potential product 
prostaglandin F2a [208]. Additionally, in order to avoid precipitation issues in aqueous buffer preparation 
for lipophilic compounds as both all-tans-retinal and prostaglandins, conjugation with BSA should be 
tested.  
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5 Chapter 2: Functional and Phenotypical Characterization Following 
DHRS7 Depletion 
In the first chapter, it was shown that DHRS7 can catalyse the reduction of the carbonyl in position 3 and 
20 (3α/20β) of the steroidal backbone of the androgen DHT, the glucocorticoid cortisone, and possibly also 
the progestin 17αOHProg. This evidence suggested that DHRS7 may play a role in steroidal hormone 
dependent cancers and/or for adrenal steroidogenesis. For this reason, cell lines expressing endogenous 
DHRS7 from breast, prostate, and adrenal gland origin, were investigated in order to functionally and 
phenotypically characterize changes following DHRS7 depletion using siRNA targeted molecules. The 
following experimental approaches were used: 
1. Cancer and steroidogenesis assays performed in breast and adrenal cancer cell lines. This 
approach tested whether the increase in proliferation, migration, and the decreased adhesion 
previously observed in the prostate cancer cell line LNCaP following DHRS7 depletion, are also 
observed in other cancer models involved in steroid hormone metabolism. In the context of breast 
cancer for example, Zhang Wei-Hong et al. [153] observed that immunohistochemical staining in 
human breast cancer in situ expressed higher DHRS7 protein compared to breast infiltrating 
carcinoma tissues, suggesting a role of DHRS7 in the context of breast cancer progression. To test 
this hypothesis, in this chapter steroid hormone dependent and independent breast cancer and 
adrenal cancer cell models were selected to investigate proliferation, adhesion and migration 
following DHRS7 depletion. 
Additionally, the adrenal cell line H295R was used to assess adrenal steroidogenesis following 
DHRS7 down-regulation. This approach aimed to support the hypothesis that DHRS7 plays a role 
in steroid metabolism in the adrenals, since DHRS7 is highly expressed in adrenal tissue [191] and 
metabolizes steroidal compounds as shown in chapter 1 (section 4); 
 
2. Untargeted proteomics approach following DHRS7 downregulation. The prostate cancer cell line 
LNCaP was investigated using an untargeted proteomics approach at multiple time points 
following DHRS7 siRNA mediated depletion. This strategy allowed to: 
• Characterize the LNCaP phenotype with regard to the protein expression of SDRs and 
nuclear receptors; 
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• Test if DHT is the relevant substrate responsible for the phenotypic changes observed in 
LNCaP cells, which endogenously express DHRS7 and AR, by quantifying changes of 
androgen receptor downstream proteins; 
• Quantify proteins related to proliferation, migration, and adhesion following DHRS7 
knock-down; 
• Generate new hypotheses underlying the observed aggressive cancer phenotype 
following DHRS7 knock-down; 
The untargeted proteomics method was first improved with the aim to reliably identify and 
quantify a high number of proteins. A number of proteins identified following analysis were further 
validated through immunofluorescence, western blotting, cell cycle analysis, and AR 
transactivation.  
 69 
 
5.1 Assessing the Phenotype of Breast and Adrenal Cancer Cell Lines under siRNA 
mediated DHRS7 Silencing  
5.1.1 Methods 
5.1.1.1 Cell Culturing 
MCF-7, HCC1954, and T47D cells were a kind gift from prof. Bentires-Alj, from FMI institute, MDA-MB-453 
were instead purchased by ATCC (Manassas, USA). MCF-7 cells were cultivated in Dulbecco's modified 
Eagle's medium (DMEM) containing 2mM L-glutamine and 4.5 g/L glucose, T47D in RPMI-1640, 
MDA-MB-453 in RPMI, HCC1569 in RPMI-1640, all supplemented with 10% FBS and 1% (v/v) penicillin–
streptomycin (Sigma–Aldrich) at 37°C in a humidified 5% CO2 atmosphere. All the cell lines were tested 
monthly for mycoplasma contamination. 
The human adrenocortical carcinoma cell line H295R (ATCC, Manassas, USA) was cultivated in Dulbecco's 
modified Eagle's medium (DMEM)/Ham's nutrient mixture F-12 (1:1, v/v) (Life Technologies, Zug, 
Switzerland), supplemented with 1% (v/v) IST + Premix (BD Bioscience, Bedford, MA, USA), 2.5% (v/v) Nu-
serum (Lot: 2342913, BD Bioscience, Bedford, MA, USA), 15 mM HEPES buffer and 1% (v/v) penicillin–
streptomycin (Sigma–Aldrich) at 37 C with a humidified 5% CO2 atmosphere. The Nu-serum consists of 
25% newborn calf serum and 75% of a proprietary formulation containing epidermal growth factor, 
endothelial cell growth supplement, insulin, transferrin, triiodothyronine, progesterone, estradiol, 
testosterone, cortisol, selenous acid, ophosphorylethanolamine, glucose, amino acids, vitamins and other 
trace elements and nutrients in its Ham's F12 medium base. The concentrations of the supplements are 
not declared by the supplier. For the functional experiments, passages between 10 and 13 were used. 
5.1.1.2 Determination of RNA Expression 
Performed as described in method section 4.2.1.3 with primers sequences depicted in supplementaries 
section 9.1.1.2. For RARα, the primers were the same as used by Kalitin et al. [212]. 
5.1.1.3 Western Blotting 
See method section 4.2.1.4. Protein loaded corresponded to 30 µg. 
5.1.1.4 SiRNA mediated Silencing of DHRS7 
For proliferation, adhesion and migration assays, 3 x 105 cells were reverse transfected in a 6 cm dish with 
7.5 μL RNAiMax reagent and final concentration of 25 nM of siRNA targeting DHRS7 (D-009573-02; Thermo 
Scientific, Waltham, MA) or a nontargeting siRNA negative control (D-001810-03-20; Thermo Scientific) 
diluted in 2 mL OptiMEM. For the steroidogenesis assay in H295R, the procedure was adapted for 24 wells 
format (1.25 µL RNAiMax and 25 nM siRNA final concentration diluted in 66.6 µL OptiMEM). 
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5.1.1.5 Cell Proliferation Measurement by xCELLigence 
Seeding in xCELLigence (ACEA Biosciences, San Diego, CA) 96-well format was after 24 h of siRNA mediated 
silencing as following: 10000 cells/well for T47D, MDA-MB-453, and HCC1569, 15000 cells/well for H295R, 
and 5000 for MCF-7. Proliferation was determined kinetically using the xCELLigence system according to 
the manufacturer’s protocol. Cell proliferation measurements were performed in triplicates with 
programmed signal detection every 15 min after seeding and background of media was subtracted. Data 
acquisition and analyses were performed using the RTCA software (version 1.2; ACEA).  
5.1.1.6 Cell Adhesion 
96-well plates were coated with 50 μg/mL fibronectin, collagen type IV (Sigma Chemical Co., St. Louis, 
MO), or nothing, and blocked with 0.5% bovine serum albumin (BSA) in cell medium for 45 min at room 
temperature. MCF7 cells were seeded at 1 × 105 cells per well and allowed to adhere for 60 min, as 
previously described [213]. Wells were then washed twice with PBS, fixed with 100 μL of crystal violet 
solution (0.1% crystal violet in 25% MeOH in water) and left for 5 min at room temperature. The number 
of adherent cells in each well was quantified through staining with 0.1% crystal violet (w/v) in 25% 
methanol (v/v), followed by optical density (OD) absorption measurement at wavelength of 565 with a 
photometer (Molecular Devices, Sunnyvale, California). Cell adhesion experiments were performed in 
triplicates. 
5.1.1.7 Transwell Cell Migration 
The migration assay for MCF-7 was performed as previously described with minor modifications [147], and 
slightly adapted for H295R according to [214]. Briefly, 24 h post transfection, 5 x 104 for MCF-7 and 2 x 105 
for H295R scrambled siRNA and DHRS7 siRNA cells were resuspended in 100 μL serum-free media and 
placed into the upper compartment of a Transwell chamber with 8.0-μm pore polycarbonate of a 24-well 
plate (Corning, New York, United States). Instead, the bottom chamber contained 600 μL of 10% FBS for 
MCF-7 and 2.5% and 5% Nu-serum for H295R supplemented cell culture media as chemo-attractant. After 
24 h incubation, cells were stained with 0.1% crystal violet (w/v) (C3886; Sigma) in 25% methanol (v/v). No 
migrated cells in the upper chamber were removed using a cotton swab. Images of migrated cells which 
adhered to the bottom of the filter were captured with 10 photos at 20× magnification using a light 
microscope (Zeiss Axiovert 100; Carl Zeiss Microscopy GmbH, Feldbach, Switzerland) and cells counted 
using the threshold setting on Image J. 
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5.1.1.8 Steroidogenesis Assay 
The H295R steroidogenesis assay was performed according to the OECD test guideline [215]. Briefly, 
H295R cells were reverse transfected with 15uL RNAiMax reagent and 25 nM of siRNA targeting DHRS7 
(D-009573-02; Thermo Scientific, Waltham, MA) or a nontargeting siRNA negative control (D-001810-03-
20; Thermo Scientific) diluted in 2mL OptiMEM and seeded in 12-well plates at a density of 400,000 
cells/well in complete medium. The medium was replaced 48 h later with fresh phenol free medium 
supplemented with 10 μM Forskolin (CAS Nr. 66575-29-9, Sigma–Aldrich (Buchs, Switzerland)), DMSO 
(0.1% (v/v)) served as vehicle control. Cells were incubated for 24 h and 950 μL culture supernatants were 
collected and stored at -20°C until further analysis. 
5.1.1.9 Extraction and Targeted Steroids Quantification by UPLC-MS/MS 
Targeted analysis of steroid hormone levels in H295R culture supernatants was performed as previously 
described [216] with the help of a selective solid-phase extraction (SPE) and a highly sensitive UPLC-
MS/MS. Extraction and steroidal measurements were performed by Dr. P. Strajhard. Briefly, for solid-
phase extraction, 1 ml of each H295R cell supernatant was mixed with 0.1 ml of protein precipitation 
solution (0.8 M zinc sulfate in water/methanol 50/50, v/v) that contained deuterium-labeled aldosterone, 
corticosterone, androstenedione and testosterone as internal standards. After incubating the samples in 
a shaker for 10 min at 4°C with thorough shaking (1300 rotations/min), they were centrifuged for 10 min 
at 16000 g at 4°C. The supernatants (950 ml) were transferred to Oasis HLB SPE cartridges, preconditioned 
with methanol and water. Steroids were eluted with 1 ml of methanol after washing once with 1 ml of 
water and twice with 1 ml of methanol/water (10/90, v/v). The samples were evaporated to dryness and 
then reconstituted in 25 ml of methanol. The separation and quantification of the steroids was performed 
by ultra-high pressure LC–MS/MS (UHPLC–MS/MS) using an Agilent 1290 UPLC coupled to an Agilent 6490 
triple quadrupole mass spectrometer equipped with a jet-stream electrospray ionization interface. The 
steroids were separated using a reverse-phase column (Waters Acquity UPLC BEH C18, 1.7 mm, 2.1 mm, 
150 mm) and a mobile phase A and B, consisting of water–acetonitrile–formic acid (95/5/0.1; v/v/v) and 
(5/95/0.1; v/v/v), respectively. For data acquisition and analysis, Mass Hunter software (Agilent 
Technologies) was used. Stock solutions (10 mM and/or 1 mM) of above mentioned steroids were 
prepared in ethanol or methanol. 
5.1.1.10 Statistic 
For the statistical analysis of proliferation, migration and adhesion assays, the Student’s t-test for 
parametric variables was used, with probabilities reported as two-tailed. Quantification of steroids was 
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analyzed through one-way ANOVA with Bonferroni post-test for multiple comparisons. The steroid levels 
measured in the supernatants of incubated H295R cells labelled with ND expressed a signal to noise 
(S/N) <3.   
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5.1.2 Results 
5.1.2.1 Cancer assays in DHRS7 depleted breast cancer cell lines 
The role for DHRS7 in different breast cancer cell lines was investigated following a promising observation 
in a pilot study in our laboratory performed by Dr. Julia Seibert in the breast cancer cell line ZR-75-1 [217]. 
The following cell lines were selected for further functional experiments based on their DHRS7 expression 
levels: T47D, MDA-MB-453, HCC1569, and MCF-7. DHRS7 was depleted using siRNA targeted molecules 
and cell proliferation was measured after 24 h by xCELLigence (Figure 23).  
  
Figure 23: Proliferation after siRNA mediated silencing in breast cancer cell lines for T47D (A), MDA-MB-453 (B), HCC1569 (C), and 
MCF-7 (D). Experiments performed in triplicates and data expressed as mean ± SD. 
No significant differences were observed in the T47D, MDA-MB-453, and HCC1569 cell lines. A small but 
significant increase in proliferation was observed in the MCF-7 cell line after 40 h. This cell line was then 
selected for adhesion and migration assays (Figure 24). 
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Figure 24: Cell adhesion with fibronectin and collagen IV (A) and cell migration (B) assays for MCF7 cells. The cell adhesion was 
performed in three independent experiments, each performed in triplicates and, and migration in three independent experiments 
based on stained cells in 10 fields scanned at 20x magnification setting and analyzed using ImageJ with two representative pictures 
shown. Data are expressed as mean ± SD. Statistical analysis was performed using the Student’s t-test. ns=not significant, *p<0.05, 
****p<0.001. 
Adhesion of MCF-7 following 24 h DHRS7 siRNA mediated depletion showed a 20% decrease in adhesion 
on plates coated in fibronectin, a glycoprotein of the extracellular matrix that binds to membrane-
spanning receptor proteins called integrins (Figure 24A). No changes in migration where observed for non-
coated and collagen IV coated plates (Figure 24B). 
5.1.2.2 Phenotype of the adrenal H295R under siRNA mediated DHRS7 silencing 
First, the expression of DHRS7 was investigated in the adrenal cell line H295R, hypothesized to have high 
DHRS7 expression levels, similar to the one observed in human adrenal tissue [55] (Figure 25A-B). 
Additionally, DHRS7 expression was also quantified through different passages (Figure 25C), to control for 
possible changes in the expression, as H295R are known to loose differentiation at higher passages in 
culture that could affect steroidogenesis [215]. 
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Figure 25: Expression of DHRS7 in the human adrenal steroidogenesis cell line H295R. mRNA expression (A) and protein expression 
in passage 5 (B) and protein expression between passages 8 and 16 (C) of DHRS7 and the housekeeping gene PPIA. 
As shown in Figure 25A-B, H295R express high levels of DHRS7 mRNA and protein, and is not influenced 
by higher cell passage number (Figure 25C). 
The functional effect of DHRS7 depletion was investigated using proliferation and migration assays. As 
shown in Figure 26, DHRS7 protein depletion is observed after 48 h and 72 h.  
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Figure 26: No significant effect on proliferation and migration on H295R cells after 24h siRNA mediated DHRS7 silencing. 
A. Expression of DHRS7 after siRNA mediated DHRS7 silencing after 24 h, 48 h, and 72 h (C: scrambled siRNA, KD: siRNA DHRS7). 
B. Proliferation of H295R cells after 24h. Experiments performed in two independent experiments in triplicates and data expressed 
as mean ± SD. C. Representative images of H295R in transwell after migration with 2.5% and 5% Nu-serum concentration. D. 
Percentage of H295R migrated cells after 24 h transfection siRNA DHRS7 versus scrambled siRNA with 5% Nu-serum.  
No significant effects were observed in proliferation and migration (Figure 26). 
To address the possible role of DHRS7 towards hormones involved in adrenal steroidogenesis, 
steroidogenesis profiling following DHRS7 depletion was performed. Briefly, following 24 h DHRS7 siRNA 
mediated depletion, H295R cells were exposed to either a medium control or Forskolin (to induce 
steroidogenesis through the cAMP pathways [218]). According to [216], Forskolin stimulation is important 
as it must be considered that the basal steroidogenesis rate in H295R cells is not under the control of a 
circadian rhythm as in the human body. The following endogenous steroid hormones were measured and 
quantified by LC-MS after a further 48 h incubation: progesterone, 17αOHProg, cortisol, cortisone, 
corticosterone, 11-deoxycorticosterone (DOC), aldosterone, 11-deoxycortisol (11-DOC), 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androstenedione, 
testosterone, DHT, and 3αAdiol (see Figure 27). For steroidal structure and enzymes related reactions, 
please refer to Figure 6 of the introduction. 
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Figure 27: Quantification of steroids in the human adrenal cell line H295R upon DHRS7 silencing and steroidogenesis induction. 
17αOHProg, androstenedione, DHEA are significantly increased and androsterone is significantly decreased in DHRS7 depleted and 
forskolin treated cells. The experiment was performed in triplicates. In green, 17αOH-pregnenolone, progesterone and 
allopregnenolone were not measured, 3αAdiol was detected only once in scrambled siRNA Forskolin condition. ***p≤0.0001, 
**p≤0.001, ns=not significant, ND=not detected as signal to noise ratio<3.  
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The quantified steroids were not changed following DHRS7 depletion under non-stimulated conditions 
(without Forskolin) (Figure 27). However, DHRS7 depletion under stimulated conditions (with Forskolin) 
showed a statistically significant upregulation in the steroids 17αOHProg, androstenedione, and DHEA. 
Additionally, under these experimental conditions, androsterone was detected to be slightly 
downregulated (Figure 27). DHT was close to the limit of detection and showed no significant changes in 
any of the conditions tested (Figure 27). 3αAdiol was detected only in the forskolin treated samples but 
was also close to the limit of detection. These two androgens are mainly produced in the prostate, as 
highlighted in Figure 2 in the introduction.  
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5.1.3 Discussion 
Amongst the breast and adrenal cancer cell lines tested, only the breast cancer cell line MCF-7 exhibited a 
small but significant difference in proliferation as measured by xCELLigence. This observation is supported 
by a report in the literature which showed an increased number of cells in the S-phase of the cell cycle in 
DHRS7 overexpressing MCF-7 cells and conversely, an increased number of cells in the G2 phase in DHRS7 
depleted MCF-7 cells, which both suggest modulation of DHRS7 affects proliferation [153]. Additionally, 
data presented in this chapter showed that MCF-7 cells exhibited a small decrease in adhesion (ca. 20%) 
using extracellular matrix protein fibronectin coated plates, yet there was an 170% increase in the number 
of migrating cells following DHRS7 depletion.  
These two functional effects often correlate with each other as they imply mechanistic changes to the 
cytoskeleton arrangement by decreasing cell contacts with neighbouring cells. However, these assays do 
not always correlate to functional differences in proliferation, as observed by Dr. Julia Seibert [147] in DU-
145 and PC3 cell lines where adhesion and migration correlated but not proliferation. Interestingly, in the 
thesis of Dr. Julia Seibert, another breast cancer cell line, ZR-75-1, showed promising differences in 
proliferation and migration following DHRS7 depletion [217].  
Functional effects observed on proliferation, adhesion and migration in breast, prostate and adrenal 
cancer cell lines studied until now, following DHRS7 depletion, may be explained by different 
characteristics of the cell lines. Among many influencing factors intrinsic to the cell lines, differential 
expression levels of endogenous DHRS7, nuclear receptor expression and doubling time kinetics may play 
an important role. For example, both the breast cancer cell lines ZR-75-1 and MCF-7, as well as the prostate 
cancer cell LNCaP have their similarities in that they are all metastatic, originate from the luminal epithelia 
of their respective organ, and are positive for the androgen receptor [185, 187, 189, 190, 219, 220]. 
However, LNCaP and ZR-75-1 cells, showed more pronounced proliferation differences following DHRS7 
depletion than MCF-7 cells. Both LNCaP and ZR-75-1 cells have a long doubling times of ca. 60 h and 54 h 
[221], respectively, whereas MCF-7 cells have a doubling time of ca. 38 h. Furthermore, LNCaP cells also 
expressed the highest DHRS7 protein levels compared to all the cell lines studied in this thesis. Whether 
the aforementioned intrinsic cell characteristics influence the behavior of the cell lines following DHRS7 
depletion remains to be confirmed and further investigations are needed to tackle this knowledge gap. 
The adrenal epithelial cancer cell line H295R, did not show any relevant effects in the functional cancer 
assays for proliferation and migration. They have a doubling time of ca. 36 h [222]. H295R cells were 
subjective to changes in proliferation, invasion or migration following downregulation of KIAA0101 [223] 
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or beta catenin [214]. However, under the tested conditions, the role of DHRS7 in this cell line might be 
related to functions independent of cancer phenotypical changes. Alternatively, the cellular machinery 
needed to enable DHRS7 cancer related effects seen in other cell models might not be expressed in this 
cell line. H295R cells derive from steroidogenic tissue (adrenals) and not androgenic tissue (prostate or 
testis) or estrogenic tissue (breast), therefore, it could be hypothesized that H295R cells are not responsive 
to DHRS7 silencing because the substrates responsible for the effects are not present. Alternatively, 
another explanation could be that the amount of DHRS7 downregulated was insufficient to exert an 
important functional difference. 
On the other side, the steroidogenesis profile in H295R cells with depleted DHRS7 showed some small 
differences in the levels of 17αOHProg, androstenedione, DHEA, and androsterone only after Forskolin 
stimulation. These small changes might be related to the modulation of CYP17A1 as all these metabolites 
are targets of this enzyme (see Figure 6 of the introduction). However, this should be addressed by 
quantitative analyses.  
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5.2 Assessing the Phenotype of LNCaP Prostate Cancer Cells under siRNA mediated 
DHRS7 Silencing by Untargeted Proteomics 
5.2.1 Methods 
5.2.1.1 Cell culturing 
The human prostate cancer cell line LNCaP was purchased from ATCC (LGC Standards GmbH, Wesel, 
Germany), cultivated in RMPI 1649 media (R8758; Sigma) supplemented with 10% fetal bovine serum (FBS) 
and penicillin (100 U/mL) /streptomycin (100 µg/mL). For the experiments, passages between 18 and 25 
were used.  
5.2.1.2 SiRNA mediated silencing of DHRS7 
3x106 LNCaP cells were reverse transfected in 10 cm dishes with 15 µL RNAiMax reagent and 25 nM of 
siRNA targeting DHRS7 (D-009573-02; Thermo Scientific, Waltham, MA) or a nontargeting siRNA negative 
control (D-001810-03-20; Thermo Scientific) diluted in 2mL OptiMEM.  
5.2.1.3 Western blotting 
Samples were heated at 95°C for 5 min in Laemmli buffer (5 mmol/L Tris HCl, pH 6.8, 10% glycerol [v/v], 
0.2% sodium dodecyl sulfate [SDS] [w/v], 1% bromophenol blue [w/v]) and stored at −20°C until used. 
20µg of lysates were separated by a 12.5% Tris- glycine SDS-polyacrylamide gel and transferred to 
ImmunBlot polyvinylidene difluoride membranes (162- 0177; Bio-Rad Laboratories, Hercules, CA) at 
constant 230 mA for 1 h. For detection of DHRS7, the membrane was blocked using 2% milk (v/v) for 1 h 
at room temperature, followed by incubation with the mouse anti-human DHRS7 poly-clonal antibody 
(ab69348; Abcam, Cambridge, UK) at a dilution of 1:1000 (v/v) in 2% milk (v/v), overnight at 4°C. After 
washing with Tris- buffered saline (20 mmol/L Tris- base, 140 mmol/L NaCl) containing 0.1% Tween20 (v/v) 
(TBS- T), the membrane was subsequently incubated with horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (Jackson Immuno Research, Suffolk, UK) for 1 h at room temperature. For PPIA 
detection, the membrane was blocked using 10% milk (v/v) overnight at 4°C, followed by incubation with 
the rabbit anti- human PPIA polyclonal antibody (ab41684; Abcam) at a dilution of 1:2000 (v/v) in 2% milk 
for 1 h at room temperature. After washing with TBS-T, the membrane was subsequently incubated with 
horseradish peroxidase- conjugated goat anti- rabbit secondary antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA) at a dilution of 1:1000 (v/v) in 2% milk (v/v). After washing the membranes in TBS- T, images 
were visualized using the Immobilon Western Chemiluminescent HRP substrate kit (Millipore, 
Schaffhausen, Switzerland), and a FujiFilm ImageQuant™ LAS-4000 detector (GE Healthcare, Glattbrugg, 
Switzerland) using the chemiluminescence detection setting. For quantification of AR, cOmplete™ Mini 
protease inhibitor cocktail [Roche] was added in the RIPA buffer for lysis, and a monoclonal anti-AR (Ref. 
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sc-7305; Santa Criz Biotechnology) in dilution 1:200, and a polyclonal goat anti-mouse (Ref. A0168; 
Sigma-Aldrich) diluted 1:2000 were used. 
5.2.1.4 Cell Proliferation Measurement by xCELLigence 
The xCELLigence DP device (ACEA Biosciences, San Diego, CA) was used to validate functional cell 
proliferation in real- time with adapted DHRS7 siRNA mediated silencing, according to [147]. The cells were 
seeded 24 h after siRNA mediated silencing. For test of proliferation following DHT treatment, cells seeded 
after 24 h siRNA mediated silencing were treated with DHT or DMSO vehicle concentrations after 24 h. 
Measurements were recorded from this time point every 5 minutes and results are presented with a 
normalized Cell Index (CI). 
5.2.1.5 Androgen Receptor-dependent transactivation assay 
LNCaP cells (50,000 cells/well for AR transfection) were seeded in poly-l-lysine coated 24-well plates, 
incubated for 24 h. For the AR transactivation assay cells were transfected with or without human AR (190 
ng/well), pCMV-lacZ β-galactosidase control (10 ng/well) and TAT3-TATA luciferase reporter (300 ng/well). 
For AR transactivation with endogenous AR under siRNA mediated DHRS7 reverse transfection, pCMV-lacZ 
β-galactosidase control (10 ng/well), TAT3-TATA luciferase reporter (300 ng/well), 1.25 µL/well siRNA 
(DHRS7 and scrambled control, see methods section 5.2.1.2) solution and 166 ng/well of lipofectamine. 
The cells were then washed with steroid-free RPMI (cRPMI) and cultivated for 2 h at 37 °C. Efficiency of 
transfection was also checked with a green-fluorescence plasmid after 24 h. This culture medium was then 
replaced with fresh cRPMI containing DHT or DMSO as vehicle control followed by incubation for 24 h. 
Cells were lysed in 60 μl of tropix lysis solution (Applied Biosystems, Foster City, CA) supplemented with 
0.5 μM dithiothreitol and frozen at −80 °C for at least 30 min. Luciferase activity was determined in 20 μl 
lysate adding 100 μl of D-luciferin-firefly substrate solution at a final concentration of 0.47 mM D-luciferin, 
53 mM ATP, 0.27 mM coenzyme A, 0.13 mM EDTA, 33.3 mM dithiothreitol, 8 mM MgSO4, 20 mM tricine, 
pH 7.8. β-galactosidase activity was measured in 20 μl lysate using the Tropix kit. Samples were measured 
using a SpectraMax-L luminometer (Molecular Devices, Devon, UK). 
5.2.1.6 Cell cycle Analysis 
After 48 h siRNA mediated silencing of LNCaP in 10 cm2 dish, cells were resuspended, washed with 5mL 
PBS, fixed in 3 mL 70% ice-cold ethanol in PBS, and stored in -20°C in 15 mL Falcon tubes until staining. 
Cells were then washed with PBS by centrifugation in swing rotor centrifuge (5 min, 200 g), resuspended 
in PBS fixed in 70% ice-cold ethanol, and stored in −20 °C until staining. Cells were stained for at least 
30 min in the dark with a solution containing 25 μg/ml propidium iodide (Sigma), 50 μg/ml RNAse (Sigma). 
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The DNA content in the treated and mock-treated groups was measured by flow cytometry analysis using 
a FACSCanto II flow cytometer (Becton–Dickinson, San Jose, CA); 50’000 events were analyzed for each 
sample. FlowJo® (Becton, Dickinson & Company, NJ, USA) was used to analyze cell cycle distribution. The 
analysis were performed in the FACS Core Facility of the Biozentrum of Basel. 
5.2.1.7 Mass Spectroscopy 
After siRNA mediated silencing of LNCaP in 10 cm2 dish, samples were washed three times with 5mL ice-
cold PBS and homogenized in 1 mL ice-cold 50 mM Tris-HCl, pH 8.0, 75 mM NaCl, 8 M urea lysis buffer with 
protease inhibitors (complete mini, Roche) and 1 mM PMSF for 10 minutes. Scraped cells were sonicated 
three times 60 sec at 4°C with 20% output with 2 min rest between cycles, centrifuged 12000 rpm for 
10 minutes at 4°C, and the supernatant collected and stored at -80°C. Bradford was performed to detect 
protein concentration.  
For further samples preparation for the preliminary analysis of DHRS7 knock-down for 48 h, proteins were 
prepared according to [224, 225], without TIO2 phosphopeptide enrichment. Breifly, the lysate was 
reduced with 2.5 mM DTT at 37°C for 1 h and alkylated with 7.5 mM iodo acetamide for 15 min in the dark 
at room temperature. The lysate was applied onto a PD10 desalting column and the proteins were eluted 
with 4 M urea buffer with 50 mM Tris-HCl, pH 8.0, and 75 mM NaCl. The protein-containing fractions (as 
measured by 280 nm absorbance) were pooled. The protein concentration was determined with the 
Bradford assay (BioRad, Medical Laboratories, CA, USA) according to the manufacturer’s 
recommendations. The protein pools were stored at -20°C. The PD10 desalted protein pools were digested 
twice with the endoproteinase LysC (Wako Chemicals, Neuss, Germany) at 1:100 enzyme to substrate ratio 
(w/w) for two hours at 37°C. The urea concentration was lowered to 2 M with 50 mM Tris-HCl, pH 8.0 
before digestion with trypsin (1:100 w/w) for two hours at 37°C. A second overnight digestion with trypsin 
(1:100 w/w) was done at 37°C. Trypsin digestion was stopped by adding trifluoro-acetic acid to 1% final 
concentration and pH<2 was checked. Peptides were desalted on C18 SepPak cartridges (50 mg packing 
material, Waters, Dättwil, Switzerland). The cartridges were primed with 250 µl methanol and 250 µl 80% 
acetonitrile/0.1% TFA and equilibrated with 750 µl 0.1% TFA. The digest was applied onto the C18 SepPak 
cartridge and the flow through was collected. The flow through was re-applied and the cartridge was 
washed with 1250 µl 0.1% TFA. Bound peptides were eluted with 350 µl 80% acetonitrile/0.1% TFA and 
collected into an Eppendorf tube. The absorbance of the eluate was measured at 280 nm and peptide 
concentration was estimated according to Wisniewski et al. [226]. For cation exchange, peptides were 
separated in six different fractions with HiTrapTM SP cartridge (GE Healthcare) with 1 ml of a saturation 
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buffer containing 7 mM KH2PO4, pH 2.65, 30% AcCN (vol/vol), 500mM KCl. Later petides were 
resuspended in a buffer containing 7 mM KH2PO4, pH 2.65, 30% AcCN (vol/vol), also used for collection of 
unbound peptides (“flow through”). The other peptides were collected by desorb the bound peptides with 
7 mM KH2PO4, pH 2.65, 30% AcCN (vol/vol), and increasing concentrations of KCl: 50 mM, 100 mM, 150 
mM, 250 mM, 350 mM. The six fractions were dried in a Speed Vac and stored at -20°C. The desalted 
digests were aliquoted and dried in a SpeedVac, resuspended in 30 µL 0.1% AcOH/2% AcCN/0.005% TFA 
and 2 µL injected onto the micro column. 
For samples preparation for the analysis of DHRS7 knock-down for the three time-points of 24 h, 36 h, and 
48 h, proteins were prepared with an imporved method as described for the preliminary analysis of 48 h 
knock-down. Briefly, the lysate was reduced with 10 mM DTT at 55°C for 30 min and alkylated with 50 mM 
iodo acetamide for 15 min in the dark at room temperature. To stop the reaction, 2-mercaptoethanol 
0.33% (v/v) was applied. The lysate was applied onto a PD10 desalting column and the proteins were 
eluted with 4 M urea buffer with 50 mM Tris-HCl, pH 8.0, and 75 mM NaCl. The protein-containing fractions 
(as measured by 280 nm absorbance) were pooled. The protein concentration was determined with the 
Bradford assay (BioRad, Medical Laboratories, CA, USA) according to the manufacturer’s 
recommendations. The protein pools were stored at -20°C. The PD10 desalted protein pools were digested 
twice with the endoproteinase LysC (Wako Chemicals, Neuss, Germany) at 1:100 enzyme to substrate ratio 
(w/w) for two hours at 37°C. The urea concentration was lowered to 2 M with 50 mM Tris-HCl, pH 8.0 
before digestion with trypsin (1:100 w/w) for two hours at 37°C. A second overnight digestion with trypsin 
(1:100 w/w) was done at 37°C. Trypsin digestion was stopped by adding trifluoro-acetic acid to 1% final 
concentration and pH<2 was checked. Peptides were desalted on C18 SepPak cartridges (50 mg packing 
material, Waters, Dättwil, Switzerland). The cartridges were primed with 250 µl methanol and 250 µl 80% 
acetonitrile/0.1% TFA and equilibrated with 750 µl 0.1% TFA. The digest was applied onto the C18 SepPak 
cartridge and the flow through was collected. The flow through was re-applied and the cartridge was 
washed with 1250 µl 0.1% TFA. Bound peptides were eluted with 350 µl 80% acetonitrile/0.1% TFA and 
collected into an Eppendorf tube. The absorbance of the eluate was measured at 280 nm and peptide 
concentration was estimated according to Wisniewski et al. [226]. The digests were aliquoted into 150 µg 
portions, dried in a Speed Vac and stored at -20°C. The desalted digests were aliquoted and dried in a 
SpeedVac. The digested samples were dissolved in 20 mM ammonium formate, pH 4.5 (solvent A) and 
injected at 30 µL/min onto a 250 x 1 mm Vydac 218TPN C18, 300 Å, packed with 5 µm particles. Bound 
peptides were eluted at 30 µL/min with a linear gradient from 2% solvent B (20 mM ammonium formate, 
pH 4.5 containing 80% acetonitrile) to 50% B in 100 min. The eluent was collected into a microtiter plate 
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and the fractions were concatenated into six pools (pools of every sixth fraction). The pools were dried 
individually and subjected to LC-MS analysis by Prof. Paul Jenö and Suzanne Moes. A separating column 
(0.075 mm x 30 cm) packed with Reprosil C18 reverse-phase material (2.4 µm particle size, Dr. Maisch, 
Ammerbuch-Entringen, Germany) was used. The column was connected on line to an Orbitrap Lumos 
instrument (Thermo Scientific, Reinach, Switzerland). The solvents used for peptide separation were 0.1% 
formic acid in water (solvent A) and 0.1% formic acid and 80% acetonitrile in water (solvent B). 1.3 µg of 
peptide digest was injected with an Easy-nLC capillary pump (Thermo Scientific) set to 0.25 µl/min. A linear 
gradient from 0 to 35% solvent B in solvent A in 150 min was delivered with the nano pump at a flow rate 
of 0.25 µl/min. The eluting peptides were ionized at 2.5 kV. The mass spectrometer was operated in data-
dependent mode. The precursor scan was done in the Orbitrap set to 120,000 resolution. Fragmentation 
of peptides was done by HCD (higher collisional dissociation) while the fragment ions were mass analyzed 
in the ion trap part of the instrument. A top twenty method was run so that the twenty most intense 
precursors were selected for fragmentation. The MS/MS spectra were then searched against a SwissProt 
human databank updated monthly. 
The MS/MS data were searched with Proteome Discoverer 2.2 (Thermo Scientific) set to Mascot and 
SEQUEST search engines with 10 ppm precursor ion tolerance, while the fragment ions were set to 0.6 Da 
tolerance. The following modifications were used during the search: carbamidomethyl-cysteine was set as 
a fixed, and oxidized methionine and protein N-terminal acetylation were set to variable modification. The 
peptide search matches were set to ‘high confidence’, which corresponds to 1% false discovery rate (FDR). 
Relative protein quantification was done with the Minora module of Proteome Discoverer 2.2. and version 
Scaffold_4.8.4 (Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and 
protein identifications. Quantification results are presented for results obtained with Scaffold_4.8.4. 
Peptide identifications were accepted if they could be established at greater than 8.0% probability to 
achieve an false discovery rate less than 1.0% by the Scaffold Local FDR algorithm. Protein identifications 
were accepted if they could be established at greater than 98.0% probability and contained at least 3 
identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii, Al 
et al, Anal. Chem. 2003;75(17):4646-58). Proteins that contained similar peptides and could not be 
differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
5.2.1.8 Statistic 
To define statistical relevant changed proteins, the software Perseus v.1.5.8.5, was used. Statistically 
changed proteins between siRNA scrambled control and siRNA DHRS7 samples were detected by 
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transforming normalize ion intensities to log2 and performing t-test with FDR of 5.0% and default settings 
for each individual time-point. For clustering analysis, data were normalized to Z-score and represented 
based on Euclidean model. 
To detect unique expressed proteins, siRNA scrambled control (labelled as “C”) and siRNA DHRS7 samples 
(labelled as “KD”) where filtered for reciprocal absence or detection of normalized ion intensities. To 
exclude false positive or false negative data, the data were compared to normalized ion intensities of 
LNCaP lysate not treated in the following ways: uniquely detected proteins in “KD” a selection of proteins 
that were never detected for “NT” and “C”, and with no opposite regulations in previous time points or 
contrasting between “NT” and “C”. On the other side, for selection of proteins uniquely detected in “C”, 
the proteins should have been always present in “C” and in “NT” but never in “KD”, and “C” and “NT” must 
correlate in previous time points. 
For cell cycle analysis, a t-test was applied. 
5.2.1.9 Indirect immunofluorescence 
LNCaP cells were seeded on glass coverslips for 24 h. Cells were than washed twice with PBS, fixed with 
4% paraformaldehyde solution for 15 min and washed three times with PBS. Complete permeabilization 
of all cell membranes was achieved by incubation of cells with 0.1% Triton X-100 for 10 min. After washing, 
blocking solution containing 1% BSA was added for 15 min, followed by incubation with primary antibody 
for 1 h. The antibodies used were mouse polyclonal anti-DHRS7 diluted 1:100 (ab69348, Abcam), and a 
monoclonal rabbit anti-E-cadherin diluted 1:50 (Ref. #3195; Cell Signaling Technology, Danvers, MA, USA). 
Cells were then washed four times and incubated for 30 min with Alexa Fluor® 488 goat anti-mouse IgG. 
Hoechst-33342 was included in the secondary antibody solution (Molecular Probes®, Eugene, OR) in a final 
concentration of 0.1 µg/µL. After three washes with PBS, the cells were mounted in Mowiol 488 and the 
slides were left to settle for several hours at room temperature. Stainings were analyzed on an Olympus 
Fluoview 1000 laser scanning confocal microscope (Olympus, Center Valley, PA).  
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5.2.2 Results 
5.2.2.1 Method development for measuring an optimized LNCaP proteome under DHRS7 silencing 
Method development was performed to increase the protein identification until at least 3000 proteins 
identified based on at least 1 peptide filtered for “high confidence” (corresponding to 1% FDR) using LC-
MS/MS detection, performed with the Thermo Finnigan TSQ Quantum Classic Mass Spectrometer System. 
To help achieve such a high coverage of proteins, 3x106 LNCaP cells were processed with two additional 
steps to a standard internal protocol used by prof. Paul Jenö: gel filtration and cation exchange (in yellow 
in the protocol flow chart in Figure 28A). This procedure allowed to increase the coverage as illustrated in 
Figure 28B. 
 
Figure 28: Overview of the approach used to increase capturing the LNCaP proteome by addition of gel filtration and cation 
exchange in the protocol. A. Sample preparation workflow (in yellow the added steps). B. Number of identified proteins before and 
after protocol improvement based on one peptide. 
By adding these additional steps, the total number of proteins identified based on single peptide detection 
was improved from 917 to 3039 (Figure 28B). The protocol was implemented for the analysis in Figure 30.  
The siRNA mediated knock-down conditions were optimized to perform DHRS7 depletion with 3x106 
LNCaP cells, as used for the increased achieved sensitivity (Figure 28). Three criteria were tested; 
morphology of the cells (microscopic evaluation), DHRS7 protein depletion (immunoblotting) and for 
condition 2 functional proliferation (performed using xCELLigence®) (figure 29A-D). 
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Figure 29: A. Validation of DHRS7 knock-down protocol for 3 millions cells. A. Conditions used for effective silencing; B. 
representative pictures with 10x magnification before lysis after 48h siRNA mediated silencing; and C. Western blotting of 20 µg 
LNCaP lysates for the three conditions used; D. Cell proliferation of LNCaP cells after 24 h siRNA mediated DHRS7 silencing with 
the selected “condition 2” in xCELLigence. The experiment was performed in duplicates and expressed as mean ± SD. 
****=p<0.0001. 
Condition 2 was selected based on appreciable DHRS7 protein downregulation whilst maintaining 
morphological integrity as observe in the representative images in Figure 29B and C. This condition also 
showed a significant increase in proliferation in the following DHRS7 depletion (Figure 29D). 
In order to help understand the mechanisms which caused the LNCaP cells to proliferate at an increased 
rate following DHRS7 siRNA depletion, a global proteomic analysis of the LNCaP cells at the 48 h timepoint 
vs. scrambled control was performed. For each condition, three biological replicates were tested. The 
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Orbitrap ELITE MS Hybrid Ion trap mass spectrometer was selected to analyze the samples. Protein 
identification was performed with 1% FDR and on at least one single peptide identification. The relative 
quantification was performed by Scaffold and the statistical analysis by Perseus. 
  
Figure 30: A. Number of identified and qualitatively regulated proteins after DHRS7 siRNA mediated depletion after 48 h in LNCaP 
based on one peptide with Scaffold; B. Regulation of DHRS7 protein according to Scaffold under the DHRS7 knock-down time point 
48 h. Data are depicted from three independent experiments measured in the six cation exchange fractions and are expressed as 
mean ± SD. ***=p<0.0005. 
Following single peptide filtering, the total number proteins identified corresponded to 5111, of which 350 
were downregulated and 251 were upregulated (Figure 31A). DHRS7 (accession number Q9Y394) was 
identified by 10 exclusive peptides which accounted for 44% protein coverage (149 amino acids out of 339) 
(Figure 30A). The protein levels of DHRS7 was depleted ca.82.6 % in the DHRS7 knock-down condition 
compared to scrambled control (Figure 30B). Fourteen of the upregulated proteins were uniquely 
expressed in the siRNA DHRS7 condition (Supplemental Table 9), and 24 of the downregulated proteins 
were uniquely expressed in the siRNA scrambled control condition (Supplemental Table 10). Proteins 
identified with expression changes of greater than 1.5 fold for both the siRNA scrambled and siRNA DHRS7 
conditions are shown in Supplemental Tables 11-12 (section 9.1.1.4).  
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Regulated proteins presented in Tables 9-12 are involved in several important cellular processes with 
regards to the phenotype observed in DHRS7 depleted LNCaP cells such as cell cycle, proliferation, 
migration and adhesion. For example, with respect to cell cycle and proliferation, Cyclin-T2, anaphase 
promoting complex 1 ANAPC1, CDK1 was downregulated with 0.5 fold. EGFR was only identified in the 
siRNA DHRS7 treated LNCaP cells. Additionally, the retinoblastoma associated protein RB1 was 
downregulated ca. 0.2 fold (Table 12). With respect to migration and adhesion, fibronectin, E-Cadherin, 
and catenin alpha 1 were downregulated ca. 0.3 fold, ca. 0.6 fold and ca. 0.6 fold, respectively. 
Desmocollin-2 and CD166 antigen also named ALCAM were upregulated ca. 9.0 fold and ca.2.4 fold, 
respectively. Interestingly, unique expression of Occludin was detected in the scrambled siRNA control 
condition. Unexpected, the androgen receptor was downregulated 0.6 fold (Table 12). Interestingly, 
among the regulated proteins with low annotated function and playing important roles in differential 
pathways, proteins involved in membrane lipid metabolic pathway such as monoacylglycerol lipase ABHD2 
[227], the lysosomal spingomyelin phosphodiesterase SMPD1 [228, 229], and LPCAT1 [230] were highly 
regulated with an upregulation of 4.6 fold, 7.7 fold and downregulated of 0.2 fold, respectively. 
The proteins in Tables 9-12 represent interesting candidates for follow up studies to further investigate 
their involvement in the observed proliferative phenotype. However, first confirmation of the altered 
expression of selected proteins must be confirmed by more traditional cell biology techniques such as 
immunoblotting. Additionally, the mass spectrometry analysis method for the identification and 
quantification of proteins can still be improved. This may be achieved by Increasing the number of peptides 
used to identify individual proteins. Furthermore, it needs to be considered that proteins uniquely 
detected in one condition (Tables 9 and 10) are often close to the limit of detection, thus may not 
contribute to the functional effects observed.  
5.2.2.2 Untargeted Proteomics Analysis Following Time-Dependent DHRS7 Silencing  
5.2.2.2.1 Samples Preparation 
The method development and the first proteomic analysis of DHRS7 depleted LNCaP cells at the 48 h 
timepoint discussed in results section 5.2.2.1 allowed for sufficient global protein identification and 
quantification, which highlighted some potentially important alterations in protein expression. In the 
following work, the sensitivity of the assay was further improved using HPLC fractionation following the 
use of sensitive Orbitrap Lumos mass-spectrometer. Combined fractions were measured in triplicate. To 
allow for more accurate coverage to perform protein quantification, only proteins identified by at least 
three unique peptides were selected. Moreover, to better discriminate between the cause and 
consequence of the observed protein alterations, three time points, 24 h, 36 h and 48 h, following DHRS7 
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depletion, were selected. Additionally, at 0 h a non-treated sample was lysed and served as a technical 
control to exclude false negative or false positive protein detection. The sample preparation protocol flow 
diagram used to analyze the proteome of DHRS7 depleted LNCaP cells shown in Figure 31A. The results of 
the proteome analysis were later compared with the results of the other functional assays tested in order 
to identify proteins which may drive the LNCaP cells aggressive phenotype following DHRS7 depletion. 
Cells transfected with DHRS7 siRNA or scrambled control showed no morphological abnormalities before 
lysis at any of the time points tested (Figure 31B). DHRS7 immunoblot confirmed the time dependent 
DHRS7 protein depletion of LNCaP cells at 24 h, 36 h and 48 h (Figure 31C). Samples in ice cold urea lysis 
buffer were reduced, alkylated and protein filtrated to remove low molecular weight proteins and 
contaminants such as EDTA. Sample proteins were collected in fractions 2 and 3 where they are 
concentrated, evident by an increased OD280 value (Figure 31D) (absolute protein concentrations of each 
sample are shown in Figure 31E). Sample protein in fractions 2 and 3 were pooled, trypsin and Lys C 
digested, and de-salted (peptide concentrations of each sample are shown in Figure 31F) and 150 µg of 
sample peptides were fractionated by high performance liquid chromatography (HPLC) and pooled into 6 
individual fractions. Peptide analysis was performed with the sensitive Orbitrap Lumos mass-spectrometer 
in triplicate. 
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Figure 31: Design and samples preparation of DHRS7 silencing in LNCaP after 24 h, 36 h, and 48 h. A. Experimental design (C= 
scrambled siRNA, KD=DHRS7 siRNA); B. Representative pictures 10x magnification of LNCaP cells after different time points of 
knock-down previous lysis, C. Western blotting of 20 µg lysed samples for DHRS7 immunodetection, D. OD280 after protein 
filtration showing signal detection of protein specific for fractions 3 and 4, E. Protein amount of pulled fractions 3 and 4, F. Peptide 
quantification based on measured OD280 after digestion of 1050 µg for the no treatment sample “0h” and of 350 µg protein for 
the other samples. C= scrambled siRNA, KD=siRNA DHRS7. 
According to the Figure 31B, cells looked optically good and were processed for lysis with ice-cold urea 
buffer. According to Figure 31C, DHRS7 was judged to be enough downregulated. After the protein 
filtration in which proteins were collected in fractions 2 and 3 (noticeable through increased OD280 in 
these two fractions as shown in Figure 31D, which amount is shown in Figure 31E), proteins were digested 
and desalted. From the measured amount of peptides (Figure 31F), 150 µg were used for HPLC 
fractionation and were further combined into six pools (pools of every sixth fraction), consequently 
subjected to the mass spectrometry and bioinformatics analysis.   
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5.2.2.2.2 Untargeted Characterization of LNCaP Phenotype  
After protein identification with a 5% FDR, the results were filtered for identification based on three 
peptides. The relative quantification was performed using Scaffold. The quantified data are presented 
following statistical analysis using Perseus. The number of identified and regulated proteins for each 
timepoint (Figure 32A, cluster analysis highlights upregulated proteins in red and downregulated proteins 
in green), and the regulation of DHRS7 (accession number Q9Y394) is shown in Figure 32B. 
 
Figure 32: Untargeted proteomics analysis under three different time points 24h, 36h, and 48h as measured by Scaffold. A. Proteins 
changed in the three different time points 24h, 36h, and 48h (data are expressed as mean of three technical replicates of an 
independent experiment measured in six HPLC fractions. Green=downregulated, red=upregulated). B. downregulation of DHRS7 
expressed as mean ± SD of precursor ion intensities values. C = scrambled siRNA, KD = siRNA DHRS7. 
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Clustering analysis showed the number of proteins with an altered expression increased with time (figure 
32A) (ca. 1.3% for 24 h, ca. 3.33% for 36 h, and ca. 5.27% for 48 h) from a total of ca. 7000 ± 62 proteins 
identified. The substantial increase in the proteins identified from the whole cell lysate compared to the 
previous method performed in results section 5.2.2.1 reflects the higher sensitivity of the assay, even 
though stricter filtering rules were applied (proteins were only identified if 3 unique peptides were 
detected not just 1 unique peptide as in the previous method).  
The expression levels of DHRS7 were depleted in a time dependent manner, ca. 54%, 63%, and 82%, for 
the time points 24 h, 26 h, and 48 h, respectively (figure 32B).  
Proteins changed consistently over the 3 time points are presented in Table 3, under the heading “always 
changed”. Proteins changed at the 24 h and 36 h time points are presented in Table 4 under the heading 
“early changed”. Proteins changed at the 36 h and 48 h timepoint are presented in Table 5 under the 
heading “late changed”. Additionally, proteins changed at the 24 h and 48 h timepoint were filtered for 
0.666 fold (downregulation) and 1.5 fold (upregulation) change of scrambled siRNA versus siRNA DHRS7 
condition and are presented in the supplemental Tables 13-14. Finally, uniquely expressed proteins 
identified following siRNA DHRS7 knock-down (labelled as “KD”) or the siRNA scrambled control (labelled 
as “C”) are depicted as average values and are presented with the additional “not treated” sample control 
(labelled as “NT”) (Table 6). 
Table 3: Proteins always changed in the three time points 24 h, 36 h, 48 h. 
Proteins always changed (24 h, 36 h, 48 h) 
Common name Short Name Regulation 
Leucine-rich repeat neuronal protein 1 LRRN1 upregulation 
Paternally-expressed gene 3 protein PEG3 upregulation 
Endoribonuclease Dicer DICER1 upregulation 
Zinc finger CCHC domain-containing protein 3 ZCCHC3 upregulation 
Anillin ANLN downregulation 
Cadherin-1 CDH1 downregulation 
Spondin-2 SPON2 downregulation 
Serine/threonine-protein kinase Chk1 CHEK1 downregulation 
Cytokine receptor-like factor 3 CRLF3 downregulation 
Dehydrogenase/reductase SDR family member 7 DHRS7 downregulation 
MAX gene-associated protein MGA downregulation 
Molybdenum cofactor sulfurase MOCOS downregulation 
Mortality factor 4-like protein 1 MORF4L1 downregulation 
Serum response factor-binding protein 1 SRFBP1 downregulation 
TATA element modulatory factor TMF1 downregulation 
Ubiquitin-conjugating enzyme E2 Q1 UBE2Q1 downregulation 
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Table 4: Proteins changed in the two time points 24 h and 36 h. 
Early changed proteins (24 h - 36 h) 
Common name Short Name Regulation 
Testis-expressed protein 2 TEX2 upregulation 
C-Maf-inducing protein CMIP upregulation 
Disintegrin and metalloproteinase domain-containing protein 10 ADAM10 downregulation 
Occludin OCLN downregulation 
Transcription initiation factor TFIID subunit 7 TAF7 downregulation 
Tumor protein p63-regulated gene 1-like protein TPRG1L downregulation 
 
Table 5: Proteins changed in the two time points 36 h and 48 h. 
Late changed proteins (36 h - 48 h) 
Common name Short Name Regulation 
Kelch repeat and BTB domain-containing protein 7  KBTBD7 upregulation 
Trinucleotide repeat-containing gene 6C protein TNRC6C upregulation 
Methionine aminopeptidase 2 METAP2 upregulation 
Hornerin HRNR upregulation 
Collagen alpha-1(VI) chain COL6A1 upregulation 
Keratin, type II cytoskeletal 1 KRT1 upregulation 
CD166 antigen ALCAM upregulation 
DNA replication licensing factor MCM2 MCM2 downregulation 
Catenin beta-1 CTNNB1 downregulation 
Fibronectin FN1 downregulation 
Signal transducer and activator of transcription 2 STAT2 downregulation 
E3 ubiquitin-protein ligase UHRF1 UHRF1 downregulation 
DNA polymerase delta subunit 2 POLD2 downregulation 
Charged multivesicular body protein 7 CHMP7 downregulation 
Putative oxidoreductase GLYR1 GLYR1 downregulation 
DNA replication licensing factor MCM7 MCM7 downregulation 
Pseudouridylate synthase 7 homolog PUS7 downregulation 
Inositol polyphosphate 5-phosphatase OCRL-1 OCRL downregulation 
TATA element modulatory factor TMF1 downregulation 
E3 ubiquitin-protein ligase CBL CBL downregulation 
Hexokinase-2 HK2 downregulation 
Replication factor C subunit 2 RFC2 downregulation 
Proline-rich protein PRCC PRCC downregulation 
Enhancer of mRNA-decapping protein 3 EDC3 downregulation 
Lymphokine-activated killer T-cell-originated protein kinase PBK downregulation 
Retinoblastoma-associated protein  RB1 downregulation 
Ubiquitin-conjugating enzyme E2 T UBE2T downregulation 
Chromosome-associated kinesin KIF4A  KIF4A downregulation 
UAP56-interacting factor FYTTD1 downregulation 
Uveal autoantigen with coiled-coil domains and ankyrin repeats UACA downregulation 
Sperm-specific antigen 2 SSFA2 downregulation 
Fibronectin type-III domain-containing protein 3A FNDC3A downregulation 
E3 ubiquitin-protein ligase ZNF598 ZNF598 downregulation 
Protein timeless homolog TIMELESS downregulation 
DnaJ homolog subfamily C member 3 DNAJC3 downregulation 
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Allograft inflammatory factor 1-like  AIF1L downregulation 
Kinetochore protein NDC80 homolog NDC80 downregulation 
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta BUB1B downregulation 
Fanconi anemia group I protein FANCI downregulation 
Kinesin-like protein KIF11 KIF11 downregulation 
Exportin-4  XPO4 downregulation 
Kinesin-like protein KIF14 KIF14 downregulation 
Zinc finger CCCH-type antiviral protein 1-like ZC3HAV1L downregulation 
Disks large-associated protein 5 DLGAP5 downregulation 
DNA polymerase delta catalytic subunit POLD1 downregulation 
Targeting protein for Xklp2 TPX2 downregulation 
UV-stimulated scaffold protein A UVSSA downregulation 
TBC1 domain family member 5 TBC1D5 downregulation 
Nuclear distribution protein nudE homolog 1 NDE1 downregulation 
Adenosine deaminase ADA downregulation 
Hyaluronan mediated motility receptor HMMR downregulation 
MICAL-like protein 1 MICALL1 downregulation 
Kinesin-like protein KIF22 KIF22 downregulation 
Interferon regulatory factor 6 IRF6 downregulation 
Kinesin-like protein KIF20A  KIF20A downregulation 
Tonsoku-like protein TONSL downregulation 
Condensin-2 complex subunit D3 NCAPD3 downregulation 
Thymidylate synthase  TYMS downregulation 
Protein regulator of cytokinesis 1 PRC1 downregulation 
Protein KHNYN KHNYN downregulation 
Uncharacterized protein KIAA1671 KIAA1671 downregulation 
RalBP1-associated Eps domain-containing protein 2 REPS2 downregulation 
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Table 6: Uniquely expressed proteins in the siRNA DHRS7 (labelled as “KD”) or the siRNA scrambled control (labelled as “C”) conditions for the time points 24 h, 36 h, and 48 h. Numbers 
represent the mean of precursor ion intensities values. 
Accession Protein Name Short Name MW 
average 
NT24h 
average 
C24h 
average 
KD24h 
average 
NT36h 
average 
C36h 
average 
KD36h 
average 
NT36h 
average 
C36h 
average 
KD36h 
Q8IZV5 Retinol dehydrogenase 10 RDH10 38 kDa 0 0 84500000 0 0 77200000 9980000 0 81800000 
Q96S53 Dual specificity testis-specific protein kinase 2 TESK2 64 kDa 0 0 41900000 19500000 0 57300000 0 0 56700000 
Q8IUH5 Palmitoyltransferase ZDHHC17 ZDHHC17 73 kDa 5820000 39800000 49200000 0 0 41800000 0 0 62800000 
O75460 Serine/threonine-protein kinase/endoribonuclease IRE1 IRE1 110 kDa 10800000 29900000 9770000 19900000 0 37800000 0 0 29800000 
Q9Y3Q8 TSC22 domain family protein 2 TSC22D2 41 kDa 378000000 595000000 416000000 95100000 53100000 222000000 0 0 257000000 
Q969E8 Pre-rRNA-processing protein TSR2 homolog TSR2 21 kDa 345000000 232000000 137000000 304000000 96300000 132000000 0 0 363000000 
Q9BXS6 Nucleolar and spindle-associated protein 1 NUSAP1 49 kDa 87500000 116000000 0 93500000 146000000 0 119000000 90900000 7860000 
Q9HAW4 Claspin CLSPN 151 kDa 55300000 62600000 0 50200000 128000000 0 31600000 37500000 0 
Q06190 Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit alpha PPP2R3A 130 kDa 12000000 48000000 0 19900000 50600000 0 26400000 33500000 0 
P50219 Motor neuron and pancreas homeobox protein 1 MNX1  41 kDa 71500000 39400000 0 34100000 72200000 0 52900000 42000000 0 
Q8TEY5 Cyclic AMP-responsive element-binding protein 3-like protein 4 CREB3L4 43 kDa 105000000 8180000 0 145000000 52600000 0 78500000 70100000 0 
O75419 Cell division control protein 45 homolog CDC45 66 kDa 117000000 16500000 45700000 107000000 100000000 0 104000000 52900000 0 
Q7Z401 C-myc promoter-binding protein DENND4A 209 kDa 775000000 44200000 26200000 27100000 81500000 0 40400000 51100000 0 
Q9UIU6 Homeobox protein SIX4 SIX4 83 kDa 154000000 41900000 13400000 159000000 50200000 0 132000000 56300000 0 
P20248 Cyclin-A2  CCNA2 49 kDa 157000000 234000000 63300000 104000000 145000000 0 125000000 125000000 0 
Q9HCJ3 Ribonucleoprotein PTB-binding 2 RAVER2 74 kDa 97200000 94400000 18400000 16100000 19700000 0 73600000 59100000 0 
Q7L2Z9 Centromere protein Q CENPQ 31 kDa 25500000 33100000 21700000 39300000 50900000 0 41700000 57700000 0 
Q9UBQ6 Exostosin-like 2  EXTL2 37 kDa 130000000 109000000 93200000 87800000 95400000 0 137000000 101000000 0 
Q6IBW4 Condensin-2 complex subunit H2 NCAPH2 68 kDa 217000000 221000000 69800000 240000000 254000000 18700000 151000000 156000000 0 
Q9NRZ9 Lymphoid-specific helicase HELLS 97 kDa 290000000 142000000 22300000 374000000 366000000 30600000 298000000 231000000 0 
Q9Y3D5 28S ribosomal protein S18c, mitochondrial MRPS18C 16 kDa 242000000 81300000 325000000 209000000 220000000 193000000 155000000 161000000 0 
P28749 Retinoblastoma-like protein 1 RBL1 121 kDa 69600000 65000000 12600000 81000000 70200000 8160000 50600000 72800000 0 
Q5MNZ6 WD repeat domain phosphoinositide-interacting protein 3 WDR45B 38 kDa 113000000 77000000 83700000 455000000 227000000 203000000 274000000 203000000 0 
Q5XKP0 MICOS complex subunit MIC13 MIC13 13 kDa 359000000 463000000 270000000 157000000 98700000 224000000 244000000 244000000 0 
Q9NPB8 Glycerophosphocholine phosphodiesterase GPCPD1 GPCPD1 76 kDa 11300000 48400000 104000000 40300000 81600000 35600000 39200000 42300000 0 
Q659A1 Little elongation complex subunit 2 ICE2 110 kDa 24400000 61000000 21100000 37000000 42900000 86400000 28800000 15600000 0 
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Some of the proteins highlighted in Tables 3-6 and 13 were selected for further analysis based on the 
change in their expression levels and of related proteins in the first proteomics analysis (results section 
5.2.2.1). 
5.2.2.2.2.1 Characterization of LNCaP Phenotype for Nuclear Receptors and SDR Expression 
Untargeted proteomics has the advantage of allowing assessment of a huge number of proteins that can 
be used also for a qualitative phenotypic characterization. However, these data are not absolute values 
and proteins can be misdetected because of not enough technical sensitivity or suboptimal samples 
preparation. For this reason, it is useful to compare and correlate proteins identified by untargeted 
proteomics with other high-throughput expression analyses such as microarray. As highlighted in section 
2.2 of the introduction, known SDRs associated to cancer are often involved in steroidal, retinoic acid, 
lipids and prostaglandins metabolism. Consequently, I first evaluated the expression of nuclear receptors 
according to [231] known to be involved in these pathways (table 7), the SDRs and the phenotypically 
related AKR family in the LNCaP cell line (table 8). This was tested by comparing the mean relative signal 
intensity obtained for the scrambled control siRNA treated LNCaP cells (24 h time point) of the microarray 
performed in [147] with the proteins identified in the untageted proteomics analysis of scrambled siRNA 
and siRNA DHRS7 in results section 5.2.2.2.2 Figure 32A (time point 24 h). 
Table 7: Identification and relative quantification of nuclear receptor expression in LNCaP. These proteins were identified based on 
three different peptides of the 24 h siRNA treated samples and compared with microarray relative signal intensity values of the 
24 h scrambled siRNA treated sample of published work [147]. 
Protein name Accession nr protein identified in 
proteomics 
mean relative signal 
intensity microarray* 
AR P10275 yes 9.75 
PPARδ Q03181 ND 8.10 
RXRα P19793 yes 7.73 
ROR1 Q01973 ND 7.46 
RXRβ P28702 yes 7.37 
RARα P10276 ND 6.86 
PTGFR P43088 ND 6.50 
RORγ P51449 ND 6.44 
PPARα Q07869 ND 6.01 
PPARγ P37231 ND 5.65 
PTGDR2 Q9Y5Y4 ND 5.61 
AHR P35869 ND 5.49 
PTGER1 P34995 ND 4.91 
PTGER2 P35408 ND 4.46 
ERβ Q92731 ND 4.23 
RORα P35398 ND 3.95 
ERα P03372 ND 3.80 
GR P04150 ND 3.60 
RORβ Q92753 ND 3.55 
RXRγ P48443 yes 3.40 
PR P06401 ND 3.35 
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Table 8: Identification and relative quantification of SDRs and AKRs in LNCaP. Receptors expression in LNCaP were identified based 
on three different peptides of the 24 h siRNA treated samples and compared with microarray relative signal intensity values of the 
24 h scrambled siRNA treated sample of published work [147]. 
Enzyme 
family 
Protein name Accession nr protein identified in 
proteomics 
mean relative signal 
intensity microarray* 
SDR 
RDH10 Q8IZV5 Yes  
(only siRNA DHRS7) 
10.05 
HSD17β4 P51659 yes 10.00 
RDH11 Q8TC12 yes 9.97 
HSD17β10 Q99714 yes 9.32 
DHRS7B Q6IAN0 yes 8.48 
HSD17β8 Q92506 yes 8.00 
HSDL1 Q3SXM5 yes 8.00 
HSDL2 Q6YN16 yes 7.90 
HSD11β2 P80365 yes 7.70 
DHRS11 Q6UWP2 yes 7.61 
HSD3β7 Q9H2F3 yes 7.60 
DHRS13 Q6UX07 yes 7.75 
DHRS7 Q9Y394 yes 7.59 
HSD17β1 P14061 ND 7.56 
HSD3β7 Q9H2F3 yes 7.67 
CBR1 P82279 yes 7.18 
CBR3 Q9BUF7 yes 7.03 
DHRS1 Q96LJ7 yes 6.89 
DHRS3 O75911 ND 6.82 
11β1L Q7Z5J1 ND 6.54 
RDH13 Q8NBN7 yes 6.46 
17β11 Q8NBQ5 yes 6.44 
17β14 Q9BPX1 ND 5.49 
DHRS12 A0PJE2 ND 5.43 
RDH12 Q96NR8 ND 5.20 
RDH16 O75452 ND 5.13 
HSD17β6 O14756 ND 5.00 
RDH8 Q9NYR8 ND 4.71 
DHRS2 Q13268 yes 4.44 
DHRS7C A6NNS2 ND 4.10 
HSD17β12 Q53GQ0 yes 3.80 
HSD11β1 P28845 ND 3.70 
HSD17β2 P37059 ND 3.63 
HSD17β3 P37058 ND 3.16 
HSD17β13 Q7Z5P4 ND 2.90 
DHRS4 Q9BTZ2 yes 2.50 
HSD17β7 P56937 yes ND 
RDH14 Q9HBH5 yes ND 
CBR4 Q8N4T8 yes ND 
AKR 
AKR1A1 P14550 yes 9.3 
AKR7A2 O43488 yes 6.3 
AKR1B1 P15121 ND 4.8 
AKR7L Q8NHP1 yes 4.3 
AKR7A3 O95154 ND 4.3 
AKR1C1 Q04828 ND 4.1 
AKR1β10 O60218 ND 4 
AKR1C2 P52895 yes 4 
AKR1β15 C9JRZ8  ND 3.7 
AKR1C3 P42330 yes 3.7 
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AKR1E2' Q96JD6 ND 3.2 
AKR1CL1 Q5T2L2 ND 2.9 
AKR1D1 P51857 ND 2.6 
AKR1C4 P17516 yes 2.2 
 
As expected, the major nuclear receptor expressed in the LNCaP prostate cancer cell line is the AR, 
supported by both proteomic analysis and microarray (Table 7). However, most of the nuclear receptor 
detected by the microarray analysis were not identified by the untargeted proteomics approach, even 
those receptors with high mean relative signal intensity values in the microarray (e.g. PPARδ, or ROR1). 
On the other side, SDRs and AKRs expressing medium mean relative signal intensity values on the 
microarray (ca. 6.8) are generally identified by the proteomics technique (Table 5). GR, PR, ERα, and ERβ 
and steroidal metabolism relevant enzymes AKR1C1-AKR1C2 and AKR1C3 seems to be absent or expressed 
at low levels (in the proteomics analysis AKR1C2 and well as AKR1C3 was not detected in all the technical 
replicates) (Table 8). The human glioma and non-small-cell lung cancer associated RDH10 (see Table 1 of 
the introduction) was detected with highest microarray value but only in the siRNA DHRS7 condition 
(Table 6). RDH11 is also highly expressed suggesting potential for retinoic acid metabolism by the LNCaP 
cells. Other identified SDRs with high mean relative signal intensity values in the microarray are HSD17β4 
and HSD17β10, known both to metabolize DHT [81, 232]. AKR1C2 showed low expression levels, however, 
has a Km for DHT of 1400 µM [206]. These observations are important to help answer my hypothesis set 
out in chapter 1, which was to evaluate if DHRS7 has the potential to metabolise DHT and effectively 
suppress AR transactivation and thus explain its possible tumor suppressive role in LNCaP cells. This aspect 
is evaluated within the next subchapter. 
 
5.2.2.2.2.2 Characterization of Protein Changes related to Androgen Receptor Regulations 
Experimental evidence in chapter 1 (section 4) revealed that DHT is metabolized by DHRS7 (observation 
also supported by the recent publication by Zemanová et al. [208]). Additionally, experiments performed 
in HEK 293 cells overexpressing DHRS7 revealed that DHRS7 might suppress AR nuclear translocation and 
downstream transcriptional regulation in the concentration range from 1 to 100 nM [191]. In this sub-
chapter, the global proteome generated following DHRS7 siRNA depletion of LNCaP cells was used to 
identify if the expression levels of the AR and its downstream target proteins KLK3 and TMPRSS2 were 
significantly altered. The relationship between DHT, the AR and DHRS7 was then tested following DHRS7 
siRNA depletion in the LNCaP cell line which endogenously express AR and DHRS7 (Figure 33).  
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Figure 33: Functional characterization of endogenous AR signaling in LNCaP with and without siRNA mediated DHRS7 knock-down. 
A-C. AR, KLK3 and TMPRSS2 relative protein quantification measured with untargeted proteomics D. Quantification of AR in the 
48 h scrambled and siRNA DHRS7 treated protein lysates; E. Time course of normalized Cell Index (CI) measurements measured 
trough xCELLigence after 24 h seeding of siRNA mediated DHRS7 knock-down of 48 h in LNCaP and 10 nM or 100 nM DHT 
treatment; F. Endogenous and overexpressed AR activation in LNCaP under 10 nM DHT (mean of duplicates ±SD); G. Endogenous 
and overexpressed AR activation in LNCaP with treatment of 1-3-10 nM DHT under DHRS7 downregulation (mean of triplicates 
±SD). 
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The proteomics experiment performed in result section 5.2.2.1 for the fixed 48 h timepoint, showed a 
downregulation of the AR following DHRS7 depletion (Table 12, section 9.1.1.4 of the supplementary data). 
However, this was not observed in the proteomic analysis of the time-dependent DHRS7 knock-down 
(tables 3-6 and 13), of which the relative quantification of the AR protein is depicted in Figure 33A. 
However, downstream KLK3 and TMPRSS2 show a tendency for downregulation against the hypothesis of 
DHRS7 mediated increased protein amount as expected in the case of a relevant increased AR 
transactivation activity under DHRS7 depletion (Figures 33B-C). AR protein was quantified by western 
blotting and no differences in expression were observed between DHRS7 depleted LNCaP cells (48 h 
timepoint) and scrambled control (Figure 33D). 
The effect of DHT (10 nM and 100 nM) on proliferation was tested by xCELLigence following siRNA DHRS7 
depletion and siRNA scrambled control in LNCaP cells. SiRNA depletion of DHRS7 in LNCaP cells 
reproducibly show an increased proliferation compared to scrambled control (light pink and light blue line) 
(Figure 33E). Under both experimental conditions, DHT induces proliferation compared to control 
(Figure 33E). Specifically, DHT treatment of siRNA depleted DHRS7 LNCaP cells showed a concentration 
and time dependent increase in proliferation which peaked at ca. 52 after seeding (blue for 10 nM DHT, 
dark blue for 100 nM) (Figure 33E). DHT treatment of siRNA scrambled control LNCaP cells only showed a 
time dependent increase in proliferation which also peaked at ca. 52 after seeding (orange 10 nM DHT and 
dark red 100 nM DHT) (Figure 33E). Further confirming the activation of the AR by DHT, the AR downstream 
target genes KLK3 and TMPRSS2, as shown by Simon Stücheli in his master thesis, were increased 
(unpublished data). Thus, the addition of DHT increased the proliferation rate of LNCaP cells confirming its 
functional ability to mediated proliferation in this cell line. The final experiments were performed using a 
Concentration range between 1- 10 nM. The AR transactivation assay, previously tested in HEK293 cells 
overexpressing DHRS7 [191] was performed in LNCaP cells. First, in a control experiment endogenous AR 
was positively transactivated 8 fold with 10 nM DHT (Figure 33F). DHT mediated AR transactivation 
following siRNA DHRS7 depletion showed a dose-dependent increase in AR transactivation, however, no 
differences were observed between siRNA DHRS7 depleted LNCaP cells and the siRNA scrambled control 
(Figure 33G). The findings of these experiments were further supported by the thesis work of Simon 
Stücheli, which conclusively show that DHRS7 plays no role in the control of the AR in the LNCaP cells line, 
by performing immunoblots and mRNA quantification showing no changes in AR nuclear translocation or 
induction of AR downstream genes in DHRS7 depleted LNCaP cells treated with DHT compared to 
scrambled siRNA control (unpublished data).  
 103 
 
5.2.2.2.2.3 Characterization of Protein Changes related to Proliferation, Adhesion and Migration 
In the context of human prostate cancer progression and LNCaP proliferation, three main clinically relevant 
mechanisms have been described according to Bluemn et al. [31]: 1) AR mediated, 2) the AR independent, 
neuroendocrine dependent, and 3) the AR independent, neuroendocrine independent. In the previous 
results section, we excluded the AR mediated pathway as a mechanism by which the LNCaP cells increase 
proliferation following DHRS7 depletion. 
Evidence to support the AR independent, neuroendocrine dependent pathway was provided by Bluemn 
et al. [31]. The study uncovered the following proteins relevant for proliferation, migration and invasion 
LNCaP that may be important for proliferation: PCSDK1, NKX2-1, CHGA, CHGB, SCG3, CHRNB2, ELAVL4, 
SYP, ENO2, and SCN3A. The global proteomic analysis data presented in this thesis was only able to detect 
ENO2, however its expression levels was not changed in the DHRS7 siRNA depleted LNCaP cells compared 
to scrambled siRNA controls (data not shown). 
Evidence to support the AR and neuroendocrine independent pathway, was also provided by Bluemn et 
al. [31]. The study uncovered to following pathways relevant for proliferation, migration and invasion in 
LNCaP: mitogen-activated protein kinase (MAPK) and fibroblast growth factor (FGF) pathways. Proteins 
relevant for these pathways detected in the global proteomic analysis data presented in this thesis in all 
the tested conditions were EGFL7 (a protein promoting metastasis in hepatocellular carcinoma [233]) 
(Figure 34 A), FGFR1 oncogenic partner (Figure 34 B), EGFR (Figure 34 C-D), and GRB10 (direct substrate 
of the p42/44 MAPK [234] (Figure 34 E).  
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Figure 34: Relative protein quantification of EGFL7 (A), FGFR1 partner (B), EGFR (C) with relative western blotting (D), and of GRB10 
(E) measured in scrambled siRNA control and siRNA DHRS7 treated LNCaP for 24 h, 36 h, and 48 h. Untargeted proteomic data are 
expressed as mean ± SD. D. 
A trend was observed for the upregulation for EGFL7 in all the three time points in the DHRS7 siRNA 
depleted LNCaP cells compared to scrambled siRNA controls (Figure 34A). A trend was observed also for 
the upregulation FGF1 oncogenic partner at the 24 h timepoint only, and trend for upregulation for EGFR 
was also noted, however, this observation was not clearly reflected in immunoblot analysis (Figure 34C 
and D). Interestingly, in Figure 34 E, GRB10 was time-dependently upregulated reaching an upregulation 
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of 1.8 fold under 48 h DHRS7 knock-down, and this was consistent with results of the 2.2 fold upregulation 
of the 1st proteomics analysis under DHRS7 knock-down of 48 h (supplemental Table 11). 
Among the most regulated proteins in the global proteomic analysis data were a series of cell cycle 
relevant proteins (tables 3-6 and 13). To better understand the dynamic of the proliferation changes and 
the potential role of the identified proteins, the cell cycle was evaluated more in detail by flow cytometry 
analysis and the cell cycle proteins identified in the proteome study at the 48 h timepoint were compared 
(Figure 35).  
 
Figure 35: Cell cycle analysis under DHRS7 depletion. Percentage of cells in cell cycle phases under 48 h DHRS7 knock-down (mean 
±SD of three independent experiments) (A). Relative quantification of the proteins involved in cell cycle regulation Cyclin-A2 (B), 
CDK1 (C), RB1 (D), CHEK1 (E), BRCA1 (F), ATR (G), ATM (H), and Cyclin T2 (I) measured in scrambled siRNA control and siRNA DHRS7 
treated LNCaP for 24 h, 36 h, and 48 h with untargeted proteomic. Results are expressed as mean ± SD. ***=p<0.0005. 
A 50% decrease in LNCaP cells in the S-phase of the cell cycle was detected following 48 h DHRS7 siRNA 
depletion compared to scrambled siRNA controls (Figure 35A). This was supported by the downregulation 
of the claspin protein, which was undetectable in the siRNA DHRS7 treated conditions (table 6), and also 
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downregulated at the mRNA level [147]. Claspin is a protein that is stabilized in S-phase but degraded in 
mitosis and is absent from cells in early G1 phase [235]. Consistent with this observation, the S-phase 
related protein Cyclin-A2 was downregulated following DHRS7 siRNA depletion at the 24 h timepoint, and 
undetectable at the 36 h and 48 h timepoint (Figure 35B). On the other side, CDK1, a protein that 
complexes with Cyclin-A2 and together are key regulators the S-phase [236], showed an ca. 20% decrease 
at 36 h and 48 h (Figure 35C). The tumor suppressor RB1, a protein downstream of Cyclin -A2 and involved 
in G1/S transition [237], however a time-dependent downregulation (Figure 35D). CHEK1 and the tumor 
suppressor BRCA1 were also downregulated (Figure 35E-F). These two proteins were also downregulated 
at the mRNA level, as showed by Seibert et al. [147]. The DNA damage sensing protein ATR and ATM [238] 
showed alternative regulatory patterns, as ATR showed a time-dependent downregulation (Figure 35G), 
whereas ATM did not change (Figure 35H). Finally, cyclin-T2, a protein that has been shown to interact 
with the C-terminal domain of RB1 [239], was upregulated at the 24 h and 48 h time points following 
DHRS7 siRNA depletion compared to scrambled siRNA controls (Figure 35I). 
In the contest of adhesion and migration, phenotypical alterations can be observed through the cell 
adhesion molecules (CAMs); transmembrane receptors that facilitate adhesion between cell membranes 
or to the extracellular membranes (ECM). As result section 5.2.2.1 and Tables 3-6 and 13 highlighted, 
adhesion related proteins E-Cadherin (also called CDH1, a calcium dependent CAM that has a crucial role 
in cell-cell adhesion), fibronectin (glycoprotein of the extracellular matrix also used for adhesion assays in 
Figure 24), spondin-2 (a secreted cell adhesion extracellular protein that has been found to be over-
expressed in prostate cancer [245]), catenin alpha 1 (forming together with CDH1 the cadherin–catenin 
complex [240]), CD166 antigen (a cell adhesion molecule that works in a calcium-independent manner 
[241]), desmocollin-2 (a transmembrane cadherin involved in the interaction of plaque proteins and 
intermediate filaments mediating cell-cell adhesion that may also contribute to epidermal cell positioning 
[242]), and occludin (a protein that is able to induce adhesion [243]) were reproducibly regulated under 
DHRS7 siRNA depletion. The relative quantification of these proteins, together with anillin (a protein that 
regulates the intracellular junctions in epithelial cells [244]), and the catenin alpha related catenin beta 1 
[240], is depicted in Figure 36. 
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Figure 36: Relative quantification of the proteins involved in adhesion CDH1 (A), Spondin-2 (B), Occludin (C), Anillin (D), FIbronectin 
(E), desmocollin-2 (F), and CD166 antigen (G) catenin alpha 1 (H), catenin beta 1 (I), measured in scrambled siRNA control and 
siRNA DHRS7 treated LNCaP for 24 h, 36 h, and 48 h with untargeted proteomic expressed as mean ± SD. 
CDH1, spondin-2, occludin, and anillin protein were all consistently downregulated at all the three time 
points tested (Figure 36A-D). Interestingly, occludin showed a time dependent downregulation (Figure 
36D). Fibronectin was downregulated after 36h and 48h with a trend to be downregulated at the 24 h 
timepoint following DHRS7 siRNA depletion (Figure 36E). On the other side, desmocollin-2 is upregulated 
ca. 1.6 fold and CD166 antigen showed a time-dependent upregulation maximizing at ca. 2 fold increase 
(Figure 36F and G). Catenin alpha 1 and catenin beta 1 show similar patterns of downregulation (Figure 
36H-I). All the trends in protein regulation described in the 2nd global proteomic analysis at three time 
points correlated with the observations made for the first proteomics experiment (results section 5.2.2.1). 
CDH-1 was previously regulated at the mRNA level [147] as well as at the protein level (unpublished data 
in the master thesis of Simon Stücheli) following DHRS7 siRNA depletion in LNCaP cells and represents an 
interesting protein with a tumor suppressor role. To further study the regulation of CDH-1 following DHRS7 
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depletion, LNCaP cells were immunostained for CDH-1 and detected under a fluorescence microscope 
(Figure 37B).  
 
Figure 37: Immunofluorescence of DHRS7 (A-B) and CDH-1 (C-D) in LNCaP under siRNA scrambled and siRNA DHRS7 48 h treatment. 
Images were taken with 40x magnification. 
Interestingly, LNCaP cells that were depleted for the endoplasmic reticulum localized DHRS7 
(Figure 37A-B), presented a disperse CDH1 signal compared to control (Figure 37C-D).  
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5.2.2.2.2.4 Characterization of Protein Changes related to Membrane Lipid Pathways 
As depicted in Figure 36, several regulated cell adhesion molecules were identified and were changed 
already after 24 h following DHRS7 siRNA depletion in LNCaP cells. These proteins are usually localized at 
the cellular phospholipid bilayer membrane and could be involved in the membrane fatty acid metabolism 
pathways, suggested in results section 5.2.2.1. The proteins involved in membrane lipid pathways SMPD1 
and LPCAT1 (regulated in Table 11 and Table 12, respectively), and the proteins involved in the membrane 
lipid transport and metabolism TEX2 (Table 4), ABHD2 (a triacylglycerol lipase and ester hydrolase [245], 
Tables 13-14), and FAR1 (an SDR enzyme that controls ether glycerophopsholipid synthesis [246] also 
depicted in Figure 3 and regulated as shown in Table 14) were analyzed according to the relative 
quantification data from the untargeted LNCaP proteome under DHRS7 time-dependent depletion (Figure 
39A-E).  
Additionally, another protein potentially involved in lipid metabolism pathway or alternatively to the 
retinoic acid metabolism pathway, is RDH10, an SDR and a potential proto-oncogene which localizes in 
lipid droplets (see chapter 2.2 of the introduction). As RDH10 was only detected in the DHRS7 siRNA 
depleted LNCaP cells at all the time points tested and not in the scrambled siRNA controls (table 6 and 8), 
it was investigated for retinoic acid metabolism activation following DHRS7 depletion. This was done first 
through evaluating the protein amount of the nuclear receptors RXR alpha and beta that did not change 
(data not shown), as well as the downstream target proteins RAI1 and RARA were selected for protein 
analysis using the global proteome data and RNA quantification (Figure 39F-H). 
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Figure 38: Relative quantification of proteins involved in membrane lipid metabolism measured in scrambled siRNA control and 
siRNA DHRS7 treated LNCaP for 24 h, 36 h, and 48 h with untargeted proteomic: SMPD1 (A), LPCAT1 (B), TEX2 (C), ABHD2 (D), and 
FAR1 (E). F. Relative quantification of RAI measured in scrambled siRNA control and siRNA DHRS7 treated LNCaP for 24 h, 36 h, 
and 48 h with untargeted proteomic; G. mRNA quantification of RARA after treatment with the RARA inhibitor LG100754 and the 
RARA inducers retinoic acid and bexarotene (mean of three replicate values); H. mRNA quantification of RARA after 48 h DHRS7 
knock-down (mean of three replicate values). 
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SMPD1 and LPCAT1 protein expression did not change following DHRS7 siRNA depletion at any time point 
compared to scrambled siRNA control (Figure 39A-B). TEX2, ABHD2 and FAR1 protein expression levels 
were upregulated following DHRS7 siRNA depletion: TEX2 with 3 fold and slightly decreasing under the 
two following time points (Figure 39C)., and ABHD2 3.3, 1.8, and 3.45 fold, for 24 h, 36 h, and 48 h time 
points, respectively (Figure 39D). Finally, FAR1, was ca 2 folds upregulated under all the time points 
compared to scrambled siRNA control (Figure 39E). 
Changes in the protein levels of RAI1 was observed (Figure 39F). RARA was undetectable in the global 
proteomic analysis. However, a control experiment using positive inducers of retinoic acid receptors, 
LG100754 and bexarotene, upregulated RARA mRNA levels in LNCaP cells (Figure 39G), however no 
changes were observed in RARA mRNA levels following DHRS7 siRNA depletion at the 48 h timepoint 
compared to scrambled siRNA control (Figure 39H), suggesting no relevant DHRS7 mediated retinoic acid 
metabolism observed downstream to the retinoic acid receptors.  
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5.2.3 Discussion 
The untargeted analysis of the LNCaP proteome following siRNA depletion first for the timepoint 48 h with 
a decreased sensitivity, and afterwards with a more sensitive approach time-dependent DHRS7 
downregulation, allowed to identify interesting groups of changed proteins to dissect mechanisms related 
to functional phenotypical changes related to knock-down of DHRS7. These groups of altered proteins are 
partly describing the phenotypical changes observed by Seibert el al. [147] for proliferation/cell cycle, 
adhesion, and migration pathways, and allowed the identification of new interesting players involved in 
membrane lipid metabolism pathway and/or with cancer associated roles. This suggested mechanisms for 
the establishment of the functional phenotype observed in the prostate cancer cell line LNCaP following 
DHRS7 depletion. Moreover, careful analysis of proteins involved in these mechanisms allowed to test 
hypotheses on a androgen-dependent effect of DHRS7 mediated regulation as discussed in chapter 1 
(section 4). 
With the conclusions made in chapter 1, DHT seemed to be a potential physiologically relevant substrate 
of DHRS7. Nevertheless, in the prostate cancer cell model LNCaP that endogenously express DHRS7, 
untargeted proteomics and endogenous AR transactivation experiments provided strong evidence against 
a physiological role of DHRS7 in DHT metabolism and the effects upon knockdown of this enzyme seem to 
be androgen-independent. This observation was also supported by the master thesis work of Simon 
Stücheli (unpublished data). 
Alternative to an AR dependent mechanism driving proliferation upon DHRS7 downregulation, prostate 
cancer cell proliferation and aggressiveness can be driven by truly AR-independent mechanisms, as also 
outlined in the introduction in chapter 2.2. In this regard, Bluemn et al. [31] identified two main 
mechanisms studied with selected LNCaP androgen independent colonies: a neuroendocrine dependent 
and a neuroendocrine independent pathway. The identification of EGFR, EGFL7 and FGFR1 and the 
observation of the trend for upregulation of EGFL7 and the upregulation of GRB10 may suggest 
investigating further the AR and neuroendocrine independent pathway. However, the phosphorylation of 
the MAPK and FGF pathways involving these tyrosine kinase activity related proteins should be studied to 
help rule in/out AR and neuroendocrine driven proliferation in the LNCaP cells following DHRS7 depletion. 
In this regard, it must be in fact considered that important proteins to assess these mechanisms might be 
not quantified because of the sample preparation, as highlighted by the disconnect between the 
microarray and proteomic analysis with respect to the nuclear receptors and SDRs and AKRs enzymes. The 
method for sample preparation was in fact not being optimized to specifically detect membrane receptors 
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or nuclear proteins (e.g. the microsomal or cytoplasmic SDRs and AKRs enzymes were increasingly 
detected compared to the nuclear receptors). 
As the modulation of proliferation depend on altered cell cycle control, cell cycle analysis and related 
proteins such as cyclins, CDKs, and cell-cycle modulators, were investigated and revealed a decrease in the 
S-phase under treatment with siRNA DHRS7 as detected by flow cytometry and the downregulation of 
Cyclin-A2 and Claspin. Interestingly, these proteins are both regulated by ubiquitination and proteosomal 
degradation processes, of which different proteins in these systems are downregulated (tables 3-6 and 13, 
14). However, these proteins might also refer to the modulation of unfolded protein response degradation 
as a consequence of cellular stress [247]. The decrease in S phase accompanied by the increase in 
proliferation as observed by xCELLigence experiments suggested proliferating cells with a short S-phase. 
This could be influenced by cell growth control relevant proteins such as RB1, CHECK1, BRCA1 and spondin-
2, that were detected ot be downregulated. The relationship of DHRS7 with S-phase modulation is also 
supported by an abstract indicating that the breast cancer cell line MCF-7 transfected with DHRS7 was 
shown to have an increased number of cells in the S-phase [153], and that LNCaP cells treated with miR-
663, which reported an increased number of cells in S-phase cell cycle, showed an upregulation in DHRS7 
protein [151]. Interestingly, Jiao et al. [151] describe these changes in relation to a transition of LNCaP 
androgen dependent phenotype towards a castration resistant prostate cancer phenotype, suggesting 
again association of DHRS7 with altered proliferation to be AR independent. 
Proteins involved in adhesion and migration were consistently and mostly early downregulated, as the 
case of the tumor suppressor CDH1. The loss of epithelial surface markers such as CDH1 or fibronectin can 
be a hallmark of epithelial-mesenchymal transition [248], however this process is also characterized by the 
acquisition of mesenchymal markers such as vimentin and N-cadherin, that were not regulated or detected 
through the untargeted proteomics approach, respectively. Alternatively, the investigated adhesion and 
migration regulated proteins can also indicate an adaptation to changed metabolism residing in the 
cellular membrane. In this regard, the potential proto-oncogene proteins involved in membrane lipid 
transport and metabolism such as RDH10 and ABHD2 were upregulated. Interestingly, literature reported 
upregulation of DHRS7 following different lipids treatments [155, 158, 159], suggesting a potential role of 
DHRS7 in lipid metabolism. 
Modulation of RDH10 and ABHD2 expression through DHRS7 may be dependent on different pathways 
and could be hypothesized according to the available literature. Indeed, RDH10 is an SDR involved in the 
transport of lipid droplets that seems to be upregulated by reduction of retinoic acid (product of all-trans 
 114 
 
retinal) [249]. This could support the hypothesis from Stambergova et al. of all-trans-retinal as a substrate 
for DHRS7 [145] which under siRNA mediated DHRS7 downregulation could lead to increased all-trans-
retinal which could upregulate RDH10 and thus lead to an increase in proliferation as observed in the 
glioma cell lines U87 and U251 [96]. However, the change in proliferation seems not to be mediated 
through retinoic acid relevant receptor activity. Alternatively, the upregulation of RDH10 might be a 
consequence of an increase in acyl ester biosynthesis with increased lipid droplet formation as investigated 
by Jiang et al. [95]. In regards to the monoacylglycerol lipase ABHD2, it is seems that the upregulation of 
ABHD2 could be due to androgens [250] or by acting with a genome-independent action, such as a 
membrane progesterone receptor [227]. Alternatively, this could be a compensatory mechanism after 
knockdown of DHRS7, possibly involving fatty acid metabolism. Interestingly, ABHD2 is able to couple 
heightened lipogenesis with lipolysis to produce fatty acid networks by mediating degradation of 
1-arachidonoylglycerol (1AG) and 2-arachidonoylglycerol (2AG) from the cellular membrane to glycerol 
and arachidonic acid converting monoglycerides [227]. Arachidonic acid, an omega-6 fatty acid, is 
associated to increased proliferation in prostate cancer [251]. Moreover, Obinata et al reported ABHD2 to 
cause changes in proliferation and migration in the prostate cancer cell lines LNCaP and VCaP upon stable 
transfection, and that higher ABHD2 protein expression positively correlated with high Gleason score and 
pathological N stage as well as low prostate cancer-specific survival rates [250]. On the other side, ABHD2 
was shown to be elevated in LNCaP versus androgen-independent human prostate cancer cell lines, where 
the siRNA mediated silencing of the functional homologous monoacylglycerol lipase MAGL was shown to 
increase prostate cancer aggressiveness and correlated to epithelial-to-mesenchymal transition [252].  
To support these hypotheses, the expression of ABHD2 and RDH10 in DHRS7 knock-down samples is being 
evaluated through western blotting and will be followed by a quantitative targeted proteomics 
experiments targeting ABHD2 and RDH10 under DHRS7 siRNA mediated downregulation. Additionally, the 
effect of DHRS7 on these proteins can be investigated by ABHD2 and/or RDH10 knock-down or inhibition 
in LNCaP as well as in androgen independent prostate cancer cell lines with functional proliferation, 
migration and adhesion experiments. In addition, the role of these proteins associated with lipid 
metabolism could be investigated trough immunofluorescence experiments with intracellular neutral and 
polar lipid stainings (e.g. with Nile Red that allows to reveal lipid droplets and their composition [253], as 
was already shown in LNCaP by Sadowski et al. [254]). 
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6 General Discussion 
The “deorphanization” of enzymes is an important step toward the uncovering of their physiological roles. 
The enzymes of the SDR superfamily are particularly difficult to deorphanize as they have a wide spectrum 
of substrates, they often lack structural information, share poor primary structure similarity, are often 
embedded in organelle membrane bilayers and do not have a common activity element that could be used 
as suitable high-throughput assay to assess potential substrates. In regard to the orphan enzyme DHRS7, 
the identification of its substrate would help to uncover its role in health and pathological conditions, as it 
has been shown to be a potential tumour suppressor in prostate cancer [147]. As the 3D protein structure 
resolution of DHRS7 has not been accomplished so far, and only few publications are available, and 
revealing conflicting results of potential substrates with suggestions of few candidates with low non-
physiological affinity, further studies are needed in order to attempt to characterize the function of DHRS7. 
This thesis is aimed (1) to identify DHRS7’s substrates through a targeted “deorphanization” approach 
(chapter 1), and (2) to understand the potential physiological role of DHRS7 through DHRS7 knock-down 
and functional assays in cancer cell lines with high endogenous DHRS7 expression as well as with an 
untargeted proteomics approach (chapter 2). These approaches allowed to characterize in vitro DHRS7 
activity by revealing 3α or 20β reduction on carbonyl moieties of steroidal structures, observe adhesion 
and migration changes in the breast cancer cell line MCF-7 under DHRS7 depletion, and suggesting 
interesting protein changes related to a proto-oncogene signature phenotype such as ABHD2 and/or 
RDH10 that could reveal a feedback mechanism established indirectly rather than by a direct DHRS7 
substrate role. However, DHRS7 remains an “orphan” enzyme and hypotheses generated with the 
untargeted proteomics approach need to be further tested. 
With a targeted deophanization approach performed in chapter 1, the substrates and products measured 
in DHRS7 overexpressing HEK 293 cells allowed to provide experimental proof of reduction of the 
endogenous metabolites DHT, cortisone, and potentially on 17αHOProg leading to products reduced on 
3α or 20β carbonyl moieties. The discovery of weak substrates is important as it can allow the search for 
more relevant substrates, as well as for inhibitors. On the other side, this will allow to test activity following 
purification of the enzyme and test for activity enrichment per amount of protein. An inhibitor, if specific, 
could help in investigating the role of DHRS7 both in vitro and in vivo as the timing would be more acute 
than upon knock-down. However, this strategy represented a low throughput and time-consuming 
approach. The in vitro screening tool with cell lysate of stably expressing DHRS7 cell lines to screen for 
novel substrates that was developed based on the observed reactivity toward DHT, was used to find novel 
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candidate substrates and inhibitors while addressing the problem of limited resources. This represented a 
valuable screening tool, as SDRs don’t have a common specific assay to monitor activity in unpurified 
conditions. Nevertheless, this approach was not successful in finding novel high affinity candidates. In 
regards to the deorphanization of SDRs using lysate activity assays, the literature reports a similarly 
negative outcome for the poorly described SDRs, hydroxysteroid dehydrogenase like 2 (HSDL2) and short-
chain dehydrogenase/reductase-orphan (SDR-O) where activity was monitored through NADPH 
consumption [255]. 
Regarding the strategy used by Zemanová et al. [208] which used a combination of in silico homology and 
substrates docking models with in vitro assays for the deorphanization of DHRS7, albeit without success in 
defining physiologically relevant endogenous substrates, I believe that this approach was novel and 
interesting since this was the first attempt of this combination of techniques to deorphanize human SDRs. 
However, in my opinion, the use of a homology model of DHRS7 based on 11βHSD1 provided a weak 
platform in order to predict potential substrates mainly due to the low homology of 38% sequence identity 
between the two proteins [208]. Additionally, the two proteins showed different affinity for cortisone and 
produced different metabolites as showed by our study with activity in intact HEK 293 cells [191]. 
Moreover, we showed that the active site of the two enzymes faced different cellular compartements with 
DHRS7 facing the cytosol, and 11βHSD1 facing the inside of the endoplasmic reticulum [191]. Interestingly, 
this strategy of in silico and in vitro assays was successful to deorphanize two plant SDRs [256], however, 
the in silico model was based on high homology with these two orphan enzymes (amino acid identity of 
79%). In silico homology studies could give important information on the pocket binding active site for 
hypotheses generation. Interestingly, in addition to Zemanová’s study, Dr. Katharina Beck, a Post-Doc in 
our lab, observed an elongated cone-shaped pocket binding site that may allow access for binding of large 
lipophilic metabolites, other lipid mediators and different eicosanoids (unpublished data). 
As highlighted in section 2.5 of the introduction, a high-throughput untargeted method is recommended 
as a “deorphanization” approach when limited information is available on the enzyme of interest [177-
179]. This approach was adopted for hypotheses generation regarding DHRS7 relevant cancer associated 
mechanisms in the prostate cancer cell line LNCaP with DHRS7 siRNA mediated knock-down. LNCaP was 
shown to be the cell model with the strongest functional effects following DHRS7 depletion compared to 
the breast cancer cell line MCF-7 and the adrenal cancer cell line H295R. The proteomic data showed 
several changed proteins potentially involved in tumor biogenesis, the regulation of which may be directly 
controlled by a substrate of DHRS7 or indirectly regulated as a result of DHRS7 depletion. Alternatively, 
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some of the changed proteins may not directly be involved in tumor biogenesis but to yet unidentified 
pathways, also observed by other SDRs associated to human cancer (see section 2.3 of the introduction). 
Another high-throughput approach to evaluate lipid metabolism supporting changes observed as for 
RDH10, TEX2, FAR1 and ABHD2, could be lipidomics. Nevertheless, limitations to use a time-dependent 
silencing approach to detect changed proteins or lipids could also mask important DHRS7 relevant changes 
and thus stable overexpression or down-regulation could be considered and used as controls in such high-
throughput experiments as performed successfully for 17βHSD1 by Aka et al. [70] with a stable expression 
and following analysis by proteomics approach. 
On the other side, novel approaches to help deorphanization could be done by better understanding 
physiological impairments in an in vivo system, for example using knock-out or knock-in animals. The 
option of performing an inducible knock-out animal would have the advantage to eliminate embryonic 
death if the mutation could be lethal, provide a kinetic assessment on DHRS7 loss of function in vivo and 
provide support of siRNA mediated silencing observation made by proteomics with a human cell model. 
Alternatively, the option of having a tissue specific knock-out mouse would allow to study specific organ 
phenotypes decreasing systemic interferences, embryonic lethal effects and gathering organ specific 
observations [178]. Relevance of prostate and breast cancer related effects observed in this thesis could 
be investigated in prostate and breast tissues in these in vivo models.  
In conclusion, DHRS7 remains an “ophan” SDR with an important role in prostate cancer but the 
investigations performed in this thesis releaved useful information for next steps towards the 
identification of a function of DHRS7. From one side the observations of in vitro reductive activity towards 
steroidal compounds according to steroidal molecular symmetry and specifically for DHT could allow to 
find functionally relevant substrates and inhibitors. On the other side, further characterization of regulated 
proteins following DHRS7 depletion in the endogenously DHRS7 expressing model LNCaP suggested an 
androgen receptor independent mechanism leading to increased cancer aggressiveness which could be 
driven by interesting upregulated proto-oncogenes, for which interactions with DHRS7 need to be further 
investigated.  
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9 Supplementary Data 
9.1.1.1 Supplementaries of the Publication “DHRS7 (SDR34C1) – a New player in the regulation of 
androgen receptor function by inactivation of 5α-dihydrotestosterone? 
 
Quantification of steroids in cell culture supernatants 
 
1.1. Chemicals and reagents 
Acetonitrile and formic acid of UHPLC-grade were purchased from Biosolve (Dieuze, France) or 
Sigma-Aldrich (St. Louis, MO, USA). Distilled water was obtained using a MilliQ water purification 
system (Millipore, Billerica, MA, USA). Cortisol-D4 (≥ 98% isotopic purity) was purchased from 
Sigma-Aldrich. Cortisol, cortisone and 20β-dihydrocortisone (20βDHE) were purchased from 
Steraloids (Newport, RI, USA) and all other chemicals were obtained from Sigma-Aldrich of the 
highest grade available. 
 
1.2. Instrumentation and analytical conditions 
Evaporation: Samples were evaporated to dryness using a Genevac EZ-2 plus centrifugal vacuum 
evaporator (Genevac, Suffolk, UK). 
Analytical instruments: Ultra-High performance liquid chromatography-tandem mass spectrometry 
(UHPLC-MS/MS) using an Agilent 1290 UHPLC instrument equipped with a binary solvent 
delivery system, an auto sampler (at 4°C), and a column oven, coupled to an Agilent 6490 triple 
quadrupole mass spectrometer equipped with a jet stream electrospray ionization interface (AJS-
ESI) (Agilent Technologies, Basel, Switzerland) were used for steroids quantification.  
Liquid chromatography: The chromatographic separation was performed on a Waters Acquity 
UPLC BEH C18, 1.7 µm, 2.1 × 150 mm column (Waters, Wexford, Ireland), at a column 
temperature of 40 ± 0.8°C. The mobile phase was water-acetonitrile-formic acid (70/30/0.1; v/v/v). 
Steroids were separated with a constant flow rate of 0.5 mL/min within 0-2.3 min, followed by 2 
min column wash with 100% acetonitrile and subsequent column re-equilibration for 2 min with 
30% acetonitrile. A methanol-water (75/25 v/v) mixture was used as needle and needle-seat 
flushing solvent for 10 s after sample injection. Samples were stored until analysis in the auto 
sampler (maintained at 4 ± 0.8°C). The injection volume was 2 µL per sample.  
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Mass spectrometry: Characteristic precursor ions and their corresponding product ions for multiple 
reaction monitoring (MRM) were defined by use of the compound optimizer software module 
included within the Mass Hunter Workstation software (Agilent Technologies, California, USA). 
Analytes were quantified using the corresponding mass transitions within individual time-
segments: Segment 1: 20βDHE m/z 363.22→163 (28 V, Dwell 150 ms) and m/z 363.22→105 (44 
V, Dwell 150 ms); Segment 2: Cortisone: m/z 361.2→163 (24 V, Dwell 100 ms) and m/z 
361.2à121.1 (36 V, Dwell 50 ms); Cortisol: m/z 363.22→121.1 (28 V, Dwell 150 ms) and m/z 
163.22à90.9 (60 V, Dwell 50 ms), Cortisol-D4: m/z 367.2→121.2 (25 V, Dwell 75 ms). The AJS-
ESI source conditions were set in the positive ion mode as following: Nitrogen gas temperature 
(290°C), gas flow (14 L/min), nebulizer (20 psi), sheath gas temperature (350°C), sheath gas flow 
(11 L/min), capillary voltage (4000 V), and nozzle voltage (1500 V) (Agilent Technologies, 
California, USA, B.08.00/Build 8.0.8023.0).  
Data analysis: The MassHunter Workstation Acquisition Software Version B.08.00/Build 
8.0.8023.0 and MassHunter Workstation Software Quantitative Analysis Version B.07.01 /Build 
7.1.524.0, respectively (Agilent Technologies, California, USA) was used for data acquisition and 
subsequent data analysis. 
Sample preparation: To each cell culture supernatant of sample or calibrator (400 μL) an internal 
standard solution containing cortisol-D4 in acetonitrile (100 µL, 125 nM) was added. Proteins were 
precipitated by adding ice cold acetonitrile (1 mL) and samples were incubated in a thermoshaker 
by thoroughly shaking (20 min, 1300 rpm, 4°C). Samples were centrifuged (10 min, 16,000 × rcf, 
4°C). Samples were evaporated to dryness and reconstituted in methanol (50 µL, 10 min, 1300 
rpm, 4°C, thermoshaker). 
Chromatographic performance: Ten-point calibration curves over the range of 0.98 to 250 nmol/L 
steroids were generated by a zero sample and nine calibrators in phenol red and serum free cell 
culture media. The coefficient of determination (R2) was 0.99 and at least 75% of all calibrators 
had to be valid. 
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9.1.1.2 Sequences of primers used for qPCR 
 
Gene Forward primer Reverse primer 
DHRS7 GAGTTTGGTAGAATCGACTTTCTG GAAAGAGGTACAGATATGATACCC 
RARα AAGCCCGAGTGCTCTGAGA TTCGTAGTGTATTTGCCCAGC 
AKR1C2 TGGAGCAATTCCCATCGACC CCCTATGTCCTCCTTTACAGAC 
PPIA ATGGTCAACCCCACCGTGT TCTGCTGTCTTTGGGACCTTGTC 
 
9.1.1.3 LC/MS peaks 
 
 
Figure 39: Absence of 3βAdiol in HEK 293 after 24 h incubation with 200 nM 3αAdiol (in red peak of 3βAdiol in calibrator with ca. 
200nM, in orange compared to the supernatant from DHRS7 stably transfectedHEK 293 cells after 8 h incubation with DHT). 
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9.1.1.4 Regulated proteins after DHRS7 depletion 48 h 
Table 9: Proteins identified with one peptide uniquely present in the siRNA DHRS7 condition after 48 h timepoint with p-value 
>0.05. *depicted values correspond to the mean of ion precursor intensities with arbitrary unit. 
Proteins only detected in siRNA 
DHRS7 48 h 
Accession 
Number 
Molecular 
Weight 
T-Test (p-
value) 
Mean scrambled 
siRNA* 
Mean siRNA 
DHRS7* 
Epidermal growth factor receptor P00533 134 kDa 0.013 0 6134233.333 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 11 
Q86Y39 15 kDa 0.0029 0 5487366.667 
Zinc transporter 1 Q9Y6M5 55 kDa 0.0031 0 9620266.667 
Glycogen phosphorylase, liver form P06737 97 kDa 0.0047 0 38062000 
Pituitary tumor-transforming gene 1 
protein-interacting protein 
P53801 20 kDa 0.00022 0 3017866.667 
DNA-directed RNA polymerase I 
subunit RPA43 
Q3B726 37 kDa 0.0014 0 6281133.333 
Putative tRNA 
(cytidine(32)/guanosine(34)-2'-O)-
methyltransferase 
Q9UET6 36 kDa 0.033 0 3461333.333 
Neuroplastin Q9Y639 44 kDa 0.032 0 5109600 
Guanine nucleotide-binding protein 
subunit beta-like protein 1 
Q9BYB4 36 kDa 0.003 0 4533733.333 
Myotubularin-related protein 14 Q8NCE2 72 kDa 0.0091 0 3747233.333 
Leucine-rich repeat neuronal protein 
1 
Q6UXK5 81 kDa 0.0027 0 1394400 
Pleckstrin homology domain-
containing family H member 3 
Q7Z736 85 kDa 0.008 0 1471443.333 
Selenoprotein M Q8WWX9 16 kDa 0.0006 0 2260400 
Dolichol-phosphate 
mannosyltransferase subunit 3 
Q9P2X0 10 kDa 0.00017 0 3827900 
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Table 10: Proteins identified with one peptide uniquely present in the siRNA scrambled control condition after 48 h timepoint with 
p-value >0.05. *depicted values correspond to the mean of ion precursor intensities with arbitrary unit. 
Proteins only deteted in scrambled 
siRNA control 48 h 
Accession 
Number 
Molecular 
Weight 
T-Test (p-
value) 
Mean scrambled 
siRNA 
Mean 
siRNA 
DHRS7 
Mitotic checkpoint serine/threonine-
protein kinase BUB1 beta 
O60566 120 kDa 0.047 4463000 0 
UAP56-interacting factor Q96QD9 36 kDa 0.036 7686600 0 
Chromosome transmission fidelity 
protein 8 homolog 
P0CG13 13 kDa 0.0098 3595166.667 0 
Serine/threonine-protein kinase TAO1 Q7L7X3 116 kDa 0.011 37481666.67 0 
Ubiquitin-conjugating enzyme E2 Q1 Q7Z7E8 46 kDa 0.041 4524733.333 0 
Neuroblastoma-amplified sequence A2RRP1 269 kDa 0.011 1187736.667 0 
Occludin Q16625 59 kDa 0.0079 7191933.333 0 
Serine/arginine-rich splicing factor 8 Q9BRL6 32 kDa 0.039 46151666.67 0 
Neurobeachin-like protein 2 Q6ZNJ1 303 kDa 0.0078 5871733.333 0 
Phosphatidylinositol 5-phosphate 4-
kinase type-2 beta 
P78356 47 kDa 0.0098 5000200 0 
Striatin O43815 86 kDa 0.046 6259166.667 0 
Putative bifunctional UDP-N-
acetylglucosamine transferase and 
deubiquitinase ALG13 
Q9NP73 126 kDa 0.0066 5257200 0 
UHRF1-binding protein 1 Q6BDS2 159 kDa 0.0043 2369066.667 0 
Amyloid-like protein 2 Q06481 87 kDa 0.0041 5008266.667 0 
Glutathione S-transferase A4 O15217 26 kDa 0.00086 1038156.667 0 
Hyaluronan mediated motility 
receptor 
O75330 84 kDa 0.0047 4065166.667 0 
Kinesin-like protein KIF23 Q02241 110 kDa 0.018 1316083.333 0 
N-acetyltransferase ESCO2 Q56NI9 68 kDa 0.02 84981 0 
TLD domain-containing protein 1 Q6P9B6 51 kDa 0.0056 6137466.667 0 
Nucleolar and spindle-associated 
protein 1 
Q9BXS6 49 kDa 0.0013 869493.3333 0 
Nicotinamide/nicotinic acid 
mononucleotide adenylyltransferase 1 
Q9HAN9 32 kDa 0.00041 1082253.333 0 
Centromere protein M Q9NSP4 20 kDa 0.00088 687093.3333 0 
Stromal membrane-associated protein 
1 
Q8IYB5 50 kDa 0.032 2196566.667 0 
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Table 11: Proteins identified with one peptide upregulated in the siRNA DHRS7 condition after 48 h timepoint with p-value >0.05. 
*depicted values correspond to the mean of ion precursor intensities with arbitrary unit. MW=Molecular weight 
Upregulated Proteins  Accession 
Number 
MW T-Test (p-
value): 
Fold 
Change 
Mean 
scrambled 
siRNA* 
Mean siRNA 
DHRS7* 
Cyclin-T2 - CCNT2 -  O60583 81 kDa 0.0005 380 10690.3333 4031333.33 
FH1/FH2 domain-containing protein 1 - FHOD1 -  Q9Y613 127 kDa 0.043 24 313033.333 7473433.33 
Anaphase-promoting complex subunit 1 - 
ANAPC1 -  
Q9H1A4 217 kDa 0.019 24 120806.667 2861966.67 
Small subunit processome component 20 
homolog - UTP20 -  
O75691 318 kDa 0.00051 19 1610613.33 30920333.3 
Protein bicaudal D homolog 2 - BICD2 -  Q8TD16 94 kDa 0.049 13 322816.667 4084033.33 
Protein phosphatase 1 regulatory subunit 21 - 
PPP1R21 -  
Q6ZMI0 88 kDa 0.0032 9.7 830966.667 8041933.33 
Transmembrane protein 238 - TMEM238 -  C9JI98 18 kDa 0.021 9.4 884370 8336033.33 
Desmocollin-2 - DSC2 -  Q02487 100 kDa 0.04 9 4548700 40950000 
Sphingomyelin phosphodiesterase - SMPD1  P17405 70 kDa 0.0093 7.7 628200 4842000 
Solute carrier family 12 member 2 - SLC12A2 -  P55011 131 kDa 0.01 7.6 809666.667 6164033.33 
Nucleolar protein 7 - NOL7 -  Q9UMY1 29 kDa 0.0039 7.2 520640 3723600 
Zinc finger CCHC domain-containing protein 3 - 
ZCCHC3 -  
Q9NUD5 44 kDa 0.0085 6.8 479500 3261500 
Ceroid-lipofuscinosis neuronal protein 5 - CLN5 -  O75503 41 kDa 0.0069 6.7 1789266.67 12043333.3 
Alpha-1-syntrophin - SNTA1 -  Q13424 54 kDa 0.018 6.2 743066.667 4602466.67 
Gamma-aminobutyric acid receptor-associated 
protein - GABARAP -  
O95166 14 kDa 0.00061 6.1 4634433.33 28303000 
Choline transporter-like protein 2 - SLC44A2 -  Q8IWA5 80 kDa 0.024 5.6 1200266.67 6666633.33 
Major vault protein - MVP  Q14764 99 kDa 0.013 5.3 3856533.33 20289333.3 
Leucyl-cystinyl aminopeptidase - LNPEP -  Q9UIQ6 117 kDa 0.0049 5.2 1600333.33 8251066.67 
Multidrug resistance-associated protein 1 - 
ABCC1 -  
P33527 172 kDa 0.033 5.1 2026166.67 10372733.3 
Gamma-aminobutyric acid receptor-associated 
protein-like 2 - GABARAPL2 -  
P60520 14 kDa 0.042 5.1 1006500 5124866.67 
Interleukin-1 receptor-associated kinase 1 - 
IRAK1 -  
P51617 77 kDa 0.019 4.9 254493.333 1257600 
MORC family CW-type zinc finger protein 3 - 
MORC3 -  
Q14149 107 kDa 0.046 4.7 383086.667 1782930 
Uridine diphosphate glucose pyrophosphatase - 
NUDT14 -  
O95848 24 kDa 0.029 4.6 261366.667 1209333.33 
Monoacylglycerol lipase ABHD2 - ABHD2 -  P08910 48 kDa 0.021 4.6 1278870 5829066.67 
Coiled-coil domain-containing protein 86 - 
CCDC86 -  
Q9H6F5 40 kDa 0.0047 4.5 5494233.33 24913333.3 
Ganglioside-induced differentiation-associated 
protein 1 - GDAP1 -  
Q8TB36 41 kDa 0.02 4.5 1288600 5780466.67 
Golgi apparatus membrane protein TVP23 
homolog B - TVP23B -  
Q9NYZ1 24 kDa 0.037 4.2 2180133.33 9203566.67 
Lysine-rich nucleolar protein 1 - KNOP1 -  Q1ED39 52 kDa 0.0077 4.2 4850166.67 20339333.3 
F-box/LRR-repeat protein 8 - FBXL8 -  Q96CD0 41 kDa 0.038 4.2 447833.333 1860833.33 
UPF0729 protein C18orf32 - C18orf32 - -  Q8TCD1 9 kDa 0.041 4.2 3027233.33 12574933.3 
Neurochondrin - NCDN -  Q9UBB6 79 kDa 0.0054 3.7 6462800 24163000 
Bystin - BYSL -  Q13895 50 kDa 0.011 3.3 4493500 14837000 
Peroxisomal 2,4-dienoyl-CoA reductase - DECR2  Q9NUI1 31 kDa 0.012 3.2 2741933.33 8741433.33 
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WD repeat-containing protein 6 - WDR6 -  Q9NNW5 122 kDa 0.03 3.1 7835033.33 24640000 
Uncharacterized protein KIAA1143 - KIAA1143 -  Q96AT1 17 kDa 0.033 3 7744633.33 23610666.7 
Mannosyl-oligosaccharide glucosidase - MOGS  Q13724 92 kDa 0.00052 3 3354200 10130733.3 
Endoribonuclease Dicer - DICER1 -  Q9UPY3 219 kDa 0.016 3 4363500 13085666.7 
Acyl-coenzyme A thioesterase THEM4 - THEM4 -  Q5T1C6 27 kDa 0.022 3 3788566.67 11254400 
Kinase D-interacting substrate of 220 kDa - 
KIDINS220 -  
Q9ULH0 197 kDa 0.023 2.9 121733.333 354840 
COBW domain-containing protein 3 - CBWD3 - -  Q5JTY5 (+3) 44 kDa 0.025 2.7 3865733.33 10616800 
Nuclear receptor-binding protein - NRBP1 -  Q9UHY1 60 kDa 0.0037 2.7 16407966.7 44028333.3 
Vacuolar protein sorting-associated protein 26B 
- VPS26B -  
Q4G0F5 39 kDa 0.027 2.7 10441900 27934666.7 
Ubiquitin carboxyl-terminal hydrolase 47 - 
USP47 -  
Q96K76 157 kDa 0.00095 2.6 14854333.3 37907666.7 
FUN14 domain-containing protein 2 - FUNDC2 -  Q9BWH2 21 kDa 0.037 2.5 10092740 25087666.7 
Syntaxin-4 - STX4 -  Q12846 34 kDa 0.033 2.4 4848833.33 11820766.7 
CD166 antigen - ALCAM -  Q13740 65 kDa 0.012 2.4 27607333.3 66789000 
F-box only protein 22 - FBXO22 -  Q8NEZ5 45 kDa 0.014 2.4 7585300 17885666.7 
Cell cycle control protein 50A - TMEM30A -  Q9NV96 41 kDa 0.0018 2.3 3180766.67 7402100 
Grancalcin - GCA -  P28676 24 kDa 0.036 2.3 15142000 34778000 
1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-4 - PLCB4 -  
Q15147 134 kDa 0.0026 2.3 10687933.3 24248000 
RNA-binding protein 24 - RBM24 -  Q9BX46 
(+1) 
25 kDa 0.0058 2.3 13974333.3 31665000 
Leucine-rich repeat-containing protein 1 - LRRC1  Q9BTT6 59 kDa 0.021 2.3 571086.667 1291366.67 
Septin-5 - SEPT5 -  Q99719 43 kDa 0.044 2.2 22010333.3 49362666.7 
Growth factor receptor-bound protein 10 - 
GRB10 -  
Q13322 67 kDa 0.015 2.2 34252666.7 76641000 
Rab3 GTPase-activating protein non-catalytic 
subunit - RAB3GAP2 -  
Q9H2M9 156 kDa 0.0023 2.2 23899000 53359333.3 
Zinc finger FYVE domain-containing protein 16 - 
ZFYVE16 -  
Q7Z3T8 169 kDa 0.031 2.2 3375433.33 7425233.33 
Deubiquitinating protein VCIP135 - VCPIP1 -  Q96JH7 134 kDa 0.014 2.2 2244100 4874566.67 
Golgin subfamily A member 7 - GOLGA7 -  Q7Z5G4 16 kDa 0.029 2.2 1003813.33 2171066.67 
Tetratricopeptide repeat protein 27 - TTC27 -  Q6P3X3 97 kDa 0.0032 2.1 984946.667 2101166.67 
Nuclear receptor 2C2-associated protein - 
NR2C2AP -  
Q86WQ0 16 kDa 0.0098 2.1 18481333.3 38990000 
All-trans-retinol 13,14-reductase - RETSAT -  Q6NUM9 67 kDa 0.013 2.1 9322400 19400000 
Conserved oligomeric Golgi complex subunit 5 - 
COG5 -  
Q9UP83 93 kDa 0.049 2 4568366.67 9364800 
Pentatricopeptide repeat domain-containing 
protein 3, mitochondrial - PTCD3 -  
Q96EY7 79 kDa 0.027 2 11595233.3 23385000 
WD repeat-containing protein 44 - WDR44 -  Q5JSH3 101 kDa 0.047 2 9840366.67 19547666.7 
Interferon-induced transmembrane protein 3 - 
IFITM3 -  
Q01628 15 kDa 0.039 2 5308833.33 10472800 
AN1-type zinc finger protein 5 - ZFAND5 -  O76080 23 kDa 0.029 1.9 2853733.33 5532633.33 
N-alpha-acetyltransferase 35, NatC auxiliary 
subunit - NAA35 -  
Q5VZE5 84 kDa 0.015 1.9 5037566.67 9718033.33 
Phospholipase D3 - PLD3 -  Q8IV08 55 kDa 0.039 1.9 15086666.7 28448333.3 
Epsin-1 - EPN1 -  Q9Y6I3 60 kDa 0.022 1.9 25987666.7 48619333.3 
Small nuclear ribonucleoprotein Sm D1 - 
SNRPD1 -  
P62314 13 kDa 0.047 1.9 309953333 577190000 
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Protein RRP5 homolog - PDCD11 -  Q14690 209 kDa 0.03 1.9 63249666.7 117323333 
Methionine aminopeptidase 2 - METAP2 -  P50579 53 kDa 0.023 1.9 65720666.7 121586667 
Electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial - ETFDH -  
Q16134 68 kDa 0.034 1.8 55942000 102983333 
Lysosomal Pro-X carboxypeptidase - PRCP -  P42785 56 kDa 0.044 1.8 21343000 39264666.7 
Ubiquitin conjugation factor E4 A - UBE4A -  Q14139 123 kDa 0.0013 1.8 31617000 57719333.3 
Signal transducer and activator of transcription 
3 - STAT3 -  
P40763 88 kDa 0.005 1.8 127090000 228426667 
Signal transducing adapter molecule 1 - STAM -  Q92783 59 kDa 0.00043 1.8 13477666.7 24119333.3 
UBX domain-containing protein 6 - UBXN6 -  Q9BZV1 50 kDa 0.03 1.8 39616666.7 70780666.7 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 4, mitochondrial - NDUFS4 -  
O43181 20 kDa 0.029 1.8 10694966.7 19078000 
Sialate O-acetylesterase - SIAE -  Q9HAT2 58 kDa 0.035 1.8 7562600 13478000 
Rho GTPase-activating protein 5 - ARHGAP5 -  Q13017 172 kDa 0.0038 1.8 5642466.67 9965666.67 
Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic - HMGCS1 -  
Q01581 57 kDa 0.02 1.8 17903333.3 31588666.7 
LanC-like protein 2 - LANCL2 -  Q9NS86 51 kDa 0.032 1.8 6997733.33 12338333.3 
Glutathione S-transferase A1 - GSTA1 -  P08263 26 kDa 0.019 1.8 54535333.3 96112666.7 
Carbonyl reductase family member 4 - CBR4 -  Q8N4T8 25 kDa 0.032 1.8 13520966.7 23691333.3 
Desmoglein-2 - DSG2 -  Q14126 122 kDa 0.032 1.7 123671000 215800000 
Myotubularin-related protein 12 - MTMR12 -  Q9C0I1 86 kDa 0.018 1.7 8086933.33 14059333.3 
Type I inositol 1,4,5-trisphosphate 5-
phosphatase - INPP5A -  
Q14642 48 kDa 0.0014 1.7 1240433.33 2130233.33 
28S ribosomal protein S34, mitochondrial - 
MRPS34 -  
P82930 26 kDa 0.036 1.7 8370833.33 14339666.7 
Prolyl endopeptidase - PREP -  P48147 81 kDa 0.00098 1.7 86911666.7 148503333 
N-acylethanolamine-hydrolyzing acid amidase - 
NAAA -  
Q02083 40 kDa 0.0085 1.7 4935133.33 8356933.33 
Histidine triad nucleotide-binding protein 3 - 
HINT3 -  
Q9NQE9 20 kDa 0.045 1.7 12915333.3 21741000 
MAP kinase-activated protein kinase 2 - 
MAPKAPK2 -  
P49137 46 kDa 0.02 1.7 11482466.7 19311333.3 
5-oxoprolinase - OPLAH -  O14841 137 kDa 0.00071 1.7 28312333.3 47448000 
Histone H3.1 - HIST1H3A -  P68431 15 kDa 0.017 1.7 131866667 218893333 
ADP-ribosylation factor GTPase-activating 
protein 2 - ARFGAP2 -  
Q8N6H7 57 kDa 0.033 1.7 19226333.3 31914000 
Neogenin - NEO1 -  Q92859 160 kDa 0.0069 1.6 640800 1044063.33 
FYVE and coiled-coil domain-containing protein 
1 - FYCO1 -  
Q9BQS8 167 kDa 0.018 1.6 17018666.7 27707333.3 
Golgi SNAP receptor complex member 1 - 
GOSR1 -  
O95249 29 kDa 0.01 1.6 23311333.3 37616000 
Protein FAM160B1 - FAM160B1 -  Q5W0V3 87 kDa 0.042 1.6 26881666.7 43170333.3 
Nardilysin - NRDC -  O43847 132 kDa 0.0024 1.6 40890333.3 65132000 
V-type proton ATPase subunit d 1 - ATP6V0D1 -  P61421 40 kDa 0.049 1.6 89861000 142870000 
Protein phosphatase 1 regulatory subunit 12A - 
PPP1R12A -  
O14974 115 kDa 0.031 1.6 126200000 199633333 
Periodic tryptophan protein 1 homolog - PWP1 -  Q13610 56 kDa 0.021 1.6 43414000 68633000 
Caldesmon - CALD1 -  Q05682 93 kDa 0.0006 1.6 258150000 406343333 
Epiplakin - EPPK1 -  P58107 556 kDa 0.0084 1.6 435493333 681030000 
P98196 P98196-
DECOY 
? 0.0062 1.6 30954333.3 48210000 
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Serine/threonine-protein phosphatase 4 
regulatory subunit 1 - PPP4R1 -  
Q8TF05 107 kDa 0.049 1.6 3398333.33 5268433.33 
Actin-related protein 2/3 complex subunit 5-like 
protein - ARPC5L -  
Q9BPX5 17 kDa 0.008 1.5 87973000 136033333 
Deoxyhypusine hydroxylase - DOHH -  Q9BU89 33 kDa 0.0029 1.5 5761033.33 8789366.67 
Vacuolar protein sorting-associated protein 4B - 
VPS4B -  
O75351 49 kDa 0.025 1.5 69679666.7 106297333 
Lysophospholipase-like protein 1 - LYPLAL1 -  Q5VWZ2 26 kDa 0.0079 1.5 123190000 187803333 
ADP-ribose pyrophosphatase, mitochondrial - 
NUDT9 -  
Q9BW91 39 kDa 0.033 1.5 20666000 31305666.7 
60S ribosomal protein L26 - RPL26 -  P61254 17 kDa 0.012 1.5 341073333 513093333 
 
Table 12: Proteins identified with one peptide that are downregulated in the siRNA DHRS7 condition after 48 h timepoint with p-
value >0.05. *depicted values correspond to the mean of ion precursor intensities with arbitrary unit. MW=Molecular weight 
Downregulated Proteins  Accession Number 
MW T-Test (p-
value): 
Fold 
Change 
Mean 
scrambled 
siRNA 
Mean siRNA 
DHRS7 
U4/U6 small nuclear ribonucleoprotein Prp31 - 
PRPF31 -  
Q8WWY3 55 kDa 0.00088 0.7 60339666.7 40210666.7 
Myeloid-derived growth factor - MYDGF -  Q969H8 19 kDa 0.0056 0.7 132110000 87550666.7 
Dynein assembly factor 5, axonemal - DNAAF5 -  Q86Y56 94 kDa 0.026 0.7 21366666.7 14145000 
Hematological and neurological expressed 1-like 
protein - HN1L -  
Q9H910 20 kDa 0.0014 0.7 372240000 246303333 
Peptidyl-prolyl cis-trans isomerase FKBP5 - FKBP5 -  Q13451 51 kDa 0.038 0.7 134650000 88972666.7 
4F2 cell-surface antigen heavy chain - SLC3A2 -  P08195 68 kDa 0.021 0.7 41083666.7 27144666.7 
Bifunctional lysine-specific demethylase and 
histidyl-hydroxylase MINA - MINA -  
Q8IUF8 53 kDa 0.00029 0.7 22610000 14917333.3 
Biotinidase - BTD -  P43251 61 kDa 0.012 0.7 3711966.67 2440166.67 
Transcriptional repressor p66-beta - GATAD2B -  Q8WXI9 65 kDa 0.035 0.7 15452666.7 10053266.7 
Structural maintenance of chromosomes protein 3 - 
SMC3 -  
Q9UQE7 142 kDa 0.047 0.6 211476667 137026667 
Protein SON - SON -  P18583 264 kDa 0.012 0.6 122663333 79457000 
Hepatoma-derived growth factor-related protein 3 - 
HDGFRP3 -  
Q9Y3E1 23 kDa 0.021 0.6 56415000 36471666.7 
Guanosine-3',5'-bis(diphosphate) 3'-
pyrophosphohydrolase MESH1 - HDDC3 -  
Q8N4P3 20 kDa 0.022 0.6 25911666.7 16704666.7 
Nuclear RNA export factor 1 - NXF1 -  Q9UBU9 70 kDa 0.036 0.6 55533666.7 35749333.3 
E3 ubiquitin-protein ligase TRIM33 - TRIM33 -  Q9UPN9 123 kDa 0.044 0.6 14755333.3 9479233.33 
Deoxycytidine kinase - DCK -  P27707 31 kDa 0.045 0.6 17360666.7 11096833.3 
Polyadenylate-binding protein 2 - PABPN1 -  Q86U42 33 kDa 0.03 0.6 117093333 74747666.7 
Calcium-transporting ATPase type 2C member 1 - 
ATP2C1 -  
P98194 101 kDa 0.049 0.6 24508666.7 15629666.7 
RNA-binding protein FUS - FUS -  P35637 53 kDa 0.043 0.6 252200000 159700000 
Serine/threonine-protein kinase PAK 4 - PAK4 -  O96013 64 kDa 0.0018 0.6 179703333 113723333 
DCC-interacting protein 13-beta - APPL2 -  Q8NEU8 74 kDa 0.016 0.6 13670333.3 8626933.33 
ER membrane protein complex subunit 8 - EMC8 -  O43402 24 kDa 0.024 0.6 28409000 17850333.3 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-1 - GNB1 -  
P62873 37 kDa 0.0025 0.6 182073333 113323333 
Flap endonuclease 1 - FEN1 -  P39748 43 kDa 0.019 0.6 232373333 143696667 
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Mitochondrial amidoxime-reducing component 1 - 
MARC1 -  
Q5VT66 38 kDa 0.037 0.6 79733333.3 49165666.7 
Protein O-GlcNAcase - MGEA5 -  O60502 103 kDa 0.0073 0.6 90049333.3 55215666.7 
Protein kinase C and casein kinase substrate in 
neurons protein 2 - PACSIN2 -  
Q9UNF0 56 kDa 0.018 0.6 155186667 94659666.7 
Replication factor C subunit 4 - RFC4 -  P35249 40 kDa 0.015 0.6 70807666.7 43170333.3 
Extended synaptotagmin-1 - ESYT1 -  Q9BSJ8 123 kDa 0.0016 0.6 113763333 68581333.3 
Guanine nucleotide-binding protein-like 3-like 
protein - GNL3L -  
Q9NVN8 66 kDa 0.032 0.6 22311000 13450000 
Serine/threonine-protein kinase PRP4 homolog - 
PRPF4B -  
Q13523 117 kDa 0.00073 0.6 27613666.7 16646333.3 
Pleiotropic regulator 1 - PLRG1 -  O43660 57 kDa 0.028 0.6 94285000 56549666.7 
Protein FAM177A1 - FAM177A1 -  Q8N128 24 kDa 0.04 0.6 9473666.67 5556700 
Protein diaphanous homolog 1 - DIAPH1 -  O60610 141 kDa 0.029 0.6 95480333.3 55918333.3 
Cadherin-1 - CDH1 -  P12830 97 kDa 0.0063 0.6 114000333 66414666.7 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1 - DDAH1 -  
O94760 31 kDa 0.005 0.6 242170000 140800000 
Deoxyuridine 5'-triphosphate nucleotidohydrolase, 
mitochondrial - DUT -  
P33316 27 kDa 0.0019 0.6 225040000 130250000 
Helicase-like transcription factor - HLTF -  Q14527 114 kDa 0.034 0.6 32126333.3 18461000 
Androgen receptor - AR -  P10275 99 kDa 0.025 0.6 15104333.3 8644300 
Dihydrofolate reductase - DHFR -  P00374 21 kDa 0.015 0.6 130416667 74368333.3 
UDP-glucuronosyltransferase 2B17 - UGT2B17 -  O75795 61 kDa 0.0014 0.6 254520000 145053333 
Src substrate cortactin - CTTN -  Q14247 62 kDa 0.0025 0.6 561090000 318900000 
Ribonuclease H2 subunit B - RNASEH2B -  Q5TBB1 35 kDa 0.034 0.6 13147666.7 7453266.67 
Cohesin subunit SA-2 - STAG2 -  Q8N3U4 141 kDa 0.031 0.6 62415333.3 35321000 
Pre-mRNA-splicing factor 38B - PRPF38B -  Q5VTL8 64 kDa 0.032 0.6 17867666.7 10084366.7 
Methyl-CpG-binding domain protein 3 - MBD3 -  O95983 33 kDa 0.023 0.6 19287333.3 10842366.7 
Spermatogenesis-defective protein 39 homolog - 
VIPAS39 -  
Q9H9C1 57 kDa 0.015 0.6 7495100 4193866.67 
Mediator of DNA damage checkpoint protein 1 - 
MDC1 -  
Q14676 227 kDa 0.023 0.6 51302333.3 28676666.7 
Importin subunit alpha-1 - KPNA2 -  P52292 58 kDa 0.029 0.6 198726667 110908667 
Catenin alpha-1 - CTNNA1 -  P35221 100 kDa 0.00015 0.6 1024306667 571203333 
RNA-binding protein 47 - RBM47 -  A0AV96 64 kDa 0.028 0.5 74103666.7 40556000 
Translocon-associated protein subunit alpha - SSR1  P43307 32 kDa 0.039 0.5 14410666.7 7840733.33 
Serine/threonine-protein kinase MARK2 - MARK2 -  Q7KZI7 88 kDa 0.024 0.5 28894666.7 15622866.7 
Acidic leucine-rich nuclear phosphoprotein 32 
family member E - ANP32E -  
Q9BTT0 31 kDa 0.0037 0.5 14957333.3 8031733.33 
U2 snRNP-associated SURP motif-containing protein 
- U2SURP -  
O15042 118 kDa 0.0045 0.5 92935000 49813666.7 
Alpha-adducin - ADD1 -  P35611 81 kDa 0.024 0.5 27185000 14544900 
DNA replication licensing factor MCM6 - MCM6 -  Q14566 93 kDa 0.0036 0.5 316050000 168463333 
Heterogeneous nuclear ribonucleoprotein L-like - 
HNRNPLL -  
Q8WVV9 60 kDa 0.032 0.5 50788333.3 26756333.3 
Specifically androgen-regulated gene protein - 
SARG -  
Q9BW04 64 kDa 0.022 0.5 280360000 147250000 
Replication factor C subunit 2 - RFC2 -  P35250 39 kDa 0.0014 0.5 44585000 23255333.3 
Sorting nexin-6 - SNX6 -  Q9UNH7 47 kDa 0.041 0.5 70926000 36871333.3 
Leucine-rich repeat flightless-interacting protein 2 - 
LRRFIP2 -  
Q9Y608 82 kDa 0.00031 0.5 27315000 14043333.3 
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BRI3-binding protein - BRI3BP -  Q8WY22 28 kDa 0.025 0.5 992646.667 503780 
Epithelial splicing regulatory protein 1 - ESRP1 -  Q6NXG1 76 kDa 0.019 0.5 27299666.7 13854166.7 
DNA replication licensing factor MCM5 - MCM5 -  P33992 82 kDa 0.00016 0.5 310466667 155763333 
Prostatic acid phosphatase - ACPP -  P15309 45 kDa 0.01 0.5 50344666.7 25106333.3 
Exosome component 10 - EXOSC10 -  Q01780 101 kDa 0.044 0.5 22266000 11036100 
Protein flightless-1 homolog - FLII -  Q13045 145 kDa 0.0016 0.5 144420000 71350333.3 
Protein NEDD1 - NEDD1 -  Q8NHV4 72 kDa 0.04 0.5 1455066.67 717840 
Cyclin-dependent kinase 1 - CDK1 -  P06493 34 kDa 0.00088 0.5 251590000 123930000 
Intron-binding protein aquarius - AQR -  O60306 171 kDa 0.03 0.5 37951333.3 18669333.3 
Ubiquitin-associated protein 2 - UBAP2 -  Q5T6F2 117 kDa 0.019 0.5 22931000 11196600 
Peptidylprolyl isomerase domain and WD repeat-
containing protein 1 - PPWD1 -  
Q96BP3 74 kDa 0.02 0.5 12883666.7 6264400 
DNA topoisomerase 2-alpha - TOP2A -  P11388 174 kDa 0.018 0.5 76214000 36937333.3 
Ubiquitin-conjugating enzyme E2 S - UBE2S -  Q16763 24 kDa 0.006 0.5 14214333.3 6843800 
DNA polymerase alpha subunit B - POLA2 -  Q14181 66 kDa 0.013 0.5 9046766.67 4331266.67 
Ladinin-1 - LAD1 -  O00515 57 kDa 0.0077 0.5 96205000 45984666.7 
UPF0696 protein C11orf68 - C11orf68 -  Q9H3H3 27 kDa 0.035 0.5 11136266.7 5304866.67 
DNA replication licensing factor MCM7 - MCM7 -  P33993 81 kDa 0.01 0.5 313270000 149110000 
Cell division cycle protein 27 homolog - CDC27 -  P30260 92 kDa 0.012 0.5 9641500 4540400 
DNA replication licensing factor MCM4 - MCM4 -  P33991 97 kDa 0.0027 0.5 320810000 150700000 
Multiple myeloma tumor-associated protein 2 - 
MMTAG2 -  
Q9BU76 29 kDa 0.035 0.5 4242100 1983000 
Vacuolar protein sorting-associated protein 41 
homolog - VPS41 -  
P49754 99 kDa 0.048 0.5 6763766.67 3142200 
FK506-binding protein 15 - FKBP15 -  Q5T1M5 134 kDa 0.011 0.5 12332000 5698400 
cAMP-dependent protein kinase type I-alpha 
regulatory subunit - PRKAR1A -  
P10644 43 kDa 0.0097 0.5 88999000 40927333.3 
Transcription elongation factor A protein 1 - TCEA1 P23193 34 kDa 0.017 0.5 127013667 58220000 
DnaJ homolog subfamily C member 9 - DNAJC9 -  Q8WXX5 30 kDa 0.049 0.5 32429666.7 14735433.3 
SLC35A4 upstream open reading frame protein - 
SLC35A4 -  
L0R6Q1 11 kDa 0.012 0.5 18572000 8383266.67 
Atlastin-2 - ATL2 -  Q8NHH9 66 kDa 0.0079 0.5 14596000 6587466.67 
AP2-associated protein kinase 1 - AAK1 -  Q2M2I8 104 kDa 0.0014 0.5 47178666.7 21255333.3 
Cysteine-rich with EGF-like domain protein 2 - 
CRELD2 -  
Q6UXH1 38 kDa 0.022 0.4 23810333.3 10658266.7 
SWI/SNF complex subunit SMARCC1 - SMARCC1 -  Q92922 123 kDa 0.0036 0.4 121870000 53397333.3 
Malectin - MLEC -  Q14165 32 kDa 0.0081 0.4 83075666.7 35951000 
DNA replication licensing factor MCM3 - MCM3 -  P25205 91 kDa 0.0024 0.4 359126667 155023333 
Glycylpeptide N-tetradecanoyltransferase 1 - NMT1 P30419 57 kDa 0.047 0.4 8332066.67 3570966.67 
T-box transcription factor TBX3 - TBX3 -  O15119 79 kDa 0.045 0.4 12850366.7 5489833.33 
Exosome complex component RRP45 - EXOSC9 -  Q06265 49 kDa 0.019 0.4 16237333.3 6861400 
RING1 and YY1-binding protein - RYBP -  Q8N488 25 kDa 0.046 0.4 2545533.33 1072473.33 
Nucleoside diphosphate-linked moiety X motif 19 - 
NUDT19 -  
A8MXV4 42 kDa 0.0041 0.4 63818333.3 26728000 
Adhesion G-protein coupled receptor G6 - ADGRG6  Q86SQ4 137 kDa 0.00079 0.4 24761333.3 10247433.3 
Thymidine kinase, cytosolic - TK1 -  P04183 25 kDa 0.021 0.4 30389666.7 12562166.7 
Serine/threonine-protein kinase VRK1 - VRK1 -  Q99986 45 kDa 0.0055 0.4 36439333.3 14997066.7 
Condensin complex subunit 1 - NCAPD2 -  Q15021 157 kDa 0.016 0.4 36208333.3 14867333.3 
Putative oxidoreductase GLYR1 - GLYR1 -  Q49A26 61 kDa 0.0017 0.4 38934333.3 15930666.7 
Structural maintenance of chromosomes protein 2 - 
SMC2 -  
O95347 136 kDa 0.0046 0.4 44526000 18206333.3 
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Bleomycin hydrolase - BLMH -  Q13867 53 kDa 0.016 0.4 140853333 57379333.3 
Putative RNA-binding protein 15 - RBM15 -  Q96T37 107 kDa 0.00057 0.4 11558333.3 4675333.33 
Protein FAM83H - FAM83H -  Q6ZRV2 127 kDa 0.038 0.4 7462933.33 2994433.33 
Condensin complex subunit 2 - NCAPH -  Q15003 83 kDa 0.0041 0.4 17202333.3 6873833.33 
DNA replication complex GINS protein PSF2 - GINS2  Q9Y248 21 kDa 0.046 0.4 3631400 1433533.33 
Rho GTPase-activating protein 1 - ARHGAP1 -  Q07960 50 kDa 0.0045 0.4 43910000 17300666.7 
Lysine-specific demethylase 3B - KDM3B -  Q7LBC6 192 kDa 0.046 0.4 6426433.33 2494966.67 
Target of EGR1 protein 1 - TOE1 -  Q96GM8 57 kDa 0.035 0.4 1726333.33 664213.333 
Trinucleotide repeat-containing gene 6B protein - 
TNRC6B -  
Q9UPQ9 194 kDa 0.024 0.4 11080100 4240933.33 
Zinc finger protein 24 - ZNF24 -  P17028 42 kDa 0.018 0.4 18022000 6877000 
Leucine-rich repeat flightless-interacting protein 1 - 
LRRFIP1 -  
Q32MZ4 89 kDa 0.00028 0.4 293090000 111086667 
Adenosine deaminase - ADA -  P00813 41 kDa 0.011 0.4 24764000 9244433.33 
Splicing factor 45 - RBM17 -  Q96I25 45 kDa 0.00017 0.4 70570666.7 25946666.7 
Ubiquitin thioesterase OTU1 - YOD1 -  Q5VVQ6 38 kDa 0.0017 0.4 6262400 2297133.33 
Crooked neck-like protein 1 - CRNKL1 -  Q9BZJ0 100 kDa 0.02 0.4 6093133.33 2218666.67 
Short coiled-coil protein - SCOC -  Q9UIL1 18 kDa 0.0037 0.4 45145000 16360666.7 
Cleavage and polyadenylation specificity factor 
subunit 1 - CPSF1 -  
Q10570 161 kDa 0.042 0.4 11132033.3 3929133.33 
DNA replication licensing factor MCM2 - MCM2 -  P49736 102 kDa 0.0047 0.3 250166667 87104000 
Peroxisomal trans-2-enoyl-CoA reductase - PECR -  Q9BY49 33 kDa 0.041 0.3 5610166.67 1940200 
Myelin basic protein - MBP -  P02686 33 kDa 0.019 0.3 13263666.7 4525833.33 
DnaJ homolog subfamily C member 3 - DNAJC3 -  Q13217 58 kDa 0.026 0.3 18292000 6123166.67 
Choline-phosphate cytidylyltransferase A - PCYT1A -  P49585 42 kDa 0.019 0.3 41143333.3 13565933.3 
Zinc finger MYM-type protein 2 - ZMYM2 -  Q9UBW7 155 kDa 0.0065 0.3 5117400 1679133.33 
Fibronectin - FN1 -  P02751 263 kDa 0.023 0.3 31833333.3 10212300 
Actin-related protein 2/3 complex subunit 5 - 
ARPC5 -  
O15511 16 kDa 0.00069 0.3 63042666.7 20153666.7 
U3 small nucleolar ribonucleoprotein protein IMP4 
- IMP4 -  
Q96G21 34 kDa 0.049 0.3 8674400 2729700 
Replication factor C subunit 1 - RFC1 -  P35251 128 kDa 0.021 0.3 10986400 3446226.67 
DNA polymerase delta subunit 3 - POLD3 -  Q15054 51 kDa 0.0029 0.3 4851666.67 1509863.33 
RAC-alpha serine/threonine-protein kinase - AKT1 -  P31749 56 kDa 0.0014 0.3 22954333.3 7135933.33 
Transcription initiation factor TFIID subunit 7 - TAF7  Q15545 40 kDa 0.041 0.3 10568766.7 3276000 
Ribonucleoside-diphosphate reductase subunit M2 
- RRM2 -  
P31350 45 kDa 0.0084 0.3 78819000 24406000 
Guanine nucleotide-binding protein G(I)/G(S)/G(O) 
subunit gamma-12 - GNG12 -  
Q9UBI6 8 kDa 0.025 0.3 7529666.67 2280966.67 
Anterior gradient protein 2 homolog - AGR2 -  O95994 20 kDa 0.014 0.3 25477000 7714833.33 
Protein virilizer homolog - KIAA1429 -  Q69YN4 202 kDa 0.012 0.3 2722833.33 818333.333 
E3 ubiquitin-protein ligase ZNF598 - ZNF598 -  Q86UK7 99 kDa 0.017 0.3 21456666.7 6362233.33 
Ubiquitin conjugation factor E4 B - UBE4B -  O95155 146 kDa 0.004 0.3 8614833.33 2550126.67 
Cyclin-dependent kinases regulatory subunit 2 - 
CKS2 -  
P33552 10 kDa 0.0033 0.3 61038333.3 17919000 
Calpain-2 catalytic subunit - APN2 - SV=6 P17655 80 kDa 0.035 0.3 8358566.67 2394166.67 
Ubiquitin-conjugating enzyme E2 T - UBE2T -  Q9NPD8 23 kDa 0.0056 0.3 21736000 6128533.33 
WD repeat and HMG-box DNA-binding protein 1 - 
WDHD1 -  
O75717 126 kDa 0.0071 0.3 23886666.7 6722830 
TRPM8 channel-associated factor 1 - TCAF1 -  Q9Y4C2 102 kDa 0.043 0.3 6704733.33 1880310 
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Phosphatidylinositol 4,5-bisphosphate 3-kinase 
catalytic subunit delta isoform - PIK3CD -  
O00329 119 kDa 0.04 0.3 7713800 2153146.67 
Proline-rich protein PRCC - PRCC -  Q92733 52 kDa 0.00086 0.3 28373333.3 7676400 
Complex I assembly factor TMEM126B, 
mitochondrial - TMEM126B -  
Q8IUX1 26 kDa < 0.00010 0.3 5279766.67 1425500 
Histone PARylation factor 1 - HPF1 -  Q9NWY4 39 kDa 0.018 0.3 13968000 3764266.67 
Kinesin-like protein KIF2C - KIF2C -  Q99661 81 kDa 0.038 0.3 2893066.67 765963.333 
Ribosomal RNA processing protein 1 homolog B - 
RRP1B -  
Q14684 84 kDa 0.002 0.3 10580000 2754833.33 
Polyhomeotic-like protein 3 - PHC3 -  Q8NDX5 106 kDa 0.017 0.3 3763466.67 971473.333 
Calcium/calmodulin-dependent protein kinase type 
1 - CAMK1 -  
Q14012 41 kDa 0.032 0.3 19511000 5030866.67 
GA-binding protein alpha chain - GABPA -  Q06546 51 kDa 0.016 0.3 6824333.33 1751523.33 
Tetratricopeptide repeat protein 19, mitochondrial 
- TTC19 -  
Q6DKK2 42 kDa 0.018 0.3 15246666.7 3825033.33 
Charged multivesicular body protein 1b - CHMP1B -  Q7LBR1 22 kDa 0.01 0.3 15579000 3905733.33 
Sperm-specific antigen 2 - SSFA2 -  P28290 138 kDa 0.0066 0.2 28975333.3 7065933.33 
General transcription factor 3C polypeptide 5 - 
GTF3C5 -  
Q9Y5Q8 60 kDa 0.039 0.2 10761300 2516400 
Lysophosphatidylcholine acyltransferase 1 - LPCAT1  Q8NF37 59 kDa 0.0056 0.2 4242533.33 989863.333 
RalA-binding protein 1 - RALBP1 -  Q15311 76 kDa 0.019 0.2 8058700 1864100 
Mitogen-activated protein kinase kinase kinase 7 - 
MAP3K7 -  
O43318 67 kDa 0.03 0.2 1491933.33 339866.667 
PHD finger protein 23 - PHF23 -  Q9BUL5 44 kDa 0.049 0.2 391750 88630 
Chromosome transmission fidelity protein 18 
homolog - CHTF18 -  
Q8WVB6 107 kDa 0.039 0.2 3861366.67 855066.667 
Integrator complex subunit 7 - INTS7 -  Q9NVH2 107 kDa 0.0076 0.2 5386066.67 1172533.33 
Upstream-binding protein 1 - UBP1 -  Q9NZI7 60 kDa < 0.00010 0.2 11561666.7 2471600 
Golgin subfamily A member 1 - GOLGA1 -  Q92805 88 kDa 0.0077 0.2 15690000 3257673.33 
Protein FAM3C - FAM3C -  Q92520 25 kDa 0.045 0.2 21694666.7 4447766.67 
Multiple C2 and transmembrane domain-containing 
protein 2 - MCTP2 -  
Q6DN12 100 kDa 0.045 0.2 1471100 300896.667 
Spondin-2 - SPON2 -  Q9BUD6 36 kDa 0.0058 0.2 39396666.7 8029333.33 
Protein FAM91A1 - FAM91A1 -  Q658Y4 94 kDa 0.023 0.2 15332000 3086156.67 
Exosome complex component RRP43 - EXOSC8 -  Q96B26 30 kDa 0.049 0.2 20437666.7 4095466.67 
Retinoblastoma-associated protein - RB1 -  P06400 106 kDa 0.004 0.2 9034666.67 1773333.33 
Glutathione S-transferase theta-2 - GSTT2 -  P0CG29 
(+1) 
28 kDa 0.021 0.2 5644866.67 1107800 
MKL/myocardin-like protein 2 - MKL2 -  Q9ULH7 118 kDa 0.0055 0.2 22776000 4356666.67 
Chromatin assembly factor 1 subunit A - CHAF1A -  Q13111 107 kDa 0.023 0.2 12338733.3 2239566.67 
Dehydrogenase/reductase SDR family member 7 - 
DHRS7 -  
Q9Y394 38 kDa 0.00047 0.2 305790000 53371333.3 
Gamma-tubulin complex component 3 - TUBGCP3 -  Q96CW5 104 kDa 0.024 0.2 1928700 320726.667 
Serine/threonine-protein kinase PLK1 - PLK1 -  P53350 68 kDa 0.012 0.2 3583100 565766.667 
Charged multivesicular body protein 7 - CHMP7 -  Q8WUX9 51 kDa 0.016 0.2 4817166.67 756566.667 
Leucine-rich repeat-containing protein 57 - LRRC57 
-  
Q8N9N7 27 kDa 0.031 0.2 3175300 495700 
Inactive ubiquitin carboxyl-terminal hydrolase 54 - 
USP54 -  
Q70EL1 187 kDa 0.00054 0.2 16648333.3 2539433.33 
Serine/threonine-protein phosphatase 6 regulatory 
subunit 1 - PPP6R1 -  
Q9UPN7 97 kDa 0.048 0.2 6080766.67 920233.333 
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Enoyl-[acyl-carrier-protein] reductase, 
mitochondrial - MECR -  
Q9BV79 40 kDa 0.034 0.1 25541000 3791000 
A-kinase anchor protein 9 - AKAP9 -  Q99996 454 kDa 0.033 0.1 9843800 1444354.67 
DNA polymerase delta catalytic subunit - POLD1 -  P28340 124 kDa 0.00072 0.1 11175366.7 1554533.33 
Ribonuclease H2 subunit A - RNASEH2A -  O75792 33 kDa 0.033 0.1 4257966.67 564733.333 
Thymidylate synthase - TYMS -  P04818 36 kDa 0.0094 0.1 9390800 1227833.33 
Rhophilin-2 - RHPN2 -  Q8IUC4 77 kDa 0.036 0.1 1127416.67 144290 
Testin - TES -  Q9UGI8 48 kDa 0.0036 0.1 49970333.3 6151400 
MICAL-like protein 1 - MICALL1 -  Q8N3F8 93 kDa 0.0014 0.1 3130633.33 379370 
CTD small phosphatase-like protein 2 - CTDSPL2 -  Q05D32 53 kDa 0.029 0.1 1544466.67 182783.333 
Telomere-associated protein RIF1 - RIF1 -  Q5UIP0 274 kDa 0.0049 0.1 3102100 342863.333 
Lymphokine-activated killer T-cell-originated 
protein kinase - PBK -  
Q96KB5 36 kDa 0.0004 0.1 82287333.3 8991266.67 
Replication factor C subunit 3 - RFC3 -  P40938 41 kDa 0.014 0.1 14326333.3 1508123.33 
Huntingtin-interacting protein 1 - HIP1 -  O00291 116 kDa 0.018 0.09 4580833.33 410300 
Anaphase-promoting complex subunit 7 - ANAPC7 -  Q9UJX3 67 kDa 0.014 0.09 14540466.7 1274900 
Kinetochore protein Spc24 - SPC24 -  Q8NBT2 22 kDa 0.011 0.08 38930666.7 3185366.67 
Zinc finger protein 281 - ZNF281 -  Q9Y2X9 97 kDa 0.0031 0.07 123798.333 8795 
InaD-like protein - PATJ -  Q8NI35 196 kDa 0.0066 0.07 10458233.3 742066.667 
E3 ubiquitin-protein ligase DTX3L - DTX3L -  Q8TDB6 84 kDa 0.037 0.07 9415500 649233.333 
Protein NipSnap homolog 3A - NIPSNAP3A -  Q9UFN0 28 kDa 0.025 0.07 8498333.33 582533.333 
Pseudouridylate synthase 7 homolog - PUS7 -  Q96PZ0 75 kDa 0.0024 0.07 30642333.3 2085766.67 
ATPase family AAA domain-containing protein 2 - 
ATAD2 -  
Q6PL18 159 kDa 0.00056 0.06 15407000 990733.333 
Polycomb protein EED - EED -  O75530 50 kDa 0.032 0.06 8449333.33 506600 
Charged multivesicular body protein 4a - CHMP4A -  Q9BY43 25 kDa 0.024 0.05 6981633.33 361400 
Interferon regulatory factor 6 - IRF6 -  O14896 53 kDa 0.021 0.05 20022333.3 905266.667 
Targeting protein for Xklp2 - TPX2 -  Q9ULW0 86 kDa 0.0046 0.04 8129233.33 345533.333 
DNA ligase 1 - LIG1 -  P18858 102 kDa 0.012 0.04 2640300 111516.667 
Zinc finger CCCH-type antiviral protein 1-like - 
ZC3HAV1L -  
Q96H79 33 kDa 0.0014 0.03 5629566.67 141623.333 
Ubiquitin-conjugating enzyme E2 R2 - UBE2R2 -  Q712K3 27 kDa 0.0021 0.02 14198666.7 284083.333 
Kinetochore protein NDC80 homolog - NDC80 -  O14777 74 kDa 0.012 0.02 7338566.67 132932.333 
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9.1.1.5 Regulated proteins after DHRS7 depletion Following Time-dependent DHRS7 Silencing 
Table 13: Proteins identified with three peptides regulated after 24 h timepoint for a time-dependent DHRS7 downregulation with 
a fold change of ≥ 1.5 fold (upregulation), or ≤ 0.666 (downregulation) and p-value >0.05. 
Proteins changed after 24 h 
Common name Regulation Fold change 
Chondroitin sulfate synthase 2 - CHPF -  upregulated 9.49 
Sorbin and SH3 domain-containing protein 1 - SORBS1 -  upregulated 6.16 
Motile sperm domain-containing protein 2 - MOSPD2 -  upregulated 5.03 
Probable RNA-binding protein 23 - RBM23 -  upregulated 4.74 
Putative Polycomb group protein ASXL1 - ASXL1 -  upregulated 4.14 
CON__ENSEMBL:ENSBTAP00000007350 upregulated 3.72 
Store-operated calcium entry-associated regulatory factor - SARAF -  upregulated 3.39 
Monoacylglycerol lipase ABHD2 - ABHD2 -  upregulated 3.31 
Leucine-rich repeat neuronal protein 1 - LRRN1 -  upregulated 3.20 
Testis-expressed protein 2 - TEX2 -  upregulated 3.09 
Paternally-expressed gene 3 protein - PEG3 -  upregulated 3.08 
Golgi apparatus membrane protein TVP23 homolog B - TVP23B -  upregulated 3.01 
Zinc finger CCHC domain-containing protein 3 - ZCCHC3 -  upregulated 3.00 
Adenomatous polyposis coli protein - APC -  upregulated 2.80 
CON__P15497 upregulated 2.80 
CON__Q2TBQ1 upregulated 2.76 
CON__Q3SZ57 upregulated 2.70 
Methylosome subunit pICln - CLNS1A -  upregulated 2.61 
SLIT and NTRK-like protein 3 - SLITRK3 -  upregulated 2.58 
Coiled-coil domain-containing protein 93 - CCDC93 -  upregulated 2.54 
CON__Q3SZH5 upregulated 2.40 
Glutathione S-transferase A2 - GSTA2 - SV=4 upregulated 2.38 
Endoribonuclease Dicer - DICER1 -  upregulated 2.24 
Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 - HACD3 -  upregulated 2.24 
Forkhead box protein J2 - FOXJ2 -  upregulated 2.21 
CON__Q95121 upregulated 2.14 
CON__ENSEMBL:ENSBTAP00000016046 upregulated 2.14 
Prolyl endopeptidase-like - PREPL -  upregulated 2.11 
ATPase family AAA domain-containing protein 1 - ATAD1 -  upregulated 2.11 
Protein FAM177A1 - FAM177A1 -  upregulated 2.10 
Cytochrome c oxidase subunit 5B, mitochondrial - COX5B -  upregulated 2.01 
Rho GTPase-activating protein 19 - ARHGAP19 -  upregulated 1.99 
Sortilin - SORT1 -  upregulated 1.98 
Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial - QRSL1 -  upregulated 1.97 
Choline dehydrogenase, mitochondrial - CHDH -  upregulated 1.97 
Protein YIPF3 - YIPF3 -  upregulated 1.96 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 - NDUFB10 -  upregulated 1.93 
Xyloside xylosyltransferase 1 - XXYLT1 -  upregulated 1.91 
CON__Q3ZBS7 upregulated 1.80 
C-Maf-inducing protein - CMIP -  upregulated 1.74 
Mortality factor 4-like protein 2 - MORF4L2 -  upregulated 1.68 
FAST kinase domain-containing protein 5, mitochondrial - FASTKD5 -  upregulated 1.66 
N-alpha-acetyltransferase 30 - NAA30 -  upregulated 1.66 
CON__ENSEMBL:ENSBTAP00000024146 upregulated 1.65 
Caldesmon - CALD1 -  upregulated 1.63 
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Polymerase delta-interacting protein 2 - POLDIP2 -  upregulated 1.57 
WD repeat-containing protein 82 - WDR82 -  downregulated 0.62 
Disintegrin and metalloproteinase domain-containing protein 10 - ADAM10 -  downregulated 0.57 
Mitofusin-2 - MFN2 -  downregulated 0.57 
Nuclear factor NF-kappa-B p100 subunit - NFKB2 - SV=4 downregulated 0.57 
InaD-like protein - PATJ -  downregulated 0.56 
Transcription initiation factor TFIID subunit 7 - TAF7 -  downregulated 0.56 
Nucleolar complex protein 3 homolog - NOC3L -  downregulated 0.54 
Probable helicase senataxin - SETX - SV=4 downregulated 0.51 
AF4/FMR2 family member 4 - AFF4 -  downregulated 0.50 
Protein 4.1 - EPB41 - SV=4 downregulated 0.50 
RalA-binding protein 1 - RALBP1 -  downregulated 0.50 
Rhophilin-2 - RHPN2 -  downregulated 0.50 
Histone H1x - H1FX -  downregulated 0.49 
Peroxisomal NADH pyrophosphatase NUDT12 - NUDT12 -  downregulated 0.49 
Cadherin-1 - CDH1 -  downregulated 0.49 
Cytokine receptor-like factor 3 - CRLF3 -  downregulated 0.48 
Serine/threonine-protein kinase Chk1 - CHEK1 -  downregulated 0.47 
Solute carrier family 2, facilitated glucose transporter member 1 - SLC2A1 -  downregulated 0.47 
Dehydrogenase/reductase SDR family member 7 - DHRS7 -  downregulated 0.46 
Keratin, type I cytoskeletal 9 - KRT9 -  downregulated 0.46 
TATA element modulatory factor - TMF1 -  downregulated 0.45 
Occludin - OCLN -  downregulated 0.42 
Ceramide synthase 4 - CERS4 -  downregulated 0.36 
UPF0415 protein C7orf25 - C7orf25 -  downregulated 0.36 
MAP kinase-activating death domain protein - MADD -  downregulated 0.35 
Molybdenum cofactor sulfurase - MOCOS -  downregulated 0.35 
Little elongation complex subunit 2 - ICE2 -  downregulated 0.35 
DCC-interacting protein 13-beta - APPL2 -  downregulated 0.34 
Spondin-2 - SPON2 -  downregulated 0.33 
Mortality factor 4-like protein 1 - MORF4L1 -  downregulated 0.33 
Ubiquitin-conjugating enzyme E2 Q1 - UBE2Q1 -  downregulated 0.33 
Probable JmjC domain-containing histone demethylation protein 2C - JMJD1C -  downregulated 0.32 
Condensin-2 complex subunit H2 - NCAPH2 -  downregulated 0.32 
FAS-associated death domain protein - FADD -  downregulated 0.31 
Metallothionein-1X - MT1X -  downregulated 0.30 
Tripartite motif-containing protein 5 - TRIM5 -  downregulated 0.28 
Zinc finger protein 460 - ZNF460 -  downregulated 0.27 
Serum response factor-binding protein 1 - SRFBP1 -  downregulated 0.23 
MAX gene-associated protein - MGA -  downregulated 0.21 
Mediator of RNA polymerase II transcription subunit 23 - MED23 -  downregulated 0.20 
Sentrin-specific protease 8 - SENP8 -  downregulated 0.19 
Small G protein signaling modulator 3 - SGSM3 -  downregulated 0.18 
Tumor protein p63-regulated gene 1-like protein - TPRG1L -  downregulated 0.14 
Anillin - ANLN -  downregulated 0.12 
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Table 14: Proteins identified with three peptides regulated after 48 h timepoint for a time-dependent DHRS7 downregulation with 
a fold change of ≥ 1.5 fold (upregulation), or ≤ 0.666 (downregulation) and p-value >0.05. 
Common name Regulation Fold 
change 
Transmembrane protein 168 - TMEM168 -  upregulated 7.69 
Keratin, type I cytoskeletal 9 - KRT9 -  upregulated 6.25 
WD and tetratricopeptide repeats protein 1 - WDTC1 -  upregulated 5.56 
Bone morphogenetic protein receptor type-2 - BMPR2 -  upregulated 5.00 
Transmembrane channel-like protein 4 - TMC4 -  upregulated 4.76 
Palmitoyltransferase ZDHHC5 - ZDHHC5 -  upregulated 4.76 
Phosphotriesterase-related protein - PTER -  upregulated 4.17 
Kinase D-interacting substrate of 220 kDa - KIDINS220 -  upregulated 4.17 
Alpha- and gamma-adaptin-binding protein p34 - AAGAB -  upregulated 4.00 
3-ketodihydrosphingosine reductase - KDSR -  upregulated 3.85 
Nesprin-1 - SYNE1 -  upregulated 3.85 
Golgi pH regulator A - GPR89A -  upregulated 3.70 
Monoacylglycerol lipase ABHD2 - ABHD2 -  upregulated 3.45 
Zinc transporter 1 - SLC30A1 -  upregulated 3.23 
Sialidase-1 - NEU1 -  upregulated 3.03 
Acyl-CoA synthetase family member 2, mitochondrial - ACSF2 -  upregulated 3.03 
Translation initiation factor IF-2, mitochondrial - MTIF2 -  upregulated 2.94 
40S ribosomal protein S14 - RPS14 -  upregulated 2.78 
Rab GTPase-activating protein 1-like, isoform 10 - RABGAP1L -  upregulated 2.70 
Integrin beta-5 - ITGB5 -  upregulated 2.70 
Squalene monooxygenase - SQLE -  upregulated 2.63 
5'-nucleotidase domain-containing protein 3 - NT5DC3 -  upregulated 2.63 
UPF0538 protein C2orf76 - C2orf76 -  upregulated 2.63 
Zinc finger and SCAN domain-containing protein 18 - ZSCAN18 -  upregulated 2.63 
Sodium bicarbonate cotransporter 3 - SLC4A7 -  upregulated 2.63 
Choline dehydrogenase, mitochondrial - CHDH -  upregulated 2.56 
Pleckstrin homology domain-containing family H member 3 - PLEKHH3 -  upregulated 2.56 
Probable Xaa-Pro aminopeptidase 3 - XPNPEP3 -  upregulated 2.44 
Golgi integral membrane protein 4 - GOLIM4 -  upregulated 2.44 
Aprataxin - APTX -  upregulated 2.44 
Testis-specific Y-encoded-like protein 1 - TSPYL1 -  upregulated 2.38 
Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial - MCCC1 -  upregulated 2.38 
Fatty acyl-CoA reductase 1 - FAR1 -  upregulated 2.33 
RNA-binding E3 ubiquitin-protein ligase MEX3C - MEX3C -  upregulated 2.27 
Probable ATP-dependent RNA helicase DDX49 - DDX49 -  upregulated 2.27 
Peroxisomal carnitine O-octanoyltransferase - CROT -  upregulated 2.22 
Succinate-semialdehyde dehydrogenase, mitochondrial - ALDH5A1 -  upregulated 2.22 
Mitochondrial peptide methionine sulfoxide reductase - MSRA -  upregulated 2.17 
Probable ATP-dependent RNA helicase DDX28 - DDX28 -  upregulated 2.17 
Probable proline--tRNA ligase, mitochondrial - PARS2 -  upregulated 2.17 
Acid sphingomyelinase-like phosphodiesterase 3a - SMPDL3A -  upregulated 2.17 
Methyl-CpG-binding protein 2 - MECP2 -  upregulated 2.17 
N-acetylgalactosamine-6-sulfatase - GALNS -  upregulated 2.13 
Cilia- and flagella-associated protein 20 - CFAP20 -  upregulated 2.13 
D-2-hydroxyglutarate dehydrogenase, mitochondrial - D2HGDH -  upregulated 2.13 
Ral GTPase-activating protein subunit alpha-2 - RALGAPA2 -  upregulated 2.04 
 151 
 
Charged multivesicular body protein 2b - CHMP2B -  upregulated 2.00 
Peptide deformylase, mitochondrial - PDF -  upregulated 2.00 
Methylmalonyl-CoA mutase, mitochondrial - MUT -  upregulated 2.00 
Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 - ENPP5 -  upregulated 2.00 
BAG family molecular chaperone regulator 1 - BAG1 -  upregulated 1.96 
Peroxisomal membrane protein PEX14 - PEX14 -  upregulated 1.96 
Zinc fingers and homeoboxes protein 1 - ZHX1 -  upregulated 1.92 
Round spermatid basic protein 1 - RSBN1 -  upregulated 1.92 
Protein prenyltransferase alpha subunit repeat-containing protein 1 - PTAR1 -  upregulated 1.92 
Transcription termination factor 4, mitochondrial - MTERF4 -  upregulated 1.89 
Autophagy protein 5 - ATG5 -  upregulated 1.89 
Delta-aminolevulinic acid dehydratase - ALAD -  upregulated 1.89 
Endoplasmic reticulum resident protein 44 - ERP44 -  upregulated 1.85 
Neurochondrin - NCDN -  upregulated 1.85 
ATP-binding cassette sub-family B member 7, mitochondrial - ABCB7 -  upregulated 1.85 
28S ribosomal protein S31, mitochondrial - MRPS31 -  upregulated 1.85 
Nitric oxide-associated protein 1 - NOA1 -  upregulated 1.85 
Malonyl-CoA-acyl carrier protein transacylase, mitochondrial - MCAT -  upregulated 1.82 
Growth factor receptor-bound protein 10 - GRB10 -  upregulated 1.82 
Probable D-lactate dehydrogenase, mitochondrial - LDHD -  upregulated 1.82 
Junction-mediating and -regulatory protein - JMY -  upregulated 1.82 
Atypical kinase COQ8B, mitochondrial - COQ8B -  upregulated 1.82 
Autophagy-related protein 2 homolog B - ATG2B -  upregulated 1.79 
RISC-loading complex subunit TARBP2 - TARBP2 -  upregulated 1.79 
Vesicle transport protein SEC20 - BNIP1 -  upregulated 1.79 
NAD-dependent protein deacetylase sirtuin-2 - SIRT2 -  upregulated 1.75 
Engulfment and cell motility protein 2 - ELMO2 -  upregulated 1.75 
Phosphatidylinositol 3-kinase catalytic subunit type 3 - PIK3C3 -  upregulated 1.75 
39S ribosomal protein L9, mitochondrial - MRPL9 -  upregulated 1.75 
28S ribosomal protein S26, mitochondrial - MRPS26 -  upregulated 1.75 
Suppressor of tumorigenicity 14 protein - ST14 -  upregulated 1.75 
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform - 
PIK3CB -  
upregulated 
1.75 
L-2-hydroxyglutarate dehydrogenase, mitochondrial - L2HGDH -  upregulated 1.72 
Type I inositol 1,4,5-trisphosphate 5-phosphatase - INPP5A -  upregulated 1.72 
Tyrosine--tRNA ligase, mitochondrial - YARS2 -  upregulated 1.72 
Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial - GATB -  upregulated 1.72 
Elongation factor G, mitochondrial - GFM1 -  upregulated 1.72 
Protein FAM45A - FAM45A -  upregulated 1.69 
2-(3-amino-3-carboxypropyl)histidine synthase subunit 2 - DPH2 -  upregulated 1.69 
Ribosome production factor 2 homolog - RPF2 -  upregulated 1.69 
[F-actin]-monooxygenase MICAL1 - MICAL1 -  upregulated 1.69 
NADH-cytochrome b5 reductase 1 - CYB5R1 -  upregulated 1.67 
cAMP-dependent protein kinase type II-beta regulatory subunit - PRKAR2B -  upregulated 1.67 
Acyl-CoA dehydrogenase family member 10 - ACAD10 -  upregulated 1.67 
SPRY domain-containing protein 4 - SPRYD4 -  upregulated 1.67 
Thyroid adenoma-associated protein - THADA -  upregulated 1.67 
Aldehyde dehydrogenase, mitochondrial - ALDH2 -  upregulated 1.64 
Zinc finger protein 217 - ZNF217 -  upregulated 1.64 
Presequence protease, mitochondrial - PITRM1 -  upregulated 1.64 
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Homeobox protein Nkx-3.1 - NKX3-1 -  upregulated 1.64 
Serine/threonine-protein phosphatase 6 regulatory subunit 2 - PPP6R2 -  upregulated 1.64 
28S ribosomal protein S11, mitochondrial - MRPS11 -  upregulated 1.61 
Citrate synthase, mitochondrial - CS -  upregulated 1.59 
Integrin beta-1 - ITGB1 -  upregulated 1.59 
Synaptojanin-2-binding protein - SYNJ2BP -  upregulated 1.59 
Sesquipedalian-1 - FAM109A -  upregulated 1.56 
Dipeptidyl peptidase 9 - DPP9 -  upregulated 1.56 
ADP-ribosylation factor-related protein 1 - ARFRP1 -  upregulated 1.56 
Protein CREG1 - CREG1 -  upregulated 1.56 
Calcium/calmodulin-dependent protein kinase type II subunit delta - CAMK2D -  upregulated 1.56 
Transcription intermediary factor 1-alpha - TRIM24 -  upregulated 1.54 
Transcription factor Sp3 - SP3 -  upregulated 1.54 
Calcium-binding protein 39 - CAB39 -  upregulated 1.54 
Peptidyl-tRNA hydrolase ICT1, mitochondrial - MRPL58 -  upregulated 1.54 
Protein fem-1 homolog B - FEM1B -  upregulated 1.54 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic - HMGCS1 -  upregulated 1.52 
Mitochondrial proton/calcium exchanger protein - LETM1 -  upregulated 1.52 
Signal transducer and activator of transcription 3 - STAT3 -  upregulated 1.52 
Microsomal glutathione S-transferase 3 - MGST3 -  upregulated 1.52 
Polypeptide N-acetylgalactosaminyltransferase 2 - GALNT2 -  upregulated 1.52 
Unconventional myosin-XVIIIa - MYO18A -  upregulated 1.52 
NAD-dependent malic enzyme, mitochondrial - ME2 -  upregulated 1.49 
DNA replication licensing factor MCM6 - MCM6 -  downregulated 0.67 
GTP-binding protein 1 - GTPBP1 -  downregulated 0.66 
DNA topoisomerase 3-beta-1 - TOP3B -  downregulated 0.66 
Protein S100-A13 - S100A13 -  downregulated 0.66 
DnaJ homolog subfamily C member 9 - DNAJC9 -  downregulated 0.66 
Thymocyte nuclear protein 1 - THYN1 -  downregulated 0.66 
Kinetochore-associated protein 1 - KNTC1 -  downregulated 0.66 
Sperm-associated antigen 5 - SPAG5 -  downregulated 0.65 
Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial - CPOX -  downregulated 0.65 
Gamma-soluble NSF attachment protein - NAPG -  downregulated 0.65 
WD repeat and HMG-box DNA-binding protein 1 - WDHD1 -  downregulated 0.65 
L-lactate dehydrogenase A chain - LDHA -  downregulated 0.65 
Cyclin-dependent kinases regulatory subunit 1 - CKS1B -  downregulated 0.65 
Tumor protein D53 - TPD52L1 -  downregulated 0.64 
Sorting nexin-17 - SNX17 -  downregulated 0.64 
Transcription initiation factor TFIID subunit 6 - TAF6 -  downregulated 0.63 
Guanine nucleotide exchange factor MSS4 - RABIF -  downregulated 0.63 
Ribosomal oxygenase 2 - RIOX2 -  downregulated 0.63 
Exosome complex component RRP41 - EXOSC4 -  downregulated 0.62 
DCC-interacting protein 13-beta - APPL2 -  downregulated 0.62 
Protein zwilch homolog - ZWILCH -  downregulated 0.62 
Crooked neck-like protein 1 - CRNKL1 -  downregulated 0.62 
Src substrate cortactin - CTTN -  downregulated 0.61 
Nucleoside diphosphate-linked moiety X motif 19 - NUDT19 -  downregulated 0.61 
Zinc finger protein 638 - ZNF638 -  downregulated 0.61 
5'-3' exoribonuclease 1 - XRN1 -  downregulated 0.61 
InaD-like protein - PATJ -  downregulated 0.61 
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Testin - TES -  downregulated 0.60 
Uncharacterized protein C1orf112 - C1orf112 -  downregulated 0.60 
Gem-associated protein 6 - GEMIN6 -  downregulated 0.59 
Forkhead box protein J2 - FOXJ2 -  downregulated 0.59 
5'-AMP-activated protein kinase subunit gamma-1 - PRKAG1 -  downregulated 0.59 
Monoacylglycerol lipase ABHD12 - ABHD12 -  downregulated 0.59 
Kinesin-like protein KIF15 - KIF15 -  downregulated 0.58 
Nucleolar pre-ribosomal-associated protein 1 - URB1 -  downregulated 0.58 
Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial - DUT -  downregulated 0.58 
Activating transcription factor 7-interacting protein 1 - ATF7IP -  downregulated 0.58 
CUE domain-containing protein 2 - CUEDC2 -  downregulated 0.57 
DNA excision repair protein ERCC-6-like - ERCC6L -  downregulated 0.57 
DNA replication complex GINS protein PSF3 - GINS3 -  downregulated 0.56 
BTB/POZ domain-containing protein KCTD3 - KCTD3 -  downregulated 0.56 
Lariat debranching enzyme - DBR1 -  downregulated 0.56 
Replication factor C subunit 4 - RFC4 -  downregulated 0.56 
Choline-phosphate cytidylyltransferase A - PCYT1A -  downregulated 0.56 
MAP/microtubule affinity-regulating kinase 3 - MARK3 -  downregulated 0.56 
Zinc finger protein 318 - ZNF318 -  downregulated 0.56 
Cholinesterase - BCHE -  downregulated 0.56 
RWD domain-containing protein 2A - RWDD2A -  downregulated 0.56 
Solute carrier family 2, facilitated glucose transporter member 1 - SLC2A1 -  downregulated 0.55 
Thymidine kinase, cytosolic - TK1 -  downregulated 0.55 
Ankyrin repeat and zinc finger domain-containing protein 1 - ANKZF1 -  downregulated 0.55 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily E member 1-related - HMG20B -  
downregulated 
0.55 
Condensin complex subunit 2 - NCAPH -  downregulated 0.54 
DNA (cytosine-5)-methyltransferase 1 - DNMT1 -  downregulated 0.53 
E3 ubiquitin-protein ligase RING1 - RING1 -  downregulated 0.53 
CDK5 regulatory subunit-associated protein 2 - CDK5RAP2 -  downregulated 0.53 
Protein 4.1 - EPB41 -  downregulated 0.53 
Non-canonical poly(A) RNA polymerase PAPD5 - PAPD5 -  downregulated 0.53 
M-phase phosphoprotein 6 - MPHOSPH6 -  downregulated 0.52 
CTD small phosphatase-like protein 2 - CTDSPL2 -  downregulated 0.52 
CLIP-associating protein 1 - CLASP1 -  downregulated 0.52 
Adhesion G-protein coupled receptor G6 - ADGRG6 -  downregulated 0.52 
Protein phosphatase 1H - PPM1H -  downregulated 0.51 
Histone-lysine N-methyltransferase NSD2 - NSD2 -  downregulated 0.51 
WD repeat-containing protein 92 - WDR92 -  downregulated 0.51 
DNA-binding protein SMUBP-2 - IGHMBP2 -  downregulated 0.51 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily D member 1 - SMARCD1 -  
downregulated 
0.51 
Protein HGH1 homolog - HGH1 -  downregulated 0.50 
ATP-dependent RNA helicase DDX55 - DDX55 -  downregulated 0.49 
Peroxisomal NADH pyrophosphatase NUDT12 - NUDT12 -  downregulated 0.49 
Ankyrin repeat domain-containing protein 13A - ANKRD13A -  downregulated 0.48 
Mitotic checkpoint serine/threonine-protein kinase BUB1 - BUB1 -  downregulated 0.48 
RalA-binding protein 1 - RALBP1 -  downregulated 0.47 
HAUS augmin-like complex subunit 4 - HAUS4 -  downregulated 0.47 
Transcription initiation factor TFIID subunit 10 - TAF10 -  downregulated 0.47 
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Telomere-associated protein RIF1 - RIF1 -  downregulated 0.47 
High affinity cationic amino acid transporter 1 - SLC7A1 -  downregulated 0.46 
POU domain, class 2, transcription factor 1 - POU2F1 -  downregulated 0.46 
DNA primase large subunit - PRIM2 -  downregulated 0.46 
Zinc finger protein 460 - ZNF460 -  downregulated 0.44 
Phosphatidylserine decarboxylase proenzyme, mitochondrial - PISD -  downregulated 0.44 
Adaptin ear-binding coat-associated protein 2 - NECAP2 -  downregulated 0.43 
Sister chromatid cohesion protein DCC1 - DSCC1 -  downregulated 0.43 
Werner syndrome ATP-dependent helicase - WRN -  downregulated 0.43 
3-keto-steroid reductase - HSD17B7 -  downregulated 0.42 
Heterogeneous nuclear ribonucleoprotein L-like - HNRNPLL -  downregulated 0.42 
Endonuclease III-like protein 1 - NTHL1 -  downregulated 0.42 
Ubiquitin-conjugating enzyme E2 R2 - UBE2R2 -  downregulated 0.41 
Small G protein signaling modulator 3 - SGSM3 -  downregulated 0.40 
Putative E3 ubiquitin-protein ligase UBR7 - UBR7 -  downregulated 0.40 
Aurora kinase B - AURKB -  downregulated 0.38 
DNA polymerase alpha catalytic subunit - POLA1 -  downregulated 0.38 
DENN domain-containing protein 4C - DENND4C -  downregulated 0.37 
Calmin - CLMN -  downregulated 0.35 
Chromosome transmission fidelity protein 18 homolog - CHTF18 -  downregulated 0.33 
Tubulin-specific chaperone cofactor E-like protein - TBCEL -  downregulated 0.32 
Telomere length regulation protein TEL2 homolog - TELO2 -  downregulated 0.32 
Leucine-rich repeat-containing protein 57 - LRRC57 -  downregulated 0.32 
Fanconi anemia group D2 protein - FANCD2 -  downregulated 0.31 
Ras GTPase-activating-like protein IQGAP3 - IQGAP3 -  downregulated 0.31 
Nuclear factor NF-kappa-B p100 subunit - NFKB2 -  downregulated 0.31 
Tetratricopeptide repeat protein 39C - TTC39C -  downregulated 0.30 
Spindle and kinetochore-associated protein 2 - SKA2 -  downregulated 0.30 
Serine/threonine/tyrosine-interacting protein - STYX -  downregulated 0.28 
Transport and Golgi organization protein 6 homolog - TANGO6 -  downregulated 0.28 
Myomegalin - PDE4DIP -  downregulated 0.27 
DNA polymerase delta subunit 3 - POLD3 -  downregulated 0.26 
Putative D-tyrosyl-tRNA(Tyr) deacylase 2 - DTD2 -  downregulated 0.25 
B-cell CLL/lymphoma 7 protein family member A - BCL7A -  downregulated 0.24 
DNA dC->dU-editing enzyme APOBEC-3B - APOBEC3B -  downregulated 0.24 
Ribonuclease P protein subunit p25-like protein - RPP25L -  downregulated 0.23 
Serine/threonine-protein kinase MARK1 - MARK1 -  downregulated 0.22 
Anterior gradient protein 2 homolog - AGR2 -  downregulated 0.22 
Ras-responsive element-binding protein 1 - RREB1 -  downregulated 0.22 
Serine/threonine-protein kinase ATR - ATR -  downregulated 0.22 
WAS/WASL-interacting protein family member 2 - WIPF2 -  downregulated 0.21 
Protein Spindly - SPDL1 -  downregulated 0.18 
Autophagy-related protein 13 - ATG13 -  downregulated 0.15 
Nucleolar and spindle-associated protein 1 - NUSAP1 -  downregulated 0.09 
 
